2024/20252024/2025

ANUAL REPORT年报

(于开曼群岛注册成立之有限公司)

股份代号

年

报

ANUAL REPORT 2024/2025

2024/2025 年报

Subject Areas 主要范畴		Subject Aspects 主要层面
Environmental 环境		A1. Emissions A1. 排放物
A2. Use of Resources A2. 资源使用
A3. Environment and Natural Resources A3. 环境及自然资源
A4. Climate Change A4. 气候变化
Social 社会	Employment and Labour Practices 雇佣及劳工常规	B1. Employment B1. 雇佣
		B2. Health and Safety B2. 健康和安全
		B3. Development and Training B3. 发展及培训
		B4. Labour Standards B4. 劳动标准
	Operating Practices 营运惯例	B5. Supply Chain Management B5. 供应链管理
		B6. Product Responsibility B6. 产品责任
		B7. Anti-corruption B7. 反贪污
	Community 社区	B8. Community Investment B8. 社区投资

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

上述ESG重要性范畴及层面将继续透过本ESG报

告所述本集团已建立的管理结构、流程、政策

及指引进行严格管理及监控。

The above ESG material areas and aspects have continued to be

strictly managed and monitored through the Group’s established

management structure, proces, policies and guidelines as

described in this ESG Report.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

本集团的环境和社会范畴及层面及其表

现

A. 环境范畴及层面

本集团是一家从事服装业务、保健及医药产品

及药品业务以及拥有IRO、CRO和内部研发业

务。总部设于香港。本集团为客户提供一站

式服装供应链管理解决方案，包括时尚趋势分

析、产品设计及开发、物料获取及采购、生

产管理、品质控制及物流服务。所有针织品均

由本集团聘用的第三方制造商生产。因此，相

关的环境法律法规并不适用于本集团本身。尽

管上述规定不适用于本集团，本集团仍要求其

供应商遵守与环境、劳工、社会和安全有关的

相关法律法规。本集团亦实施环保政策，以减

少其业务活动可能导致的环境污染。这些政策

包括但不限于减少二氧化碳（「CO2」）排放和水

耗用、废弃物管理以及本集团业务运营中的其

他环保措施。本集团通过以下方式推行这些政

策：(i)提醒员工只在需要时才开灯，并在员工

离开办公室时随手关灯；(i)提醒员工将冷气机

的温度设定为节能水平；(i)强调使用再生纸打

印内部文件，而在打印外部文件时，应使用双

面打印；(iv)提醒员工及相关负责人妥善处理日

常废弃物，珍惜水资源，避免浪费；(v)提醒员

工使用后及时关闭水龙头；及(vi)大力推动各办

事处的节水工作，以在报告期间尽力减少耗水

量。本集团将继续审查其营运对环境的影响，

并评估其环保政策是否在所有重大方面符合香

港、中国及日本适用的环境法例及法规包括但

不限于(i)《中华人民共和国环境保护法》；(i)《中

华人民共和国水污染防治法》；(i)《中华人民共

和国环境噪音污染防治法》；(iv)《香港特别行政

区空气污染管制条例》；及(v)《香港特别行政区

水污染管制条例》。于报告期内，本集团的业

THE GROUP’S ENVIRONMENTAL AND SOCIAL

AREAS AND ASPECTS AND THEIR PERFORMANCE

A. ENVIRONMENTAL AREAS AND ASPECTS

The Group is principaly engaged in the Garment Busines,

Healthcare and Medicated Products Busines and IRO, CRO and

in-house R&D busines which headquartered in Hong Kong. The

Group provides one-stop aparel suply chain management

solutions for its customers ranging from fashion trend analysis,

product design and development, sourcing and procurement of

materials, production management, quality control and logistics

services. Al of the knitwear products were produced by the

third-party manufacturers engaged by the Group. As such, the

relevant environmental laws and regulations are not aplicable

to the Group itself. Notwithstanding the aforementioned, the

Group required its supliers to comply with the relevant laws

and regulations relating to not only environmental but also labor,

social and safety. The Group also implemented environmental

protection policies in order to reduce the posible polution

resulted from its busines activities on the environment. These

policies including but not limited to the policies on reducing

carbon dioxide (“CO

”) emision and water consumption, waste

management and other eco-friendly measurements in the

Group’s busines operations. The Group implemented these

policies through (i) reminding staf to switch the light on only

when it is neded and turn of when staf are out of ofice; (i)

reminding staf to set the temperature of air-conditioner to an

energy-eficient level; (i) emphasising on the use of recycle

paper when printing internal documents and double-sided

printing for external documents; (iv) reminding staf and relevant

person-in-charge to proces daily waste properly and to treasure

water resources and avoid wasting; (v) reminding staf to turn

of water taps after use; and (vi) endeavouring to promote water

conservation in the ofices which resulted a limited amount of

water consumption during the Reporting Period. The Group wil

continue to review the environmental impact of its operations

and ases whether its environmental protection policies are in

compliance in al material respects with aplicable environmental

laws and regulations in Hong Kong, the PRC and Japan including

but not limited to (i) Environmental Protection Law of the PRC;

(i) Water Polution and Control Law of the PRC; (i) Prevention

and Control of Polution from Environmental Noise Law of the

PRC; (iv) Air Polution Control Ordinance Law of Hong Kong; and

(v) Water Polution Control Ordinance Law of Hong Kong. During

the Reporting Period, the Group’s busines operations are wholy

ofice operations, and thus, the key environmental impacts from

2025
二零二五年
54,756
18.67

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

务运作全部为办公业务，因此，本集团业务对

环境的主要影响主要与(i)能源；(i)纸张消耗；

及(i)本地及海外商务差旅有关。因此，与许

多其他行业相比，本集团的营运对环境的影响

较小。于报告期内，本集团并无严重违反或不

遵守有关环境保护、废气及温室气体排放、水

及土地排污、有害及无害废弃物的产生的适用

法律及规例。

A1. 排放

(i) 有害气体、无害气体排放

二氧化碳（CO2）是在营运过程中使用电力间接

产生的无害温室气体（「GHG」）。

下表记录并比较了报告期与上一个报告期的间

接无害气体排放结果：

the Group’s operations mainly related to (i) energy; (i) paper

consumption; and (i) local and overseas busines travels. As

such, the environmental impact from the Group’s operation

is minimal compared to that of many other industries. During

the Reporting Period, there was no material breach of or non-

compliance with the aplicable laws and regulations related to

environmental protection, air and grenhouse gas emisions,

discharges into water and land, and generation of hazardous and

non-hazardous waste by the Group.

A1. EMISIONS

(i) Hazardous and Non-Hazardous Air Emisions

Carbon dioxide (CO

) is the non-hazardous grenhouse gas

(“GHG”) generated indirectly from the use of electricity in our

operation.

The table below recorded and compared the Reporting Period

and the Last Reporting Period’s resultant indirect air polutant

emisions:

Year ended 31 March

截至三月三十一日止年度

Items of emisions

Note (1)

Unit2024Changes

排放项目注

附注(1)

单位二零二四年变化

indirect emision

Note (2)

Kg65,992-17.03%

二氧化碳间接排放

附注(2)

公斤

Intensity (CO

flor space of Hong Kong,

the PRC and Japan ofices)

Kg30.88-39.54%

每平方米楼面积的排放强度（香港、内地及

日本办公室）

公斤╱平方米

Note 1: Emision factors for calculations in this ESG Report made

reference to the “How to prepare an ESG Report-Apendix 2:

Reporting Guidance on Environmental KPIs (version updated

on 31 December 2024)” by The Stock Exchange of Hong

Kong Limited, unles otherwise specified.

Note 2: Emision factors for purchased electricity are sourced from 中

国产品全生命周期温室气体排放系数库 and based on data

stated in “JICA Climate – FIT Version 6.0” published by Japan

International Coperation Agency.

To reduce indirect CO

emisions, we have formulated a

sustainability strategy that wil continue to improve our energy

saving practices, including strictly controling the electricity

consumption of our production facility. We target to lower the

indirect CO

emision per m

per year by 1-2% through the

reduction of electricity consumption per m

附注1：本ESG报告中计算的排放因子，参考香港

联合交易所于2024年12月31日更新的《如

何编制ESG报告－附录2：环境关键绩效指

标(KPI)报告指南》进行，除非另有说明。

附注2：购买电力的排放因子，取自中国产品全

生命周期温室气体排放系数库及日本国际

协力机构发布的《JICA Climate-FIT 6.0版》。

为了减少间接二氧化碳排放，我们制定了可持

续发展策略，将持续改善我们的节能措施，包

括严格控制生产设施的用电量。我们的目标是

通过降低每平方米的用电量，每年将间接二氧

化碳排放量降低1-2%。

2025
二零二五年
0.26
0.01
0.02

2025
二零二五年
2.46
Insignificant (<0.01tonnes/m2)
不重大 (<0.01吨╱平方米）

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

在未来一年，本集团的目标是至少保持或可能

的话，进一步减少空气污染物排放量1-2%。

(i) 有害废弃物、无害废弃物和包装材料

由于其业务性质，本集团没有产生╱消耗任何

重大的有害废弃物、无害废弃物及包装材料。

下表记录并比较报告期和上一个报告期在香

港、中国和日本的用纸总量：

运输是其中一个排放项目，本集团亦提供指引

控制空气污染。下表记录并比较报告期和上一

个报告期在香港（本集团拥有的车辆所在地）的

空气污染物排放量：

Transportation is one of the emision areas where the Group

also provides guidance to control air polution. The table below

recorded and compared the Reporting Period and the Last

Reporting Period’s resultant air polutant emisions in Hong Kong,

where the vehicle owned by the Group is located:

Year ended 31 March

截至三月三十一日止年度

Air PolutantsUnit2024Changes

空气污染物单位二零二四年变化

Nitrogen Oxides (“NOx”)Kg0.33-19.63%

氮氧化物(NOx)公斤

Sulphur Oxides (“SOx”)Kg0.01-19.63%

硫氧化物(SOx)公斤

Particulate Mater (“PM”)Kg0.02-19.63%

悬浮粒子(PM) 公斤

In the coming year, the Group targets to at least maintain and if

posible, continue to reduce its air polutants emisions by 1-2%.

(i) Hazardous waste, non-hazardous waste and packaging

materials

The Group generated/consumed no significant hazardous waste,

non-hazardous waste and packaging materials due to its busines

nature. The table below recorded and compared the Reporting

Period and the Last Reporting Period’s total amount of paper

usage in Hong Kong, the PRC and Japan:

Year ended 31 March

截至三月三十一日止年度

WastesUnit2024Changes

废弃物单位二零二四年变化

Non-hazardous waste, paper for

recycling purpose

Tones2.65-7.17%

无害废弃物（用于回收的纸张）吨

Intensity of non-hazardous waste per m

flor space of Hong Kong, the PRC and

Japan ofices

Tones/m

Insignificant

(<0.01tones/m

)

N/A

密度（无害废弃物╱香港、中国和日本

办公室面积）

吨╱平方米不重大

(<0.01吨╱平方米）

不适用

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

在来年，本集团的目标是至少维持现有的无害

废弃物和包装材料弃置水平，如果可能的话，

将其持续降低1-2%。

(i) 噪音与光污染排放

本集团不会对周围的邻居产生任何噪音和光污

染，因为我们的业务运营和活动都在办公室内

进行。在我们的运作中，某些部分会产生噪

音，但其程度远低于国家和行业标准的限制。

在报告期内，未收到任何投诉或警告通知。

(iv) 缓解措施和减排举措

本集团倡导减排、节能、节约资源，致力于实

现可持续经营。为此，我们在减少排放、提高

能源使用效率和用水效率方面设定了初步的方

向性目标。本集团将检讨实时进程，并探索更

多机会，以达成各种环保目标。未来，我们将

设定更具体的量化环境目标，以保护环境并珍

惜自然资源。

In the coming year, the Group targets to at least maintain and if

posible, continue to reduce its non-hazardous waste by 1-2%.

(i) Noise and Light Polution Emision

The Group does not generate any noise and light polution to the

surounding neighbors as our busines operations and activities

are conducted inside our ofices. Within our operation, in certain

parts of the operation, noise is generated, but the extent is far

below national and industry standard limits. During the Reporting

Period, no complaints nor warning notices were received.

(iv) Mitigation measures and reduction initiatives

The Group advocates emision reduction, energy saving and

resources saving, and is comited to achieving sustainable

operations. To this end, we have set preliminary directional

targets in terms of reducing emisions, energy use eficiency and

water eficiency. The Group wil review the progres and explore

more oportunities for various environmental protection goals. In

the future, we wil set more specific quantitative environmental

goals to nurture the environment and cherish natural resources.

Environmental AspectsTargetsSteps Taken To Achieve The Targets

环境层面目标采取的措施

Air Polutants EmisionsThe Group wil actively implement

the air polutants control plan and

measures to maintain or reduce the

intensity of air polutants emisions.

– Carying out regular maintenance of vehicles

with god condition for operational eficiency

– Encouraging the use of public transportations

空气污染物排放本集团将积极推行空气污染物管

制计划及措施，以维持或减少空

气污染物排放密度

– 对状态良好的车辆进行定期保养，提高运

营效率

– 鼓励使用公共交通工具

Grenhouse Gas EmisionsThe Group wil actively implement

the electricity-saving plan and

measures to maintain or reduce

the intensity of grenhouse gas

emisions.

– Adopting LED lighting in some ofices

– Seting the temperature of air-conditioning

system in a range betwen 25˚C to 26˚C

– Switching of lights and unecesary energy-

consuming devices when they are not in use

– Promoting environmental protection such

as saving water and electricity by slogan or

poster in ofice

温室气体排放本集团将积极推行节电计划及措

施，以维持或减少温室气体排放

密度

– 部分办公室采用LED照明

– 将空调系统的温度设定在25˚C至26˚C的范围

内

– 在不使用时关掉灯及不必要的耗能设备

– 在办公室以标语或海报的形式促进环境保

护，如节水、节电

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

A2. 资源使用

(i) 能源消耗

能源是本集团营运的重要组成部分，本集团必

须获取源自化石燃料的能源，这是一种可耗竭

且不可再生的能源。因此，本集团设立以长远

眼光为方向目标的节能减排路径。因此，本集

团致力通过不同能源措施减少能源消耗。

，如节

水、节电；

• 在不使用时关掉灯光和不必要的耗能设

备；

˚C至26˚C的范

围内；

；及

Environmental AspectsTargetsSteps Taken To Achieve The Targets

环境层面目标采取的措施

Waste ReductionThe Group wil actively implement

the material-saving plan and

measures to maintain or reduce

the intensity of waste production.

– Using electronic document procesing

system to minimise the use of paper

– Encouraging printing or photocopying on

both sides of paper, where aplicable

– Focusing on quality management to reduce

wastage and scrap for les polution resulted

减少废弃物本集团将积极实施节约材料计划

及措施，以维持或减少废弃物的

生产力度

– 使用电子文件处理系统，尽量减少纸张的

使用

– 鼓励双面打印或复印纸张（如适用）

– 注重品质管理以减少浪费和报废，减少污

染

A2. USE OF RESOURCES

(i) Energy Consumption

Energy is the critical component of the Group’s operation, and

the Group has to acquire energy that originates from fosil fuels,

which is exhaustible and non-renewable energy. The Group has

thus established an energy consumption reduction pathway with

a long-term perspective as a directional target. Because of that,

the Group makes its every efort to reduce energy consumption

by diferent energy measures.

• Established a resources management procedure to regulate

energy use;

• Promoting environmental protection such as saving water

and electricity by slogan or poster in ofice;

• Switching of lights and unecesary energy-consuming

devices when they are not in use;

• Seting the temperature of air-conditioning system in a

range betwen 25˚C to 26˚C;

; and

• Adopting LED lighting in some ofices.

2025
二零二五年
137,798
47
411
3,984
2
141,782

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

附注3：汽油所用能源转换因子乃基于ESG报告指

引中所述的转换因子。

于报告期间，耗电量的下跌是由于本集团处理

了七家子公司。

下表记录并比较报告期和上一个报告期的能源

消耗量：

The table below recorded and compared the Reporting Period

and the Last Reporting Period’s resultant energy consumption:

Year ended 31 March

截至三月三十一日止年度

Energy Consumption2024Changes

能源消耗二零二四年变化

– Electricity

– 电力

Consumption (kWh)

消耗量（千瓦时）155,801-11.56%

Intensity (kWh/m

flor space of Hong Kong,

the PRC and Japan ofices)

密度（千瓦时╱香港和中国办公室面积平方米）73-35.62%

– U nleaded petrol

– 无铅汽油

Consumption (Litres)

消耗量（升）512-19.73%

Consumption (kWh)

Note (3)

消耗量（千瓦时）

附注(3)

4,957-19.63%

Intensity (kWh/m

flor space

of Hong Kong ofice)

密度（千瓦时╱香港办公室面积平方米）6-66.67%

TotalConsumption (kWh)

共计消耗（千瓦时）160,758-11.80%

Note 3: Energy conversion factors used for petrol are based on the

conversion factor mentioned in the ESG Reporting Code.

The significant decrease in electricity consumption was due

to the disposals of 7 of the Company’s subsidiaries during the

Reporting Period.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

(i) 用水量

由于本集团不开展任何与制造相关的业务，因

此在获取所需水源方面没有遇到任何问题。本

集团的耗水量主要用于办公室的日常一般清洁

及卫生所需。我们香港和中国的办公场所是租

赁的办公室，其供水和排放量由楼宇管理公司

控制，因此并无获得办公室耗水量数据。对于

日本办公室而言，水主要用于日常卫生需求，

我们认为是微不足道的。

(i) 目标与措施

(i) Water Consumption

As the Group does not conduct any busines relating to

manufacturing, it does not encounter any isue in sourcing water

that is fit for purpose. The Group’s key water usage arises from

consumption in ofices, including toilet flushing, water tap and

drinking water. For the PRC and Hong Kong ofices, we operate in

leased ofice premises of which water suply and discharge are

controled by building management who considered provision of

water usage data to individual ocupant is not feasible. For Japan

ofice, the water are mainly used for daily hygiene neds and is

considered insignificant.

(i) Targets and steps

Energy ConservationThe Group wil actively implement the

electricity-saving plan and measures

to maintain or reduce the intensity of

electricity consumption.

– Adopting LED lighting in some ofices

– Seting the temperature of air-conditioning

system in a range betwen 25˚C to 26˚C

– Switching of lights and unecesary energy-

consuming devices when they are not in use

节能本集团将积极推行节电计划及措

施，以维持或减少用电力度。

– 部分办公室采用LED照明

– 将空调系统的温度设定在25˚C至26˚C的范围内

– 在不使用时关掉灯及不必要的耗能设备

Water ConservationThe Group wil actively implement

the water-saving plan and measures

to maintain or reduce the intensity of

water consumption.

– Promoting environmental protection such as

saving water and electricity by slogan or poster

in ofice

节约用水本集团将积极推行节水计划及措

施，维持或减少用水量密度。

– 在办公室通过标语或海报的形式促进环境保

护，如节水、节电

Paper and Packaging

Materials and Other

Raw Materials

Consumption

The Group wil actively implement

the paper-saving plan and measures

to maintain or reduce the intensity of

paper consumption.

– Avoid unecesary printing and print on both

sides

– Use recycled papers and reuse paper-made

products such as envelops and folders

– Replace the use of papers by sharing and

storing information and documents in electronic

formats

– Adopt company-wide cloud based working

environment to reduce the ned of printed

documentation

纸张和包装材料及

其他原材料消耗

本集团将积极实施节纸计划和措

施，保持或降低纸张消耗强度。

– 避免不必要的列印，使用双面列印

– 使用再生纸并重复使用纸制产品，如信封和

资料夹

– 通过分享和存储电子格式的资讯和档案来取

代纸张的使用

– 在全公司范围内采用云端，以减少对印刷文

件的需求

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

A3. 环境及自然资源

本集团通过教育和培训的方式提高员工对环境

问题的认识，并征求员工支持，以改善本集团

的绩效，提高客户、业务伙伴及股东的环保意

识，支持与环境保护和可持续发展有关的社区

活动，支持社区有关环境保护和可持续性发展

的活动，并定期评估和监控过去和现在的业务

活动对健康，安全和环境问题的影响。通过整

合本ESG报告第A1(i)和A2(i)节中提到的政策，

本集团努力将对环境及天然资源的影响降至最

低。本集团的主要业务活动对环境及天然资源

并无重大影响。

A4. 气候风险和抗灾管理

气候变化导致极端天气频繁发生，并对本集团

的业务运营产生影响。因此，本集团制定了工

作机制，以识别、预防和减轻可能产生重大影

响的气候变化问题，同时，我们将调整资源和

能源的利用。为了应对极端天气可能引发的灾

害事故，我们会持续提高灾害应对能力。

A3. Environment and Natural Resources

The Group raises staf’s awarenes on environmental isues

through education and training and enlists employes’ suport

in improving the Group’s performance, promotes environmental

awarenes amongst the customers, busines partners and

shareholders, suports comunity activities in relation to

environmental protection and sustainability, and evaluates and

monitors regularly the impact of past and present busines

activities impacting upon health, safety and environmental

maters. With the integration of policies mentioned in Sections

A1(i) and A2(i) of this ESG Report, the Group strives to

minimise the impacts to the environment and natural resources.

The principal busines activities of the Group do not have a

significant impact on the environment and natural resources.

A4. Climate Risk and Resilience Management

Climate change has caused frequent extreme weather and has an

impact on the busines operations of the Group. Therefore, the

Group has formulated working mechanisms to identify, prevent

and mitigate climate change isues that may have a significant

impact. At the same time, we would adjust the use of resources

and energy. In response to disasters and acidents which are

easily induced by extreme weather, we always enhance the

capability to the disaster response.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

治理

气候变迁已导致频繁的极端天气，并对营运产

生了影响。因此，董事会认为气候变迁风险是

重要的风险，并负责监督及制定工作机制，以

识别、预防及减缓可能产生重大影响的气候变

迁议题。

本集团了解，利益相关者期望我们按照本地

及全球的承诺与建议来管理及减缓气候变迁风

险。我们也认识到，气候变迁的影响多样且

长远，所识别的风险可能阻碍我们达成策略目

标，并可能带来不利的营运、合规及财务影

响。董事会定期召开会议，监督我们与气候风

险和机遇相关的策略和管理方法，以及资讯披

露。本集团已制定《气候变化政策声明》，以指

导我们的营运，减少对气候变化的影响，同时

加强我们的业务韧性。

随著全球朝向低碳、可持续的经济转型，本集

团可以在一些不可避免的领域做出贡献。经过

与利益相关者的讨论，我们已确定能源和水资

源是我们可以立即著手解决的重点领域，这不

仅有助于应对气候变迁，也能降低未来的潜在

成本。

管理层的角色包括：

1. 气候相关的风险与机会的监督由董事会直

接管理。执行长(CEO)负责确保董事会制

定的策略和政策能在整个组织中有效落

实。

Governance

Climate change has caused frequent extreme weather and

has had an impact on the busines operations of the Group.

Therefore, climate change risks are considered by our Board to

be material risks and the Board is responsible for overseing

and formulating working mechanisms to identify, prevent and

mitigate climate change isues that may have a significant

impact.

The Group understands that stakeholders expect us to be

managing and mitigating climate change risks in line with

local and global comitments and recomendations. We

recognise that the impacts of climate change are varied and

long-ranging and the risks identified could prevent us from

meting our strategic objectives and could result in adverse

operational, compliance and financial impacts. Thus, the Board

mets regularly to overse our strategies and management

aproaches related to climate risks and oportunities, as wel as

the disclosure of information. We have implemented a climate

change policy statement to guide our operations and reduce

our impact on climate change while strengthening our busines

resilience.

As the world transitions toward a lower-carbon sustainable

economy, there are inevitable areas that our Group can

contribute to this. After discusions with our stakeholders, we

have identified energy and water as imediate areas that we can

tackle to both combat climate change and reduce potential costs

in the future.

Management’s role include:

1. Oversight of climate-related risks and oportunities is

managed directly by the Board. The CEO holds the overal

responsibility for ensuring that the strategies and policies

set by the Board are efectively implemented acros the

organisation.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

、专业发展机

会和能力评估，来发展适当的技能和专业

能力，确保董事会成员及相关人员具备监

督和应对气候相关风险与机会的能力。

3. 由执行长领导的管理团队在气候相关风险

与机会的治理中扮演关键角色。管理团队

负责检视和应对气候相关的风险与机会，

以及日常执行董事会制定的政策。

，例如内部审

计、绩效评估和永续报告，来支持气候

相关风险与机会的监督。这些控制措施与

财务、营运、人力资源等其他内部功能

整合，确保我们在永续发展方面采取一致

的策略。

策略

我们努力了解气候变化对我们业务营运带来的

影响，从而不断寻求推进相关研究以及我们的

行动计划和缓解措施。根据我们气候相关风险

评估和管理实践的持续发展，我们将进一步研

究将气候相关风险和其他可持续发展议题的财

务影响纳入企业及项目层面财政规划的可行性

和实用性。

急性实体风险

本集团已确认极端天气，例如台风、大雨、雷

霆和闪电以及洪水，可导致集团的财务损失。

潜在的后果包括导致延迟交付或装运，损害文

件，设备甚至员工的健康和生命。上述潜在

后果将会对本集团造成经济损失及增加营运成

本。

2. The Board is also responsible for the development of

apropriate skils and competencies through training

programs, profesional development oportunities, and

asesments of curent capabilities. This ensures that

the board members and relevant personel are wel-

equiped to overse and adres climate-related risks and

oportunities.

3. The Management Team, led by the CEO, plays a critical role

in the governance of climate-related risks and oportunities.

The Management Team is responsible for examining and

adresing climate related risks and oportunities, and day

to day implementation of policies set by the Board.

4. The Group utilises various controls and procedures, such

as internal audits, performance reviews, and sustainability

reporting, to suport the oversight of climate-related risks

and oportunities. These controls and procedures are

integrated with other internal functions, such as finance,

operations, and human resources, to ensure a cohesive

aproach to sustainability.

Strategy

We strive to understand the impacts brought by climate change

to our busines operations and thus continuously sek to

advance the relevant studies, as wel as our action plans and

mitigation measures. Subject to the on-going development

of our climate-related risk asesment and management

practices, we wil further study the feasibility and practicality of

integrating the financial impacts of climate-related risk and other

sustainability isues into our financial planing at the corporate

and project levels.

Physical Acute Risk

The Group has identified extreme weather such as typhons,

heavy rain, thunder and lightning and floding that can cause

physical acute risk. The potential consequences include delivery

or shipment delay as wel as damage to documents, equipment

and even employes’ health and life. The above potential

consequences wil cause economic loses to and increase

operating costs of the Group.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

慢性实体风险

本集团已确定极端天气，例如一年中持续的高

温，可能会导致集团的财务损失，导致的潜在

后果包括员工中暑几率增加，员工流失率上升

和工伤事故增加。工作环境的制冷需求将会增

加，可能导致本集团的电力需求及营运成本增

加。

Physical Acute Risk

急性实体风险

Extreme weatherPreventative and mitigation measures

极端天气预防和缓解措施

Typhons– Atach duct tapes to windows to avoid damage

– Move equipment to safety areas in advance

– Reinforce equipment and components that may be blown away

– Inform and negotiate with clients and third-party supliers of potential delays in

advance

– Arange work from home for staf acording to the guidelines of local observatory

台风– 窗户用胶带粘贴，避免损坏

– 提前将设备转移至安全区域

– 加固可能会被吹走的设备和部件

– 提前通知客户和第三方供应商并协商潜在的延误

– 根据当地观测站的指引，安排工作人员在家工作

Heavy Rain and Floding– Check that al windows are shut as secure as posible

– Reinforce equipment and asets which may be damaged or blown away

– Arange work from home for staf acording to the guidelines of local observatory

大雨和洪水– 检查所有窗户是否尽可能地安全关闭

– 加固可能会被损坏或吹走的设备和资产

– 根据政府不时颁布和公布的规则和指引安排员工在家工作

Thunder and Lightning– Kep god conditions of earthing devices

– Remind employes to save data and turn of computers

雷电– 保持接地装置的良好状态

– 提醒员工保存数据并关闭计算机

Physical Chronic Risk

The Group has identified extreme weather such as sustained

high temperature during the year could cause physical chronic

risk. The potential consequences include a higher chance of

geting heatstroke for employes, increasing turnover rate and

work-related injuries. The demand for coling for the working

environment wil be increased, which may lead to an increase in

power demand and operating costs of the Group.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

气候相关的过渡风险

本集团已制定以下多项措施，以防止及减少极

端天气的负面影响。

The Group has established diferent measures as below to

prevent and minimise the negative efects of extreme weather.

Physical Chronic Risk

慢性实体风险

Extreme weatherPreventative and mitigation measures

极端天气预防和缓解措施

Sustained high temperature– Kep a First-aid kit convenient

– Kep cold water available 24 hours a day

持续高温– 在集团所有场所备有急救箱

– 全天24小时提供冷水

Climate-related Transition Risk

Transition riskRisk descriptionPotential Busines ImpactMitigation Measures

风险类型风险描述潜在的商业影响缓解措施

Legal and

policy risk

Local governments may enforce

stricter carbon emision reduction

policies, potentialy raising

the carbon emision costs for

enterprises’ production and

operations. This includes changes

to government policies, laws,

and regulations, such as carbon

pricing and renewable electricity

pricing.

– Increase operation

cost and potential for

litigation.

– Regular review of

relevant legislation.

– Set up near term target

to demonstrate the

Group’s decarbonisation

efort.

法律和政策风险所在地政府可能实施更加严格的

碳排放减少政策，可能增加企

业的碳排放成本相关于生产和营

运

– 增加营运成本－定期审查相关法规。

－设定近期目标，以展示

集团的减碳成果。

Technology RiskTechnological improvements that

suport the transition to a lower-

carbon system.

– Failing to upgrade

to more eficient,

sustainable,

or automated

technologies

could result in

higher operation

costs and reduced

competitivenes.

– Explore new

technologies, and

techniques.

– Adapt to changes in the

cost and availability of

raw materials and utilities

like renewable electricity,

water, and gas, including

the relevant costs of

securing and maintaining

suficient suply.

技术风险支持低碳化系统的技术改进– 未能升级到更高效、

可持续或自动化技术

可能导致高营运成本

和竞争力下降

－探索新技术和新方法。

－适应原材料和公用事业

（如可再生电力、水和

天然气）成本及供应情

况的变化，包括确保和

维持充足供应的相关成

本。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

Transition riskRisk descriptionPotential Busines ImpactMitigation Measures

风险类型风险描述潜在的商业影响缓解措施

Market and

reputation risk

Customers have increasingly strict

requirements for carbon emision

management of their supliers,

while the decarbonisation of

products and services may

become an important standard

for customers to chose from.

Products or services that are

not low-carbon may lead to a

decrease in demand.

There are stricter requirements

for transparent carbon emisions

information, and enterprises

ned to increase investment

in the management of related

performance. Por performance

in climate information disclosure

may lead to reputation damage,

declined stock price, or dificulties

in financing.

– There wil be a risk of

a decline in sales and

reputation if end-user

is geting more prefer

on environmentaly

friendly products or

services and we do not

have these options for

our customers.

– Expand the product/

service range to cater

to a broader audience

and adapt to changing

customer preferences,

including eco-

friendly and ethicaly

produced lines to

atract environmentaly

conscious consumers.

– Obtain environmental

related certifications

like to demonstrate

comitment to

sustainability.

– Adopt environmentaly

friendly production

proceses, such as waste

reduction and circularity

programs.

市场和声誉风险顾客对供应商的碳排放管理要求

日益严格，商品和服务的去碳

化可能成为顾客选择的重要标

准，非低碳商品可能导致需求

下降。需要对碳排放信息进行

更加透明的要求，企业需要增

加相关表现的投资。披露气候

相关信息表现差可能导致声誉受

损、股票价格下跌或融资困难。

－如果终端用户越来越

偏好环境友善的商品

或服务，我们不提供

这些选项给客户则存

在销售下降和声誉受

损的风险。

－扩展产品范围，以满足

更广泛的客群并适应不

断变化的客户偏好，包

括推出环保和道德生产

的产品线，吸引注重环

境的消费者。

－获取相关的环境认证，

以展示公司对可持续发

展的承诺。

－采用环保的生产流程，

例如减少废弃物和推行

循环经济计划，促进更

可持续的生产方式。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

气候变化机遇

本集团知道气候变化不仅带来一系列实体及过

渡风险，也为我们的业务提供新兴机遇。措施

如提高能源效益、增加可再生能源使用率、过

渡到可持续资源管理的实务以及采用绿色低碳

技术等不仅直接节省成本，还减少能源支出。

我们预计未来长期监管框架和碳交易将带来机

遇。这些机制将使我们能够探索利用可持续金

融工具应对气候变化的替代方法。随著全球经

济向碳中和转型，我们将继续致力于评估和管

理与我们的业务相关的气候相关风险和机遇。

风险评估和管理

我们更新了根据《气候相关财务披露工作小组》

(TCFD)的建议而进行的气候情景分析评估方

法，在两种综合情景下，重新对本集团在香

港、中国和日本的业务单位的气候风险和机遇

进行评估。根据对气候风险的重新评估，我们

亦对各业务领域的缓解措施作出相应更新。下

文概述我们在气候风险评估过程中采用的情景

和假设这两个整合的气候情景是基于公开可用

的情景构建的，资料来源包括气候变化政府间

专门委员会（「IPC」）、国际能源署（「IEA」）以

及金融系统绿色化网络（「NGFS」）。根据我们对

气候风险评估结果的重新评估，我们已在各个

运营领域更新了减缓措施。以下将概述在我们

气候风险评估中所采用的情景和假设。

Climate-related Oportunities

The Group recognises that climate change not only presents

a range of physical and transitional risks, but also provides

emerging oportunities for our busineses. Measures such

as improving energy eficiency, increasing the utilisation

of renewable energy, transitioning to sustainable resource

management practices, and adopting gren and low-carbon

technologies have not only resulted in direct cost savings but

also a reduction in energy expenses.

Loking ahead, we anticipate the oportunities that wil arise

from long-term regulatory frameworks and carbon trading. These

mechanisms wil enable us to explore alternative aproaches

to combat climate change, leveraging sustainable financial

instruments. As the global economy transitions towards carbon

neutrality, we remain comited to asesing and managing

the climate-related risks and oportunities asociated with our

busines.

Risk Asesment and Management

We have updated the asesment methodology through

a climate scenario analysis to reases climate risks and

oportunities acros our operations in Hong Kong, the PRC and

Japan under two consolidated scenarios in acordance with

Task Force on Climate-related Financial Disclosure (“TCFD”)

recomendations. The two consolidated climate scenarios

are constructed based on public available scenarios which

include Intergovernmental Panel on Climate Change (“IPC”),

International Energy Agency (“IEA”) and Network for Grening

the Financial System (“NGFS”). Based on the revaluation of our

climate risk asesment results, we have updated our mitigation

measures acros various operational area. The folowing outlines

the scenarios and asumptions employed during our climate risk

asesment.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

通过深入了解影响我们价值链各环节的重大气

候风险，我们制定了有效的策略和措施来管理

这些风险，减轻其对财务和非财务方面的影

响。在我们的框架内，我们承认气候变化是一

个战略性的商业风险，并将与气候相关的风险

和机遇整合到我们的整体业务策略中。我们的

目标是通过全面评估、管理和监控可能影响我

们业务运作的气候风险，提高长期韧性。

指标和目标

本集团致力有效管理及评估气候变化带来的风

险及机遇。于报告年内，我们持续监测重要指

标，特别是温室气体排放量，此乃评估气候相

关风险的关键指标。

Consolidated ScenarioBrown ScenarioTurquoise Scenario

综合情景棕色情景绿松色情景

TimeframeShort-term – til 2030

Medium to long-term – til 2100

时间范围短期至2030年

中长期至2100年

Global Mean TemperatureGlobal mean temperature rises of above 3°C

by 2100

Global mean temperature rises of 1.5 to

2°C by 2100

全球平均温度到2100年全球平均温度上升超过3°C 到2100年全球平均温度上升1.5至2°C

Scenario DescriptionThe scenario represents the future that only

curent policies and nationaly determined

contribution are implemented with limited

investments and climate actions to

decarbonise. This would usualy lead to

high level of physical risk and low level of

transition risk.

The scenario represents the future that

stringent and imediate policies wil

be implemented by the companies that

are actively comited to climate action

goals. This would usualy result in high

level of transition risks and low level of

physical risks.

情景假设此场景代表只有落实现有措施或国家自主

贡献的未来，并对脱碳进行有限度投资及

气候行动。这通常会导致高实体风险和低

过渡风险。

此场景代表企业积极承诺气候行动目标

的同时，政府实施严格及即时政策的

未来。这通常会导致高过渡风险和低

实体风险。

By gaining insight into the significant climate risks that afect

our busines acros our value chain, we can develop efective

strategies and measures to manage these risks and mitigate

their financial and non-financial impacts. Within our framework,

we acknowledge climate change as a strategic busines risk

and have integrated climate-related risks and oportunities into

our overal busines strategy. Our objective is to enhance long-

term resilience by comprehensively asesing, managing, and

monitoring climate risks that may impact our operations.

Metrics and Targets

We strive to efectively manage and evaluate the risks and

oportunities arising from climate change. Throughout the

Reporting Period, we maintained continuous monitoring of key

metrics, specificaly GHG emisions, which serve as indicators of

climate-related risks. These targets aim to reduce overal GHG

emisions and electricity consumption.

2025
二零二五年
55,849
1,093
54,756
20

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

附注4：范围1指的是集团拥有的车辆所产生的直

接排放。

附注5：范围2指的是由于购买的电力（在集团内消

耗）所产生的间接排放。

Grenhouse Gases (GHG) Emision

Grenhouse gases (GHG) include carbon dioxide (CO2) and its

non-hazardous equivalents including nitrous oxide and methane

(colectively with CO2, “CO2e”). The Group has established an

emision reduction pathway with a long-term perspective as a

directional target. The primary source of GHG emision of the

Group is from purchased electricity and secondarily from the fuel

consumption by company vehicles.

The table below recorded and compared the Reporting Period

and the Last Reporting Period’s resultant GHG emisions in Hong

Kong, the PRC and Japan:

Year ended 31 March

截至三月三十一日止年度

GHG EmisionsUnit2024Changes

温室气体排放

附注(1)

单位二零二四年变化

Total GHG emisions (Scope 1 and 2)CO2e kg67,353-17.08%

温室气体排放总量（范围1和2）二氧化碳当量（公斤）

Scope 1

Note (4)

CO2e kg1,361-19.69%

范围1

附注(4)

二氧化碳当量（公斤）

Scope 2

Note (5)

CO2e kg65,992-17.03%

范围2

附注(5)

二氧化碳当量（公斤）

Intensity (Scope 1 and 2) per m

flor

space of Hong Kong, the PRC and

Japan ofices

CO2e kg/m

32-37.50%

密度（范围1和2）╱香港、中国和日

本办公室面积

二氧化碳当量（公斤）╱平方米

Note 4: Scope 1 refers to direct emisions from vehicles that the

Group owns.

Note 5: Scope 2 refers to indirect emisions resulting from the

generation of purchased electricity (consumed within the

Group).

温室气体（「GHG」）排放

温室气体(GHG)包括二氧化碳(CO2）及其无害等

效物，包括一氧化二氮及甲烷（与CO2统称二氧

化碳当量）。本集团已建立了以长远眼光为方

向目标的减排途径。本集团的温室气体排放量

的主要来源是购置的电力，其次是公司车辆的

燃料消耗。

下表记录并比较报告期和上一个报告期在香

港、中国和日本所产生的温室气体排放量：

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

在来年，本集团的目标是至少维持现有的温室

气体排放水平，如果可能的话，进一步将其降

低1-2%。

在报告期内，本集团的业务运营和活动未引发

或参与任何可能影响气候或导致气候显著变化

的事件或问题。本集团已经采取措施，旨在降

低未来一年的间接二氧化碳排放和淡水消耗。

B. 企业社会责任

1.1 社会范畴概览

本集团遵循诚信和透明的原则行事，旨在支持

和谐社会的建设，并与我们的持份者，包括员

工、客户、供应商、专业服务提供者、当地

社群以及管理机构建立互利的关系。在制定和

实施我们的环境、社会和管治策略、政策、

规则和条例的过程中，我们结合长期及短期目

标，顾及持份者及社会。本集团相信，我们的

绵薄之力终可使持份者和整体社会受益。

1.2 雇佣及劳工常规层面

B1. 雇佣

作为一家具有社会责任感的企业，本集团不仅

对客户负责，还对员工负责。在追求实现经济

目标的同时，本集团还须承担社会责任，以

实现可持续发展。本集团重视员工，因为员

工是成功的关键。本集团承诺实施透明和公平

的征聘制度，为所有工作人员提供一个不受歧

视的工作场所以及平等的机会。本集团严格遵

守劳动法律法规，包括但不限于《中华人民共

和国劳动合同法》、《中华人民共和国社会保险

法》、《最低工资条例》（香港法例第608章）、《强

制性公积金计划条例》（香港法律第485条）及其

他对本集团有重大影响的相关法律法规，并采

取切实有效的措施保障员工权益。

In the coming year, the Group targets to at least maintain and if

posible, continue to reduce its GHG emisions by 1-2%.

For the Reporting Period, the Group’s busines operations and

activities did not lead or participate in any events or isues that

might impact the climate or result in the change of the climate

significantly. The Group has already taken measures to lower

indirect CO2 emision and fresh water consumption for the

coming year.

B. SOCIAL ASPECTS

1.1 Social Areas Overview

The Group acts in an honest and transparent principle and

aims to suport the building of a harmonious society and a

mutualy beneficial relationship with our stakeholders including

employes, customers, supliers, profesional services providers,

local comunities as wel as the governing authorities. During

the formulation and implementation of our ESG strategies,

policies, rules and regulations, the Group incorporates our long

and short-term goals with consideration for our stakeholders and

society. The Group believes that our modest acts wil ultimately

benefit the stakeholders and general society.

1.2 Employment and Labour Practices Aspects

B1. Employment

As an enterprise with social responsibility, the Group shal not

only be acountable to its customers, but also to its employes.

When seking for acomplishment of economic targets, the

Group also asumes responsibility to the society, which in turn

enables it to achieve sustainable development. The Group

values its employes as they are key to its suces. It comits

to implement a transparent and fair recruitment system and

provide a working place without discrimination and with equal

oportunities for al staf. The Group strictly complies with the

laws and regulations related to labour including but not limited

to the Labour Contract Law of the PRC (《中华人民共和国劳动合

同法》), the Social Insurance Law of the PRC (《中华人民共和国

社会保险法》), Minimum Wage Ordinance (Cap 608 of the laws

of Hong Kong), Mandatory Provident Fund Schemes Ordinance

(Cap 485 of the laws of Hong Kong) and other relevant laws and

regulations that have a significant impact on the Group, and

takes practical and efective measures to protect employes’

rights.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

本集团致力于消除工作场所的偏见和歧视，并

禁止其雇员歧视：(i)在规定的活动领域内以性

别，婚姻状况，怀孕或母乳喂养为由的人；(i)

在规定的活动领域内以残疾为由的人；及(i)以

家庭状况为由的人（「家庭状况」是指对直系亲

属负有照顾义务的状况，而「直系亲属」又指与

某人有血缘、婚姻、收养或亲缘关系的人）。

集团员工也必须禁止以种族为由进行歧视、骚

扰和诽谤。本集团遵守其子公司所在司法管辖

区的反歧视法。

本集团的员工年假和福利待遇参照当地劳动法

执行。本集团根据个人的工作表现，以公平的

薪酬奖励员工，以激发他们的工作热情。此外

本集团还采取激励制度，根据该制度，管理层

的薪酬与本集团的经营业绩有关，为本集团的

管理层提供合理的奖励。

The Group is comited to eliminating prejudice and

discrimination in the workplace and prohibiting its employes

to discriminate against: (i) a person on the ground of gender,

marital status, pregnancy or breastfeding in prescribed areas

of activities; (i) a person on the ground of disability when

comited in prescribed areas of activities; and (i) a person on

the ground of family status. “Family status” means the status

of having a responsibility for the care of an imediate family

member, and “imediate family member”, in turn, means a

person who is related to someone by blod, mariage adoption

or afinity. The employes of the Group must also be prohibited

from their acts of discrimination, harasment, and vilification on

the ground of someone’s race. The Group complies to the anti-

discrimination laws in the jurisdictions of its subsidiaries located.

Staf anual leaves and benefit packages of the Group were

enforced with reference to the local labour laws. The Group

rewards employes with fair remuneration based on an

individual’s work performance in order to inspire their working

enthusiasm. Further, the Group adopts an incentive system under

which the management’s remuneration is related to the Group’s

operating results, which provides reasonable rewards to the

managements of the Group.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

截至二零二五年三月三十一日，本集团在香

港、中国和日本共雇用了一百三十五名员工，

其中一百三十人是全职员工，五人是兼职员

工。本报告期和上一个报告期的雇佣情况明细

概述如下：

As of 31 March 2025, the Group employed 135 employes in

Hong Kong, the PRC and Japan, among which 130 are ful-time

stafs and 5 are part-time stafs. Further analysis of the Group’s

employment situations for the Reporting Period and the Last

Reporting Period are sumarised as below:

MaleFemale

二零二五年

二零二四年

男性女性

Ful timePart time

全职兼职

二零二五年

二零二四年

Figure 1: Number of Employes by GenderFigure 2: Number of Employes by Employment Type

图一：按性别划分的雇员人数图二：按就业类型划分的雇员人数

General

Staf

Senior

Management

Midle

Management

基层员工中层管理人员高级管理层

二零二五年

二零二四年

Under 3051 or above

31-40

41-50

30岁或以下31-40岁41-50岁51岁或以上

二零二五年

二零二四年

Figure 3: Number of Employes by RoleFigure 4: Number of Employes by Age

图三：按职级划分的雇员人数图四：按年龄划分的雇员人数

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

于报告期内，概无发生任何对本集团构成重大

影响，有关补偿及辞退、招聘及晋升、工作

时数、休息时间、平等机会、多元化、反歧

视以及其他福利的相关法律及规定的不合规事

件。本集团相信我们于来年将可取得相同成

果。

The PRCJapan

Hong Kong

中国香港日本

二零二五年

二零二四年

Figure 5: Number of Employes by Geographical Region

图五：按地区划分的雇员人数

During the Reporting Period, the Group did not have any

incidents of non-compliance with relevant laws and regulations

that have a significant impact on the Group relating to

compensation and dismisal, recruitment and promotion,

working hours, rest periods, equal oportunity, diversity, anti-

discrimination, and other benefits and welfare. The Group is

confident to achieve the same result for the coming year.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

下表分别按性别、年龄组别及地区列出在本报

告期内的雇员流失率：

The table below shows the employe turnover rate of the

busines segment under our reporting scope by gender, age

group, and geographical region, respectively.

12.00%

12.50%

13.00%

13.50%

14.00%

14.50%

15.00%

15.50%

16.00%15.79%

Female

13.33%

Male

男性女性

0.00%

5.00%

10.00%

15.00%

20.00%

25.00%

17.65%

31-40

0.00%

Under 30

22.00%

3.57%

41-50

51 or

above

30岁或以下31-40岁41-50岁51岁或以上

Figure 6: Employment Turnover Rate by GenderFigure 7: Employment Turnover Rate by Age

图六：按性别划分的雇员流失比率图七：按年龄划分的雇员流失比率

0.00%

2.00%

4.00%

6.00%

8.00%

10.00%

12.00%

14.00%

16.00%

18.00%

16.67%

9.38%

The PRCJapan

16.33%

Hong Kong

中国香港日本

Figure 8: Employment Turnover Rate by Geographical Region

图八：按地区划分的雇员流失比率

To the best knowledge of the Directors, there is no material

violation of relevant standards, rules and regulations regarding

remuneration and dismisal, recruitment and promotion, working

hours, holidays, fair oportunity, diversity and other remuneration

package and benefits during the Reporting Period.

据董事们所知，报告期内并无违反任何有关薪

酬与解雇、招聘与晋升、工作时数、假期、

平等机会、多元化及其他薪酬待遇和福利的相

关法律、法规及规例。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

B2. 健康与安全（「OHS」）

为加强对员工健康及安全的关怀，本集团通过

建立安全管理监察程序，为所有员工建立安全

及健康的工作环境。本集团严格遵守有关就业

及劳动保护的相关法律及法规，包括但不限于

《职业安全及健康条例》（香港法例第509章）、

《劳动基准法》（1947年4月7日第49号修订）、《劳

工安全卫生法》（1972年第57号法例）和《劳动契

约法》（2007年12月5日第128号法）。

在过去三年中，包括报告期间在内，本集团并

没有录得工伤死亡事故或因工伤而损失的工作

日数。董事知悉，在报告期间内，就提供安全

工作环境及保障雇员免受职业损害方面，并无

严重违反相关法例及规例。

本集团将员工的健康和安全作为首要任务，

并及时采取行动和措施来保护和防止员工被感

染。本集团采取的卫生措施如下：

、酒精类消

毒剂和紫外线烘手器；

• 如果员工出现呼吸道症状或体温高于37.5

摄氏度，则需要就医。

董事会将继续确保遵守所有适用的法律规章制

度。

B2. Ocupational Health and Safety (“OHS”)

To indicate its care for employe’s health and safety, the Group

established a safe and healthy working environment for al

employes by establishing monitoring procedures for safety

management. The Group strictly complies with relevant laws

and regulations regarding employment and labour protection

including but not limited to Ocupational Safety and Health

Ordinance (Chapter 509) of the laws of Hong Kong, the Labour

Standard Act (Act No. 49 of April 7, 1947, as amended), the

Industrial Safety and Health Act (Act No. 57 of 1972, as amended),

and the Labor Contract Act (Act No. 128 of December 5, 2007).

In the past thre years including the Reporting Period, no work-

related fatalities or lost days due to work injury were recorded.

To the best knowledge of the Directors, there is no material

violation of relevant laws and regulations regarding provision

of safe working environment and protecting employes from

ocupational damage during the Reporting Period.

The Group places health and safety of its employe as its highest

priority and has taken timely actions and measures to protect

and prevent its employes from being infected. The hygiene

measures adopted by the Group are as folows:

alcohol-based sanitisers and ultraviolet light hand dryer;

• Employes are required to wear a face mask in the ofice if

they are not feling wel; and

• If an employe has respiratory symptoms or body

temperature higher than 37.5 degre celsius, they are

required to sek for medical treatments.

The Board wil continue to ensure to comply with al aplicable

laws, rules and regulations.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

B3. 发展及培训

本集团为员工提供职业发展机会。本集团员工

可根据其工作能力，从初级职位晋升至高级职

位来促进个人发展。

本集团为初级职位的新员工提供在职培训。特

别是，我们指定具有足够经验的员工为新员工

提供指导，以协助他们的工作，旨在提高新员

工作所需的专业知识和技能，并帮助他们尽

快适应集团的运营和文化。于报告期间内，本

集团为董事及高级管理层举办了有关(i)可持续

发展全球趋势；及(i)科技安全管理的培训课程

及研讨会。此外，本集团的设计及营销、采购

及销售部门的部分员工参加了一系列材料及产

品的学习培训，内容涵盖产品种、针织品的

功能及服装产品趋势等主题，协助员工提升有

关服装行业方面的知识及业务能力。

B3. Development and Training

The Group provides ocupational development oportunities for

its employes. Employes of the Group may pursue, depending

on their working capabilities, personal developments by means

of promotion from junior to senior positions.

The Group provides on-the-job trainings for the new employes

serving the junior positions. In particular, employes with

adequate experience are designated to provide guidance to

new employes to asist with their works, aiming to improve

new employes’ expertise and skils as required for works and to

asist them to adapt to the operations and culture of the Group

as son as posible. During the Reporting Period, the Group

organised training sesions and seminars relating to (i) global

trend on sustainable development; and (i) security management

of information and technologies for the Directors and senior

management of the Group. Further, certain employes amongst

design and promotion, procurement and merchandising

departments of the Group participated in a series of trainings

in learning of materials and products covering the topics such

as product variety, functions of knitwear materials and trends of

aparel products to help employes improve their knowledge in

the aparel industry and busines capabilities.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

本报告期和上一个报告期的受训雇员百分比明

细如下：

The participation rates of training of the Group during the

Reporting Period and the Last Reporting Period are tabulated as

folows:

Training (No. of employes)InternalExternal

受训雇员数目内部培训外部培训

Percentage of employes trained受训雇员百分比

2025二零二五年–8.89%

2024二零二四年–8.09%

Percentage of trained employes by gender按性别划分受训雇员百分比

Male男性

2025二零二五年–16.67%

2024二零二四年–18.18%

Female女性

2025二零二五年–83.33%

2024二零二四年–81.82%

Percentage of trained employes by

operational role

按职级划分受训雇员百分比

Senior management高级管理层

2025二零二五年–8.33%

2024二零二四年–18.18%

Midle management中层管理人员

2025二零二五年–33.33%

2024二零二四年–81.82%

General staf基层员工

2025二零二五年–58.33%

2024二零二四年–

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

本报告期和上一个报告期的雇员培训时数明细

如下：

The training hours of the Group during the Reporting Period and

the Last Reporting Period are tabulated as folows:

Average training hours per employeInternalExternal

每位员工平均受训时数内部培训外部培训

Total average training hours per employe每名雇员的平均培训时数

2025二零二五年–5.31

2024二零二四年–3.75

按性别划分的每名雇员完成

的平均培训时数

Average training hours for male男性

2025二零二五年–2.51

2024二零二四年–2.34

Average training hours for female女性

2025二零二五年–6.45

2024二零二四年–4.36

按职级划分的每名雇员完成

的平均培训时数

Average training hours for senior management高级管理人员

2025二零二五年–2.40

2024二零二四年–7.09

Average training hours for midle management中层管理人员

2025二零二五年–10.95

2024二零二四年–18.57

Average training hours for general staf基层员工

2025二零二五年–4.49

2024二零二四年–

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

B4. 劳工标准

本集团充分意识到，童工和强制劳工侵犯了基

本人权，也对可持续的社会和经济发展构成威

胁。本集团严格遵守相关法律法规，包括但不

限于《中华人民共和国劳动法》、《中华人民共

和国劳动合同法》、《中华人民共和国禁止使用

童工规定》及《雇佣条例》（香港法例第57章）。

本集团亦严格遵守有关最低工作年龄的相关法

律及规例。本集团按照社会责任管理的要求和

规定，妥善处理童工问题，禁止各部门聘用童

工。

本集团制定了强制劳工及奴隶劳动的管理政

策，禁止任何强制劳工，并规定本集团雇员必

须自愿受雇，承诺(i)不得有强迫行为；(i)不得

以欺骗性手段吸引工人到本集团工作；及(i)不

得威胁，惩罚或从员工那里获得任何利益或强

制员工作。

本集团严格禁止使用任何童工及强制劳工。为

了防止企业经营中出现任何形式的童工现象，

只能雇佣达到法定就业年龄的员工。新员工在

受雇时必须提供真实准确的个人信息。招聘人

员应严格审查所录入的资料，包括体检报告、

学历证明、身份证、户籍、学位证书等信

息。本集团已设立全面的招聘程序，检查候选

人的背景，以防止任何童工或强制劳工。一旦

发现任何违规行为，本集团将根据实际情况，

以严肃的方式跟进，并按照国家和地方法律法

规以及集团内部规则处理此类案件。例如，我

们会及时了解孩子的教育状况，并及时联系当

地教育部门及其监护人，为孩子保驾回家。

于报告期间内，本集团已遵守有关防止童工及

强制劳工的政策及相关法律法规。

B4. Labour Standards

The Group is fuly aware that child labour and forced labour

violate fundamental human rights and also pose threat to

sustainable social and economic development. The Group

strictly complies with relevant local labour laws and regulations

including but not limited to the Labour Law of the PRC,

the Labour Contract Law of the PRC, the Provisions on the

Prohibition of Using Child Labor of the PRC and the Employment

Ordinance (Cap 57 of the Laws of Hong Kong). The Group also

strictly complies with relevant laws and regulations in respect of

minimum working age. The Group properly handled child labour

isues in acordance with requirements of social responsibility

management and regulations to prohibit al departments to

employ child labour.

The Group established management policy for forced labour

and captive labour to prohibit any forced labour and regulate

that employe of the Group must be employed voluntarily,

undertaking that (i) no forced acts shal be alowed; (i) no

deceptive means shal be aplied in atracting workers to work

in the Group; and (i) no threats, punishments or to gain any

benefit from employes or force employes to work.

The Group strictly prohibits the employment of any child labour

and forced labour. To prevent and any form of child labour in the

busines operation, employment wil only be permited for staf

at the legal age of employment. New employes are required to

provide true and acurate personal data when they are employed.

Recruiters should strictly review the entry data including medical

examination reports, academic credentials, ID cards, household

registration, degre certificates and other information. The Group

has established comprehensive recruitment procedures to check

the background of candidates in order to prevent any child

labour or forced labour in operation. Once any violation is found,

the Group wil folow up in a serious maner and handle such

case in acordance with national and local laws and regulations,

and the Group’s internal rules depending on the actual situation.

For example, we wil timely understand the child’s education

status, and timely contact the local education department and its

guardian to escort the child home.

During the Reporting Period, the Group has complied with

policies and relevant laws and regulations regarding prevention

of child labour or forced labour.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

B5. 供应链管理

为将本集团的资源集中于提供IRO、CRO及服

装供应链管理服务，本集团并不拥有或经营任

何制造业务。相反，本集团将劳动密集型制造

流程外包给在中国、泰国和╱或柬埔寨设有制

造业务的第三方制造商。本集团致力改善其业

务。本集团已建立挑选第三方制造商的程序和

完整的监控系统，包括但不限于考察第三方制

造商为其客户生产品的能力及效率。此外，

我们评估第三方制造商是否考虑环境和社会标

准，包括禁止招聘童工和强制劳工，消除员工

歧视，提供安全的工作环境，考虑所提供的产

品和服务是否有利于环境保护并满足本集团的

内部环境要求，同时尽量减少对自然环境的负

面影响，并严格遵守法律。本集团的运作模式

是管理不同规模的第三方制造商，本集团不与

第三方制造商签订任何长期合同，本集团视乎

客户的需求和要求，因人制宜选择聘用方。本

集团设定标准和目标，并提供数据分析，以衡

量其业务的绩效，包括但不限于环境和社会绩

效。此外，本集团与纱线供应商、第三方制造

商及客户紧密合作，确保在其业务各阶段按照

客户需求提供最新资讯，并关注市场需求的讯

息，做出相应的改进。

B5. Suply Chain Management

To focus the Group’s resources on the provision of IRO, CRO

and aparel suply chain management services, the Group does

not own or operate any manufacturing operations. Instead,

the Group outsourced the labour intensive manufacturing

proceses to third-party manufacturers with manufacturing

operations in the PRC, Thailand and/or Cambodia. The Group

strives to improve its busineses. The Group has established

procedures and a complete monitoring system for selection

of third-party manufacturers including but not limited to the

ability and eficiency of third-party manufacturers to produce

products for its customers. In adition, we evaluate if third-party

manufacturers consider the environmental and social criteria

including the prohibition on the recruitment of child and forced

labour, eliminating discrimination to employes, providing a safe

working environment, considering if the products and services

provided are beneficial to environmental protection and fulfiling

the Group’s internal environmental requirement while minimising

the negative impact to natural environment, and strictly obeying

the law. The operation model of the Group is to manage the

third-party manufacturers of diferent scales, the Group does not

enter into any long term contracts with third-party manufacturers

and the Group engages them on a case-by-case basis depending

on the neds and requirements of customers. The Group sets

standards and goals and provides data analysis to measure the

performance of its busineses, including but not limited to the

environmental and social performance. In adition, the Group

closely coperates with yarn supliers, third-party manufacturers

and customers to ensure the provision of the latest information

on customer demands at every stage of its busineses, and

pays atention to the signal of market demands and makes

coresponding improvements.

2025
二零二五年
24
165
291
480

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

下表记录报告期和上一个报告期按地理位置划

分的供应商数量：

The folowing is an analysis of the Group’s number of supliers

by geographical location for each of the year ended 31 March

2024 and 31 March 2025:

Year ended 31 March

截至三月三十一日止年度

Number of supliers

by geographical location按地理位置划分的供应商数量

二零二四年

Hong Kong香港35

The PRC中国91

Others其他213

Total共计339

The Group set up strict guidelines to prevent any employe,

outsourcing contractor or suplier from breaching the anti-

coruption guideline requirements by implementing apropriate

disciplinary punishment(s). The Group also stated in its anti-

coruption policy that it wil not work with supliers who

had previously violated the anticoruption requirements. As

mentioned above, the Group conducts analysis to continuously

measure the environmental and social performance of its suply

chains.

The Group complied with the child labour and forced labour

law. Supliers were also required to comply with the same. The

Group also requires supliers to comply with al relevant laws

and regulations to ensure health and safety of employes in al

operating conditions and environment.

B6. Product Responsibilities

Compliance with relevant laws and regulations

The Group is not aware of any material non-compliance with

relevant laws and regulations, including but not limited to the

Product Quality Law of the PRC, the Trademark Law of the PRC,

the Advertising Law of the PRC, the Sale of Gods Ordinance (Cap

26 of the Laws of Hong Kong), the Trade Descriptions Ordinance

(Cap 362 of Laws of Hong Kong) and the Trade Marks Ordinance

(Cap 559 of the laws of Hong Kong), that have a significant

impact relating to health and safety, advertising, labeling and

privacy maters regard to products and services provided by the

Group during the Reporting Period.

本集团设立严格的指引，通过实施适当的纪律

处分，防止任何员工、外包承包商或供应商违

反贪污指引的规定。本集团还在反贪污政策

中表示，不会与曾违反贪污规定的供应商合

作。如上所述，本集团会持续衡量其供应链的

环境和社会绩效。

本集团遵守童工和强制劳工法，且要求供应商

遵守同样的规定。本集团还要求供应商遵守所

有相关法律法规，以确保员工在所有操作条件

和环境下的健康和安全。

B6. 产品责任

遵守相关法律和法规

在报告期内就本集团提供的产品及服务，本集

团并没有对健康及安全、广告、标签及私隐事

宜有重大影响的任何违法行为，包括但不限于

《中华人民共和国产品质量法》、《中华人民共

和国商标法》、《中华人民共和国广告法》、《货

品售卖条例》（香港法例第26章）、《商品说明条

例》（香港法例第362章）及《商标条例》（香港法

例第559章）。

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

品质控制

作为服装供应链管理服务的供应商，本集团的

服务涵盖从选择原材料到将成品最终交付给客

户指定装运港的整个供应链。本集团重视其针

织品质。且董事们确信，对针织品质的高

标准控制，是本集团成功的关键因素之一。在

整个供应链中建立了严格的品质控制程序，例

如在运送成品至本集团客户之前由第三方检查

中心对成品进行检查，并按照生产计划监控生

产过程，以确保所供应的针织品的质量始终如

一的可靠和高标准。

为确保针织品的品质符合客户的要求，本集团

会对第三方制造商在生产过程的各个阶段的半

成品进行随机抽查。为确保颜色符合客户的要

求及标准，本集团会通过颜色检查灯箱对半成

品及成品的颜色进行目视检查。产品质量控制

人员将检查半成品是否没有重大缺陷，并确保

针织图案符合客户的设计和规格。在包装交付

之前，所有成品将由第三方检查中心检验。任

何不符合标准的产品将通知第三方制造商进行

整改。

于报告期内，本集团已遵守产品责任的相关规

定，并无因安全及健康理由而须回收的已售或

已运送产品。

Quality Control

As an aparel suply chain management services provider, the

Group’s services encompas the total suply chain from the

selection of raw materials until the final delivery of finished

products to the customers at their designated port of shipment.

The Group places great emphasis on the quality of its knitwear

products and the Directors believe that the comitment to the

high standard for quality control of its knitwear products is one

of the key factors contributing to the Group’s suces. Stringent

quality control procedures such as inspection of the finished

products by a third-party inspection center prior to shiping to

the Group’s customers and monitoring the production proces

by keping a production schedule have ben established

throughout the total suply chain so as to ensure the quality

of the knitwear products is suplied in consistently reliable and

high standard.

To ensure that the quality of the knitwear products is in

conformity with the customers’ specifications, the Group wil

perform random checks on semi-finished products produced by

the third-party manufacturers at various stages of the production

proces. To ensure that the colour conforms to the customers’

specifications and standards, the Group wil visualy inspect the

colour on the semi-finished and finished products with colour

check light box. The merchandising quality control staf wil

check whether the semi-finished products are fre from major

defects and to ensure that the kniting paterns conform with

the customers’ designs and specifications. Before packaging for

delivery, al finished products wil be checked by a third-party

inspection centre. Any products that fail to met the standards

wil be notified to the third-party manufacturers for rectification.

During the Reporting Period, the Group has complied with the

relevant requirements on product liabilities and there is no

product sold or shiped subject to recal for safety and health

reasons.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

客户服务和产品退货

本集团所有针织品均接受第三方检验中心的最

终检验，以确保针织品符合客户的规格和要

求。然而，作为一家负责任的供应链管理服务

供应商，为维护本集团的商誉及与客户的业务

关系，本集团会调查每一例事件，并向客户

提供解决方案以解决该事件。我们一直鼓励客

户通过服务热线和社交媒体平台提供反馈和意

见。在报告期内，我们没有接获客户就我们产

品的质量提出的任何重大索赔或投诉，也没有

发生过对我们的业务运营产生重大影响和不利

影响的品质控制程序失败事件。

知识产权

作为IRO、CRO及服装供应链管理服务提供商，

本集团尊重知识产权。本集团致力于保护客户

的商标和专利，并限制任何人将商标和专利用

于任何未经授权的目的。我们严格遵守所有与

知识产权相关的法律法规，如《中华人民共和

国商标法》和香港条例之《商标条例》。本集团

制定了保护本集团及其客户的知识产权政策及

程序。产品设计草图及说明书可能包含有关本

集团客户专有产品设计的机密资料。每位客户

的此类机密文件将存储在指定位置，并且只有

负责该客户的销售团队，设计人员和授权人员

才能访问此类信息。本集团员工不得复制或公

布与本集团及或其客户的产品设计有关的任何

信息。任何载有本集团或其客户的草图及或产

品设计的废纸，均须在本集团的设计登记册上

登记，并在销毁前交由行政部门集中管理。

本集团已成立内部管理团队，负责监察上述政

策的实施情况，并侦查其他人员或本集团的任

何侵权行为。

Customer Service and Product Return

Al of the Group’s knitwear products are subject to final

inspections by third-party inspection centers to ensure that

the knitwear products are in conformity with the customers’

specifications and requirements. Nevertheles, as a responsible

suply chain management services provider and in order to

maintain the Group’s godwil and the busines relationships

with its customers, the Group would investigate every incident

and ofer solutions to its customers to resolve such incident.

Customers are always encouraged to give their fedback and

opinions via service hotline and social media platforms. During

the Reporting Period, we did not receive any material claims

or complaints by our customers in respect of the quality of our

products and there was no incident of failure of our quality

control procedures which had a material and adverse impact on

our busines operations.

Intelectual Property Rights

As an IRO, CRO and aparel suply chain management services

provider, the Group respects intelectual property rights. The

Group is comited to protecting trademarks and patents of

customers and restricts any person from using the trademarks

and patents for any unauthorised purposes. We strictly abide by

al laws and regulations related to intelectual property, such as

the Trademark Law of the PRC and Trade Marks Ordinance of

Hong Kong. The Group has policies and procedures to protect

the intelectual properties of the Group and its customers. The

product design sketches and instruction shets may contain

confidential information regarding proprietary product designs

of the Group’s customers. Such confidential documents for each

of the respective customers wil be stored in the designated

place and only the responsible merchandising team, design

staf and authorised personel are alowed to aces such

information. The Group’s employes are forbiden to reproduce

or publicise any information related to the product designs of

the Group and/or its customers. Any waste paper containing

sketches and/or product designs of the Group or its customers is

required to record in the Group’s design register and provide to

the administrative department for central management before

destruction.

The Group has established an internal management team

responsible for monitoring the implementation of the

aforementioned policy and detecting any infringement by others

or by the Group.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

于报告期内，本集团并无发现本集团任何成员

侵犯或可能侵犯任何第三方拥有的知识产权，

亦未接获客户就侵犯其知识产权向本集团提出

的任何重大投诉或索赔。

隐私信息

在遵守相关隐私保护制度的前提下，本集团将

努力保护客户信息的隐私，并在员工培训和内

部会议中反复强调信息安全的重要性。未经本

集团相关授权，任何组织或人员不得访问客户

信息。本集团已成立内部管理团队，负责监察

上述程序的实施。

广告及标签

秉承其务实的原则，本集团不允许存在任何有

关其产品和服务的误导性、不准确及夸大性信

息。在销售过程中，我们确保有关我们的服务

和产品的描述均符合《中华人民共和国广告法》

和《商品说明条例》（香港法例第362章）以及政

府和行业协会制定的所有其他适用的法律和标

准。本集团已成立内部管理团队，负责监察上

述程序的实施。于报告期内，本集团并无收到

任何有关广告及标签方面的投诉。

During the Reporting Period, the Group was not aware of any

infringement or potential infringement by any member of the

Group of the intelectual property rights owned by any third

parties, and no material complaint was received and no claim

was made against the Group by its customers in relation to

infringement of their intelectual property rights.

Data Privacy

Subject to compliance with the relevant privacy protection

regime, the Group wil strive to protect the privacy of customer

information and repeatedly emphasise the importance of

information security in employe training and internal metings.

Any organisations or personel are prohibited to aces customer

information without relevant authorisation by the Group. The

Group has established an internal management team responsible

for monitoring the implementation of the aforementioned

procedures.

Advertising and Labeling

Adhering to its pragmatic principle, the Group does not alow

any misleading, inacurate and exagerating information about

its products and services. In the sale proces, we ensure that any

descriptions of our services and products are in compliance with

the Advertising Law of the PRC and Trade Descriptions Ordinance

(Chapter 362 of Laws of Hong Kong) and al other aplicable

laws and standards enacted by the government and industry

asociations. The Group has established an internal management

team responsible for monitoring the implementation of the

aforementioned procedures. During the Reporting Period, the

Group did not receive any complaint in relation to advertising

and labeling.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

ANUAL REPORT 2024/2025

2024/2025 年报

B7. 反贪污

秉承诚信和道德的原则，本集团制定了相关标

准并遵守有关法律法规，禁止雇员从供应商、

客户或与本集团旗下公司有业务或商业关系的

任何一方获得任何利益，或向该等公司提供利

益。本集团要求(i)所有员工遵守其商业行为和

道德准则；(i)禁止雇员利用其职位，向客户、

供应商或与本集团有业务往来的任何一方提供

任何奖励或其他利益，或从中获得任何奖励或

其他利益；及(i)所有与本集团有业务往来的供

应商或个人不得以任何方式向本集团的员工或

管理层提供任何商业贿赂或转让其他利益。

本集团要求所有员工遵守员工守则，并将适当

权力下放给每个职位的员工，以避免滥用职责

牟取暴利或涉嫌制造利益冲突。由于本集团的

业务涉及客户的个人信息，因此本集团制定了

员工保密守则和相关准则，以降低信息泄露的

风险。

本集团禁止员工未经本集团管理层事先批准，

擅自使用本集团各公司的印章，禁止超出本人

权限的签字，禁止批准签署或终止任何外部合

同，以及改变合同的履行情况。本集团的举报

及报告制度允许员工通过有效渠道向相关部门

主管报告任何可疑的失当或欺诈行为。本集团

管理层负责监督本集团有关防止贿赂、勒索、

欺诈及洗黑钱及上述程序的措施的实施及监察

过程。

本集团正在调拨资源安排反贪污培训，因此在

本报告期间没有开展培训。未来，我们将继续

投入更多资源开展反贪污培训，扩大反贪污培

训数据披露范围。

B7. Anti-coruption

The Group operates under integrity and moral principles. The

Group established relevant standards and complied with laws

and regulations, prohibiting employes from receiving any

benefits from the supliers, customers or any party having

busines or comercial relationship with companies under the

Group or ofering benefits to the same. The Group requires (i) al

employe shal comply with its code of busines conduct and

ethics; (i) employes are prohibited to, through taking advantage

of their positions, ofer any reward or other benefits to or receive

the same from customers, supliers or any party having busines

with the Group; and (i) al supliers or individuals dealing with

the Group shal not ofer any comercial bribe or transfer other

benefits by any means to employes or management of the

Group.

The Group requires every employe to comply with the code of

employes and delegates apropriate authority to employes

in every job position to avoid abuse of his or her duties for

profitering or suspected conflicts of interest. As the Group’s

busineses involve the customers’ personal data, the Group has

established confidentiality codes and relevant guidelines for the

employes to reduce the risk of information leakage.

The Group prohibits employes from using the company seal/

chop of each company of the Group without prior aproval

from the management of the Group, to sign beyond one’s

authority, and to aprove the signing of any external contract

or terminating it and to vary the performance of contracts. The

whistle-blowing and reporting system of the Group permits

employes to report any suspected misconduct or fraud to

relevant department head through efective chanels. The

management of the Group is responsible for overseing the

implementation and monitoring of the Group’s measures to

prevent bribery, extortion, fraud and money laundering and

abovementioned procedures.

The Group is in the proces of alocating resources to aranging

training on anti-coruption, and therefore no training is aranged

during the Reporting Period. Loking ahead, we wil continue to

invest more resource to our anti-coruption training and expand

the scope of anti-coruption training data disclosure.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

环境、社会及管治报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

于报告期内，本集团并无发现任何重大不遵守

有关防止贿赂、勒索、欺诈及洗黑钱法例的行

为，亦没有发现本集团或其雇员触犯贿赂、勒

索、欺诈及洗黑钱的法律案件。本集团的营

运符合有关反贿赂、勒索、欺诈及洗黑钱的

政策及相关法律规例，包括但不限于《中华人

民共和国公司法》、《中华人民共和国招标投标

法》、《中华人民共和国反不正当竞争法》及香

港条例之《打击洗钱及恐怖分子资金筹集条例》

及《防止贿赂条例》。

B8. 社区投资

本集团深知为社区带来资源，同时为经济和环

境作出贡献，长远而言将造福社会，因此本集

团一直致力为社会作出贡献，致力回馈社会。

报告期内，本集团一直鼓励员工参与支持节能

计划等环保措施，参与社区义工作。本集团

尚未安排捐款或慈善活动。未来，本集团将(i)

寻求机会与慈善组织合作，参与各种社区项目

并为社区做出贡献；(i)组织体育健身活动以促

进员工和客户的身体健康；及(i)向慈善机构捐

款。

During the Reporting Period, the Group did not identify any

material non-compliance of laws and regulations related to the

prevention of bribery, extortion, fraud and money laundering,

and there was no legal case regarding corupt practices,

extortion and money laundering brought against the Group

or its employes. The operations of the Group complied with

policies and relevant laws and regulations regarding anti-bribery,

extortion, fraud and money laundering, including but not limited

to the Company Law of the PRC, the Tendering and Biding Law

of the PRC, the Law Against Unfair Competition of the PRC and

Hong Kong’s Anti-Money Laundering and Terorist Financing

Ordinance and Prevention of Bribery Ordinance.

B8. Comunity Investment

In recognising that bringing resources to the comunity while

at the same time contributing to the economy and environment

would benefit the society in the long run, the Group is in the

proces of devoting time and efort to return to the society as it

has always encouraged its employes to take part in suporting

environmental protection initiatives such as energy saving

initiatives, and participating in volunter work for the comunity

during the Reporting Period, and there were no donation or

charitable campaign aranged. In the future, the Group wil (i)

sek oportunities to work with charitable organisations to get

involved in various comunity programes and to contribute

to the society; (i) promote the health of its employes and

customers by organising and taking part in sports and fitnes

activities; and (i) make donations to the charitable organisations.

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

The Directors hereby present this report and the audited

consolidated financial statements of the Group for the year

ended 31 March 2025.

PRINCIPAL ACTIVITIES

The principal activity of the Company is investment holding. The

major activities of its principal subsidiaries are set out in note

35 to the consolidated financial statements of the Group in this

anual report. There were no significant changes in the nature of

the Group’s principal activities during the year ended 31 March

2025.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE

The Environmental, Social and Governance Report of the

Company for the year ended 31 March 2025 contained the

information as required by the standards set out in Apendix C2

to the Listing Rules is disclosed on pages 64 to 106 of this anual

report.

COMPLIANCE WITH THE RELEVANT LAWS AND

REGULATIONS

As the Board is aware, there was no material breach of or

non-compliance with the aplicable laws and regulations by

the Group that had a significant impact on the busines and

operations of the Group for the year ended 31 March 2025.

RELATIONSHIP WITH STAKEHOLDERS

The Group’s relationship with its stakeholders is disclosed in the

section headed “Management Discusion and Analysis” on page

27 of this anual report.

董事谨此呈列本报告及本集团截至二零二五年

三月三十一日止年度之经审核综合财务报表。

主要业务

本公司之主要业务为投资控股。其主要附属公

司之主要业务载于本年报所载本集团综合财务

报表附注35。截至二零二五年三月三十一日止

年度，本集团之主要业务性质并无重大变动。

环境、社会及管治

本公司载有上市规则附录C2所载准则规定资

料之截至二零二五年三月三十一日止年度之环

境、社会及管治报告于本年报第64至106页披

露。

遵守相关法律及法规

据董事会所知，本集团于截至二零二五年三月

三十一日止年度并无严重违反或不遵守适用法

律及法规而对本集团之业务及经营造成重大影

响。

与持份者之关系

本集团与其持份者之关系于本年报第27页「管

理层讨论与分析」一节披露。

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

业绩及分派

本集团截至二零二五年三月三十一日止年度之

业绩及分派载于本年报第140页之综合损益及

其他全面收益表。

董事建议派付截至二零二五年三月三十一日止

年度之末期股息每股1.0港仙（截至二零二四年

三月三十一日止年度：无）。

物业、厂房及设备

本集团截至二零二五年三月三十一日止年度之

物业、厂房及设备变动详情载于本年报综合财

务报表附注14。

业务回顾

截至二零二五年三月三十一日止年度有关本集

团表现之讨论及分析中，影响其业绩及财务状

况之主要因素载于本年报「管理层讨论与分析」

一节。此外，有关本集团业务之公平回顾及揭

示相当可能出现之未来前景的指标载于本年报

「主席报告」及「管理层讨论与分析」章节。

主要风险及不确定因素

本集团之财务状况、经营业绩、业务及前景受

包括外币风险、利率风险、信贷风险及流动资

金风险等多项主要风险影响。本集团之金融风

险管理政策及常规于本年报综合财务报表附注

33中披露。

RESULTS AND APROPRIATIONS

The results and apropriations of the Group for the year ended

31 March 2025 are set out in the consolidated statement of profit

or los and other comprehensive income on page 140 of this

anual report.

The Directors recomended a final dividend of HK1.0 cent per

share for the year ended 31 March 2025 (for the year ended 31

March 2024: Nil).

PROPERTY, PLANT AND EQUIPMENT

Details of the movements during the year ended 31 March 2025

in the property, plant and equipment of the Group are set out in

note 14 to the consolidated financial statements of this anual

report.

BUSINES REVIEW

A discusion and analysis of the Group’s performance for the year

ended 31 March 2025, the key factors afecting its results and

financial position are set out in the section headed “Management

Discusion and Analysis” of this anual report. Further, a fair

review of, and an indication of likely future prospects in the

Group’s busines are set out in the sections headed “Chairman’s

Statement” and “Management Discusion and Analysis” of this

anual report.

PRINCIPAL RISKS AND UNCERTAINTIES

The Group’s financial position, results of operations, busineses

and prospects would be afected by a number of principal risks

including foreign curency risk, interest rate risk, credit risk and

liquidity risk. The financial risk management policies and practices

of the Group are disclosed in note 33 to the consolidated

financial statements of this anual report.

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

此外，本集团之营运涉及若干并非本集团所能

控制的其他风险。尤其是，本集团倚赖若干主

要客户，且本集团并无与彼等订立任何长期合

约。本集团亦面临以下业务风险：(i)与第三方

生产商之关系或彼等生产业务之任何中断可对

本集团业务构成不利影响；(i)向本集团供应商

作出付款及自客户收取付款之间存在时间差。

本集团之现金流量及财务状况或会因无法处理

有关现金流量错配而受到不利影响；(i)本集团

之纯利率相对微薄且对销售成本、售价及销量

的任何不利变动高度敏感；(iv)任何日本及美国

服装零售市场零售额及销量之进一步下跌或会

对本集团之经营业绩及表现造成不利影响；及

(v)本集团之表现及盈利能力可能受到日圆汇率

波动影响。

财务概要

本集团最近五个财政年度之业绩、资产及负债

概要载于本年报第256页。

股本

截至二零二五年三月三十一日止年度，本公司

的资本架构概无发生变动。本公司之股本仅由

普通股组成。

于二零二五年三月三十一日，本公司已发行股

本为5.2百万港元，分为522,177,419股每股面值

0.01港元之普通股。

本公司于截至二零二五年三月三十一日止年度

之股本变动详情载于本年报综合财务报表附注

30。

Further, there are certain other risks involved in the Group’s

operations which are beyond its control. In particular, the Group

relies on several major customers and the Group does not enter

into any long term contracts with them. The Group also faces

busines risks such as (i) any disruption in the relationships with

the third-party manufacturers or their manufacturing operations

could adversely afect the Group’s busines; (i) there are time

lags betwen making payments to the Group’s supliers and

receiving payments from its customers. Failure to handle this

cash flow mismatch may adversely afect the Group’s cash flow

and financial position; (i) the Group has relatively thin net profit

margin and is highly sensitive to any unfavourable change in

the cost of sales, seling price and sales volume; (iv) any further

decrease in retail sales value and sales volume of aparel

retail markets in Japan and the USA may adversely afect the

Group’s operating results and performance; and (v) the Group’s

performance and profitability may be afected by the fluctuation

of the exchange rate of Japanese Yen.

FINANCIAL SUMARY

A sumary of the results, asets and liabilities of the Group for

the latest five financial years is set out on page 256 in this anual

report.

SHARE CAPITAL

There has ben no change in the capital structure of the

Company for the year ended 31 March 2025. The share capital of

the Company only comprises ordinary shares.

As at 31 March 2025, the Company’s isued share capital was

HK$5.2 milion divided by 522,177,419 ordinary shares of HK$0.01

each.

Details of the movements in the Company’s share capital for

the year ended 31 March 2025 are set out in note 30 to the

consolidated financial statements of this anual report.

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

优先购买权

细则或开曼群岛法例并无有关优先购买权之规

定，使本公司必须按比例向现有股东提呈发售

新股份。

购买、出售或赎回本公司上市证券

截至二零二五年三月三十一日止年度，本公司

或其任何子公司概无购买、出售或赎回本公司

任何上市证券（包括出售库存股（定义见上市规

则）。截至二零二五年三月三十一日，本公司

并无持有任何库存股。

储备

年内，本公司及本集团之储备变动详情分别载

于本集团综合财务报表附注41及本年报第143

页至第144页之综合权益变动表。

可供分派储备

于二零二五年三月三十一日，本公司之可供分

派储备根据开曼群岛法例第22章公司法（一九

六一年第3号法例，经综合及修订）计算为约

55.8百万港元（于二零二四年三月三十一日：约

51.6百万港元）。

主要客户及供应商

截至二零二五年三月三十一日止年度，本集团

之最大客户及五大客户之总额分别占本集团总

收益约27.3%（截至二零二四年三月三十一日止

年度：约37.7%）及53.2%（截至二零二四年三月

三十一日止年度：约63.4%）。本集团之最大供

应商及五大供应商之总额分别占本集团销售成

本约31.4%（截至二零二四年三月三十一日止年

度：约39.7%）及55.33%（截至二零二四年三月三

十一日止年度：约69.8%）。

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Articles

or the laws of the Cayman Islands which would oblige the

Company to ofer its new shares on a pro-rata basis to existing

Shareholders.

PURCHASE, SALE OR REDEMPTION OF THE

COMPANY’S LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold

or redemed any of the Company’s listed securities (including

the sale of treasury shares (as defined under the Listing Rules)

for the year ended 31 March 2025. As at 31 March 2025, there

were no treasury shares held by the Company.

RESERVES

Details of the movements in the reserves of the Company

and the Group during the year are set out in note 41 to the

consolidated financial statements of the Group and in the

consolidated statement of changes in equity on pages 143 to

144 in this anual report, respectively.

DISTRIBUTABLE RESERVES

As at 31 March 2025, the Company’s reserves available for

distribution, calculated in acordance with the Companies

Act, Cap. 22 (Act 3 of 1961, as consolidated and revised) of the

Cayman Islands, amounted to aproximately HK$55.8 milion (as

at 31 March 2024: aproximately HK$51.6 milion).

MAJOR CUSTOMERS AND SUPLIERS

During the year ended 31 March 2025, the Group’s largest

customer and five largest customers’ agregate amount

represented aproximately 27.3% (for the year ended 31 March

2024: aproximately 37.7%) and 53.2% (for the year ended 31

March 2024: aproximately 63.4%) of the Group’s total revenue,

respectively. The Group’s largest suplier and five largest

supliers’ agregate amount represented aproximately 31.4%

(for the year ended 31 March 2024: aproximately 39.7%) and

55.33% (for the year ended 31 March 2024: aproximately 69.8%)

of the Group’s cost of sales, respectively.

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

就董事所深知，截至二零二五年三月三十一日

止年度，概无董事或彼等之任何紧密联系人

（定义见上市规则）或据董事所知任何拥有本公

司已发行股本5%以上之股东于本集团任何五大

客户及╱或供应商中拥有任何实益权益。

董事

于年内及截至本年报日期之董事如下：

执行董事

鹫北健一郎先生（主席兼行政总裁）

（于二零二四年十一月八日获委任）

宫野积先生

鸣海尚一先生

（于二零二四年十二月二日获委任）

赵俊德先生

杜垚女士（于二零二四年十二月二日获委任）

梁非先生（于二零二四年十二月二日获委任）

岛田达二先生

（于二零二四年十一月八日辞任）

前崎匡弘先生

（于二零二四年十二月二日辞任）

宫里启晖先生

（于二零二四年十二月二日辞任）

非执行董事

植松高宏先生

（于二零二四年十二月二日获委任）

严平先生

草场拓也先生（于二零二四年十二月二日辞任）

独立非执行董事

陈卓豪先生

蔡冠明先生

斋藤宏畅先生

张翠萍女士

（于二零二四年十二月二日获委任）

谷口恭彦先生

（于二零二五年一月十日辞任）

To the best knowledge of the Directors, none of the Directors

nor any of their close asociates (as defined in the Listing Rules)

nor any Shareholders who or which to the knowledge of the

Directors own more than 5% of the Company’s isued share

capital had any beneficial interest in any of the Group’s five

largest customers and/or supliers during the year ended 31

March 2025.

DIRECTORS

The Directors during the year and up to the date of this anual

report were as folows:

Executive Directors

Mr. Washikita Kenichiro (Chairman and Chief Executive Oficer)

(apointed with efect from 8 November 2024)

Mr. Miyano Tsumoru

Mr. Narumi Shoichi

(apointed with efect from 2 December 2024)

Mr. Chiu Chun Tak

Ms. Du Yao (apointed with efect from 2 December 2024)

Mr. Liang Fei (apointed with efect from 2 December 2024)

Mr. Shimada Tatsuji

(resigned with efect from 8 November 2024)

Mr. Maezaki Masahiro

(resigned with efect from 2 December 2024)

Mr. Miyazato Hiroki

(resigned with efect from 2 December 2024)

Non-executive Directors

Mr. Uematsu Takahiro

(apointed with efect from 2 December 2024)

Mr. Yan Ping

Mr. Kusaba Takuya (resigned with efect from 2 December 2024)

Independent Non-executive Directors

Mr. Chan Cheuk Ho

Mr. Choi Kon Ming

Mr. Saito Hironobu

Ms. Zhang Cuiping

(apointed with efect from 2 December 2024)

Mr. Taniguchi Yasuhiko

(resigned with efect from 10 January 2025)

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

根据细则第83(3)条及企业管治守则之守则条文

第A.4.2条，任何获董事会委任以填补临时空缺

的董事，其任期至其获委任后第一次本公司股

东大会为止，并须于该大会上重选连任，而

获董事会委任为现有董事会新增成员的任何董

事，其任期则仅至本公司下届股东周年大会为

止，届时将有资格重选连任。所有由二零二四

年十一月八日及二零二四年十二月二日起获委

任的董事均须退任，并符合资格于本公司应届

股东周年大会上重选连任。

董事之履历详情

董事之履历详情于本年报「董事及高级管理层

之履历详情」一节中披露。

董事服务合约

各执行董事已与本公司订立服务协议，据此，

彼已同意担任执行董事，初步为期二年，并

将于有关初步任期届满后自动重续。任何一方

有权发出不少于三个月之通知书以终止服务协

议。

各非执行董事乃按固定任期获委任，初步为期

二年，并将于有关初步任期届满后自动重续，

除非任何一方透过发出至少三个月不重续通知

书终止。除董事袍金外，预期概无非执行董

事将就担任非执行董事职务而收取任何其他酬

金。

除上文披露者外，拟于应届股东周年大会上重

选连任的董事概无建议或已经与本公司或其任

何附属公司订立任何本集团不可在一年内毋须

支付补偿（法定补偿除外）而终止的服务协议或

委任函。

Pursuant to Article 83(3) of the Articles and the code provision

A.4.2 of the CG Code, any Director apointed by the Board

to fil a casual vacancy shal hold ofice until the first general

meting of members of the Company after his apointment

and be subject to re-election at such meting and any Director

apointed by the Board as an adition to the existing Board shal

hold ofice only until the next folowing anual general meting

of the Company and shal then be eligible for re-election. Al

Directors apointed with efect from 8 November 2024 and 2

December 2024 shal retire and be eligible for re-election at the

forthcoming anual general meting of the Company.

BIOGRAPHICAL DETAILS OF DIRECTORS

The biographical details of the Directors are disclosed in the

section headed “Biographical Details of Directors and Senior

Management” of this anual report.

DIRECTORS’ SERVICE CONTRACTS

Each of the executive Directors has entered into a service

agrement with the Company pursuant to which he has agred

to act as an executive Director for an initial term of two years

and shal be renewed automaticaly upon the expiry of such

initial term. Either party has the right to give not les than thre

months’ writen notice to terminate the service agrement.

Each of the non-executive Directors has ben apointed for an

initial fixed term of two years and shal be renewed automaticaly

upon the expiry of such initial term unles terminated by either

party giving at least thre months’ writen notice of non-renewal.

Save for the Directors’ fes, none of the non-executive Directors

is expected to receive any other emolument for holding his ofice

as a non-executive Director.

Save as disclosed above, none of the Directors proposed for

re-election at the forthcoming anual general meting has

proposed or entered into any service agrement or apointment

leter with the Company or any of its subsidiaries which is not

determinable by the Group within one year without payment of

compensation other than the statutory compensation.

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

更新董事资料

并无根据上市规则第13.51B(1)条之规定须予披

露之本公司董事最新资料。

确认独立非执行董事之独立性

本公司已接获各独立非执行董事根据上市规则

第3.13条就其独立性发出之年度确认书，并认

为全体独立非执行董事均为独立人士。

获准许之赔偿条文

根据细则，董事有权从本公司的资产或溢利中

获得弥偿，以赔偿其作为董事在执行职务或其

他与执行职务有关的事宜时可能招致或蒙受的

一切损失或责任。这些规定在截至二零二五年

三月三十一日的财政年度期间有效，并截至本

报告之日仍然有效。

截至二零二五年三月三十一日止年度，本公司

已投购适当的董事及高级职员责任保险，为董

事及本集团高级管理层提供保障。

UPDATE ON DIRECTORS’ INFORMATION

There is no updated information of directors of the Company

required to be disclosed pursuant to Rule 13.51B(1) of the Listing

Rules.

CONFIRMATION OF INDEPENDENCY OF

INDEPENDENT NON-EXECUTIVE DIRECTORS

The Company has received from each of the independent non-

executive Directors a writen anual confirmation of independence

pursuant to Rule 3.13 of the Listing Rules and considers al the

independent non-executive Directors to be independent.

PERMITED INDEMNITY PROVISIONS

Pursuant to the Articles, the Directors shal be entitled to be

indemnified out of the asets or profits of the Company against

al loses or liabilities which he/she may sustain or incur in or

about the execution of the duties of his/her ofice or otherwise in

relation thereto. Such provisions were in force during the course

of the financial year ended 31 March 2025 and remained in force

as of the date of this report.

The Company has aranged apropriate directors’ and oficers’

liability insurance coverage for the Directors and senior

management of the Group during the year ended 31 March

2025.

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

TAX RELIEF AND EXEMPTION

The Directors are not aware of any tax relief and exemption

available to the Shareholders by reason of their holding of the

Company’s securities.

EMOLUMENTS OF THE DIRECTORS AND THE FIVE

HIGHEST PAID INDIVIDUALS

Details of the emoluments of the Directors and the five highest

paid individuals are set out in note 11 to the consolidated

financial statements in this anual report.

EMOLUMENT POLICY

The executive Directors, non-executive Directors, the

independent non-executive Directors and senior management

receive compensation in the form of directors’ fes, salaries,

benefits in kind and/or discretionary bonuses with reference

to those paid by comparable companies in the industry, time

comitment and performance of the Group. The Group also

reimburses the Directors and senior management for expenses

which are necesarily and reasonably incured for provision of

services to the Group or executing their functions in relation

to the Group’s operations. The Group regularly reviews and

determines the remuneration and compensation packages of the

Directors and senior management by reference to, among other

things, market level of remuneration and compensation paid by

comparable companies in the industry, respective responsibilities

of the Directors and performance of the Group.

The Remuneration Comite reviews and determines the

remuneration and compensation packages of the Directors

with reference to their experience, responsibilities, workload,

time devoted to the Group and performance of the Group. The

Directors may also be ofered options under the share option

scheme.

There was no arangement under which a Director waived or

agred to waive any emolument during the year.

税务优惠及豁免

董事并不知悉股东因持有本公司证券而可获任

何税务优惠及豁免。

董事及五名最高薪酬人士之薪酬

董事及五名最高薪酬人士之薪酬详情载于本年

报综合财务报表附注11。

薪酬政策

执行董事、非执行董事、独立非执行董事及高

级管理层以董事袍金、薪金、实物福利及╱或

酌情花红形式收取报酬，金额经参考行业可资

比较公司所支付者、投放的时间及本集团的表

现而定。本集团亦会就董事及高级管理层为本

集团提供服务或执行彼等与本集团业务有关的

职能而必需及合理产生的开支，向彼等作出补

偿。本集团定期检讨及厘定董事及高级管理层

的薪酬及报酬待遇，当中参考（其中包括）行业

可资比较公司所支付薪酬及报酬的市场水平、

董事各自的职责及本集团的表现。

薪酬委员会参考董事之经验、职责、工作量、

投放于本集团之时间及本集团之表现，检讨及

厘定彼等之薪酬及报酬待遇。董事亦可根据购

股权计划获授购股权。

年内并无董事放弃或同意放弃任何酬金的安

排。

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

董事及最高行政人员于本公司及其相联

法团之股份、相关股份及债权证中之

权益及淡仓

于二零二五年三月三十一日，本公司下列董事

或最高行政人员于本公司或任何相联法团（定

义见香港法例第571章证券及期货条例（「证券

及期货条例」）第XV部）之股份、相关股份或债

权证中，拥有或被视为拥有，(a)根据证券及期

货条例第XV部第7及8分部须知会本公司及联交

所之权益或淡仓（包括根据证券及期货条例有

关条文该等董事及本公司最高行政人员被当作

或视为拥有之权益及淡仓）；或(b)根据证券及期

货条例第352条须记入该条所指之登记册之权

益或淡仓；或(c)根据上市规则附录C3所载上市

发行人董事进行证券交易之标准守则（「标准守

则」）有关董事进行证券交易之规定须知会本公

司及联交所之权益或淡仓。

于本公司之权益

INTERESTS AND SHORT POSITIONS OF DIRECTORS

AND CHIEF EXECUTIVE IN THE SHARES,

UNDERLYING SHARES AND DEBENTURES OF THE

COMPANY AND ITS ASOCIATED CORPORATION

As at 31 March 2025, the folowing Directors or the chief

executive of the Company had or were demed to have interest

or short position in the shares, underlying shares or debentures of

the Company or any asociated corporation (within the meaning

of Part XV of the Securities and Futures Ordinance (Chapter 571

of the Laws of Hong Kong) (the “SFO”) which (a) would have to

be notified to the Company and the Stock Exchange pursuant to

Divisions 7 and 8 of Part XV of the SFO (including interests and

short positions which such Directors and chief executives of the

Company were taken or demed to have under such provisions

of the SFO); or (b) would be required, pursuant to Section 352

of the SFO, to be entered in the register refered to therein; or

Transactions by Directors of Listed Isuers (the “Model Code”) as

set out in Apendix C3 to the Listing Rules relating to securities

transactions by the Directors to be notified to the Company and

the Stock Exchange.

INTERESTS IN THE COMPANY

Name of Directors

Nature of interest/

holding capacityNumber of ordinary Shares held

Percentage of

isued share

capital of the

Company

董事名称

权益性质╱

持有身份持有普通股数量

占本公司已发行

股本百分比

Mr. Chiu Chun TakBeneficial owner5,000,000 (L)

(Note 2)（附注2）

0.96

赵俊德先生实益拥有人

Notes:

1. As at 31 March 2025, the Company’s isued ordinary share capital

was HK$5.2 milion divided into 522,177,419 ordinary shares of

HK$0.01 each.

2. These represent the underlying shares which may be isued in

respect of options granted under the share option scheme of the

Company.

3. The leter “L” denotes a long position in the Shares.

附注：

，本公司已发行

普通股本为5.2百万港元，分为522,177,419股每

股面额0.01港元的普通股。

2. 此等股份代表依本公司购股权计划所授出的购

股权可能发行的相关股份。

「L」指于股份中之好仓。

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

于本公司相联法团的权益

主要股东于本公司股份、相关股份及

债权证中之权益及淡

于二零二五年三月三十一日，就董事或本公司

最高行政人员所知，以下人士（董事或本公司

最高行政人员除）于本公司股份或相关股份中

拥有根据证券及期货条例第XV部第2及3分部之

条文须向本公司披露之权益或淡仓，或根据

《证券及期货条例》第336条，该等资料已记录

于本公司须备存的登记册中：

INTERESTS IN ASOCIATED CORPORATION(S) OF

THE COMPANY

Name of Directors

Name of

asociated

corporationCapacity

Number of

share(s) held in

the asociated

corporation

Percentage of

isued share

capital of the

asociated

corporation

董事姓名相联法团名称身份

所持相联法团

股份数目

占相联法团

已发行股本之

百分比

Mr. Miyano Tsumoru

宫野积先生

EPS Holdings, Inc.

(“EPS HD”)

Beneficial owner

实益拥有人

10,0000.04

Mr. Chiu Chun Tak

赵俊德先生

EPS HDBeneficial owner

实益拥有人

30,0000.12

Mr. Yan Ping

严平先生

EPS HDBeneficial owner

实益拥有人

30,0000.12

INTERESTS AND SHORT POSITIONS OF

SUBSTANTIAL SHAREHOLDERS IN THE SHARES,

UNDERLYING SHARES AND DEBENTURES OF THE

COMPANY

As at 31 March 2025, so far as it is known to the Directors or

chief executive of the Company, the folowing persons, other

than a Director or chief executive of the Company, had an

interest or short position in the shares or underlying shares of

the Company which would fal to be disclosed to the Company

under the provisions of Divisions 2 and 3 of Part XV of the SFO,

or, which were recorded in the register required to be kept by

the Company under Section 336 of the SFO:

Name of substantial

shareholders

Nature of interest/

holding capacityNumber of ordinary Shares held

Percentage of

isued share

capital of the

Company

(Note 1)

主要股东

名称╱姓名

权益性质╱

持股身份所持普通股数目

占本公司已发行

股本之百分比

（附注1）

EPS HDBeneficial owner

实益拥有人

375,000,000 (L)

(Notes 2 and 4) (附注2及4)

71.81%

Y&G LimitedInterest of a controled corporation

受控制法团权益

375,000,000 (L)

(Notes 2 and 4) (附注2及4)

71.81%

Mr. Yan Hao (“Mr. Yan”)

严浩先生（「严先生」）

Interest of a controled corporation

受控制法团权益

375,000,000 (L)

(Notes 2 and 4) (附注2及4)

71.81%

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

附注：

，本公司之已发行

普通股本为5.2百万港元，分为522,177,419股

每股面值0.01港元之普通股

2. EPS HD由Y&G Limited拥有约67.22%，Y&G

Limited是一家在日本注册成立的公司，而Y&G

Limited又由严先生全资拥有。严先生亦直接

持有EPS HD约2.32%股权。根据证券及期货条

例，严先生被视为于EPS HD持有的该等股份中

拥有权益。

3. RIN HOLDING由TAIGA INDUSTRIAL（一家于日本

注册成立的公司）持有95%权益，而该公司则

由何先生持有93%权益。根据证券及期货条

例，TAIGA INDUSTRIAL及何先生各自被视为于

RIN HOLDING持有的该等股份中拥有权益。该

等股份是指依本公司、RIN HOLDING及创健商

贸有限公司于二零二三年三月二十八日签订的

买卖协议，在对价资本化时可能配发及发行的

对价股份，详情如下载于本公司日期为二零二

三年三月二十八日的公告。

4 字母「L」指于股份中之好仓。

购股权计划

本公司于二零一七年五月三十一日采纳一项购

股权计划（「计划」）。计划主要旨在向合资格雇

员及计划指定之其他经选定人士提供激励或奖

励。

Name of substantial

shareholders

Nature of interest/

holding capacityNumber of ordinary Shares held

Percentage of

isued share

capital of the

Company

(Note 1)

主要股东

名称╱姓名

权益性质╱

持股身份所持普通股数目

占本公司已发行

股本之百分比

（附注1）

RIN HOLDING CO., LIMITED

(“RIN HOLDING”)

Beneficial owner

实益拥有人

100,000,000 (L)

(Notes 3 and 4) (附注3及4)

19.15%

TAIGA INDUSTRIAL CO., LTD

(“TAIGA INDUSTRIAL”)

Interest of controled corporation

受控制法团权益

100,000,000 (L)

(Notes 3 and 4) (附注3及4)

19.15%

Mr. He Jun (“Mr. He”)

何军先生（「何先生」）

Interest of controled corporation

受控制法团权益

100,000,000 (L)

(Notes 3 and 4) (附注3及4)

19.15%

Notes:

1. As at 31 March 2025, the Company’s isued ordinary share capital

was HK$5.2 milion divided into 522,177,419 ordinary shares of

HK$0.01 each.

2. EPS HD is owned as to aproximately 67.22% by Y&G Limited, a

company incorporated in Japan which is in turn wholy-owned by

Mr. Yan. Mr. Yan is also directly interested in aproximately 2.32%

of the shareholding interest of EPS HD. By virtue of the SFO, Mr.

Yan is demed to be interested in these shares held by EPS HD.

3. RIN HOLDING is 95% owned by TAIGA INDUSTRIAL, a company

incorporated in Japan which is in turn 93% owned by Mr. He. By

virtue of the SFO, each of TAIGA INDUSTRIAL and Mr. He is demed

to be interested in these shares held by RIN HOLDING. These

shares refer to the consideration shares which may be aloted and

isued in the event of the capitalisation of consideration pursuant

to the sale and purchase agrement dated 28 March 2023 and

entered into by the Company, RIN HOLDING and EPS Healthcare

Limited, details of which are set out in the anouncement of the

Company dated 28 March 2023.

4. The leter “L” denotes a long position in the Shares.

SHARE OPTION SCHEME

The Company adopted a share option scheme (the “Scheme”) on

31 May 2017. The primary purpose of the Scheme is to provide

incentives or rewards to eligible employes and other selected

participants as specified under the Scheme.

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

于行使所有根据计划及本集团任何其他购股权

计划已授出但尚未行使之未获行使购股权时可

发行股份之最高数目，须不超过本公司不时已

发行股本之30%。未经股东事先批准情况下，

计划及本集团任何其他购股权计划项下将授出

之所有购股权（就此而言，不包括根据计划及

本集团任何其他购股权计划之条款而失效之购

股权）获行使时可予配发及发行的股份总数目

合共不得超过股份首次于联交所开始买卖时已

发行股份之10%，即50,000,000股份（占本报

告日期本公司已发行股本总额的约9.58%）。待

通函刊发后、在股东于股东大会批准之情况下

及╱或根据上市规则订明之其他规定，本公司

可随时更新此上限至于获股东批准当日已发行

股份总数之10%。未经股东事先批准情况下，

于任何12个月期间行使根据计划及本集团任何

其他购股权计划已授出之购股权时已发行及可

能将发行予各参与者之股份总数，不得超过本

公司当时已发行股本之1%。倘向主要股东或独

立非执行董事或彼等各自之联系人（定义见计

划）授出之购股权将导致行使于12个月期间直

至授出日期（包括该日）计划项下之所有已授出

或将授出之购股权（包括已行使、已注销及未

获行使之购股权）时已发行及将发行予该人士

之股份合共超过本公司已发行股本之0.1%且总

值超过5.0百万港元，有关授出必须获得股东事

先批准。

购股权须于提呈授出购股权要约日期起21日内

获接纳，接纳授出购股权时应付名义代价1.00

港元。

The maximum number of shares which may be isued upon

the exercise of al outstanding options granted and yet to

be exercised under the Scheme and any other share option

scheme of the Group must not exced 30% of the isued share

capital of the Company from time to time. The total number of

shares which may be aloted and isued upon exercise of al

options (excluding, for this purpose, options which have lapsed

in acordance with the terms of the Scheme and any other

share option scheme of the Group) to be granted under the

Scheme and any other share option scheme of the Group must

not in agregate exced 10% of the Shares in isue at the time

dealings in the Shares first comence on the Stock Exchange,

i.e. 50,000,000 Shares (representing aproximately 9.58% of

the total isued share capital of the Company as at the date

of this report), without prior aproval from the Shareholders.

The Company may, subject to the isue of a circular, the

Shareholders’ aproval in general meting and/or such other

requirements prescribed under the Listing Rules, refresh this

limit at any time to 10% of the total number of shares in isue

as at the date of the Shareholders’ aproval. The total number

of shares isued and which may fal to be isued upon exercise

of the options granted under the Scheme and any other share

option scheme of the Group to each participant in any 12-month

period shal not exced 1% of the isued share capital of the

Company for the time being, without prior aproval from the

Shareholders. Options granted to substantial Shareholders or

independent non-executive Directors or any of their respective

asociates as defined under the Scheme which would result in

the shares isued and to be isued upon exercise of al options

under the Scheme already granted and to be granted (including

options exercised, canceled and outstanding) to such person in

the 12-month period up to and including the date of such grant

represent in agregate in exces of 0.1% of the Company’s isued

share capital and with an agregate value in exces of HK$5.0

milion must be aproved in advance by the Shareholders.

Options granted must be taken up within 21 days of the date

of the ofer of grant of the option. A nominal consideration of

HK$1.00 is payable on aceptance of the grant of an option.

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

购股权可于购股权获接纳日期起至董事厘定的

有关日期（惟无论如何不超过10年）内随时行

使。行使价由董事厘定，惟不得低于(i)股份于

授出要约日期（须为营业日）在联交所每日报价

表所报的收市价；(i)股份于紧接提呈授出购股

权要约日期前五个交易日在联交所每日报价表

所报的平均收市价；及(i)股份面值的最高者。

本计划不设最低归属期。任何购股权的行使均

须遵守董事会全权酌情决定的归属时间表，该

时间表应在要约函中列明。

二零二五年二月二十八日，本公司授予本集

团员工购股权，依该计划可发行合共5,600,000

股。

Options may be exercised at any time from the date of

aceptance of the share option to such date as determined

by the Directors but in any event not exceding 10 years. The

exercise price is determined by the Directors, but shal not be les

than the highest of (i) the closing price of the shares as stated

in the Stock Exchange’s daily quotation shets on the date of

the ofer of grant, which must be a busines day; (i) the average

closing price of the shares as stated in the Stock Exchange’s daily

quotation shets for the five trading days imediately preceding

the date of the ofer of grant of the option; and (i) the nominal

value of a share. The Scheme does not provide for any minimum

vesting period. The exercise of any options may be subject to a

vesting schedule to be determined by the Board in its absolute

discretion, which shal be specified in the ofer leters.

On 28 February 2025, the Company granted share options to

employes of the Group in respect of which a total of 5,600,000

Shares may be isued under the Scheme.

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

The movement of share options during year ended 31 March

2025 is presented as folows:

Number of share options

购股权数目

Name or category of

grante

受让者姓名或类别

Date of grant

授出日期

At 1 April

二零二四年

四月一日

Granted

during the

year

年内授出

Exercised

during the

year

年内行使

Canceled

during the

year

年内撤消

Lapsed

during the

year

年度内失效

At 31 March

二零二五年

三月三十一

日

Exercise period

行使期

Exercise

price

行使假

HK$ per

每股港元

Closing

price

imediately

before date

of grant

紧接授出日

期前之股份

收市价

HK$ per

每股港元

Director

董事

Mr. Chiu Chun Tak

赵俊德先生

28 February 2025

二零二五年二月二

十八日

–5,000,000–5,000,00028 February 2025 to 27

February 2028 (Note)

二零二五年二月二十八日

至二零二八年二月二十

七日 (附注)

0.600.49

Other employes

其他雇员

28 February 2025

二零二五年二月二

十八日

–600,000–600,00028 February 2025 to 27

February 2028 (Note)

二零二五年二月二十八日

至二零二八年二月二十

七日 (附注)

0.600.49

Total 总计–5,600,000–5,600,000

Note: The exercise period of the options is 3 years from the date of

grant of the options subject to the vesting schedule. The share

options granted shal vest in six tranches of aproximately 16%,

16%, 16%, 16%, 16% and 20% on 28 February 2025, 28 August

2025, 28 February 2026, 28 August 2026, 28 February 2027 and 28

August 2027, respectively.

截至二零二五年三月三十一日止年度的购股权

变动如下：

注：购股权的行使期间为自授出日起计三年，并

须遵守归属期间。已授出的购股权分六批归

属，分别于二零二五年二月二十八日、二零

二五年八月二十八日、二零二六年二月二十

八日、二零二六年八月二十八日、二零二七

年二月二十八日及二零二七年八月二十八日归

属约16%、16%、16%、16%、16%、16%、

16%、16%、16%、16%、20%的股份。

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

根据该计划授予的选择权，年度内可发行的股

份数目除以年度内已发行普通股（不包括库存

股）的加权平均数约为1.08%。授予选择权于授

予日的公允价值以及所采用的会计准则及政策

已在合并财务报表附注31中揭露。

在本财政年度之年初和年末，根据该计划授

权可授出的购股权数目分别为50,000,000和

44,400,000。计划将自其获采纳日期起计10年内

有效。

该计划的更多详情已在合并财务报表附注31中

揭露。

股权挂钩协议

除上文所披露计划外，概无任何将会或可能导

致本公司发行股份或规定本公司须订立任何将

会或可能导致本公司发行股份之协议之股权挂

钩协议乃由本公司于截至二零二五年三月三十

一日止年度内订立或于二零二五年三月三十一

日存续。

董事于交易、安排或合约之权益

除下文「关联交易及持续关连交易」一节及本年

报综合财务报表附注38所披露者外，概无董事

或董事的任何关连实体于本公司或其任何附属

公司所订立与本集团业务有关且于年内或年末

仍然存续的任何重大交易、安排或合约中直接

或间接拥有任何重大权益，本集团与控股东

或其任何子公司之间亦无订立任何重大合同。

The number of shares that may be isued in respect of options

granted under the Scheme during the year divided by the

weighted average number of ordinary shares in isue (excluding

treasury shares) for the year is aproximately 1.08%. The fair

value of options granted at the date of grant and the acounting

standard and policy adopted is disclosed in note 31 to the

consolidated financial statements.

The number of options available for grant under the scheme

mandate at the begining and the end of the financial year were

50,000,000 and 44,400,000 respectively. The Scheme wil remain

in force for a period of 10 years comencing on the date on

which the Scheme is adopted.

Further details of the Scheme are disclosed in note 31 to the

consolidated financial statements.

EQUITY-LINKED AGREMENTS

Save for the Scheme disclosed above, no equity-linked

agrements that wil or may result in the Company isuing shares

or that require the Company to enter into any agrements that

wil or may result in the Company isuing shares were entered

into by the Company during the year ended 31 March 2025 or

subsisted as at 31 March 2025.

DIRECTORS’ INTERESTS IN TRANSACTIONS,

ARANGEMENTS OR CONTRACTS

Save as disclosed in the section headed “Conected Transactions

and Continuing Conected Transactions” below and in note 38

to the consolidated financial statements of this anual report,

no Director nor any conected entity of a Director had any

material interest, either directly or indirectly, in any transactions,

arangements or contracts of significance in relation to the

busines of the Group, to which the Company or any of its

subsidiaries was a party, subsisting during or at the end of the

year, nor had there ben any contract of significance entered

into betwen the Group, and a controling shareholder or any of

its subsidiaries.

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

董事于竞争业务之权益

截至二零二五年三月三十一日止年度，董事或

彼等各自的任何紧密联系人（定义见上市规则）

概无从事与本集团业务构成或很可能直接或间

接构成竞争之任何业务或与本集团有任何其他

利益冲突。

关联方交易

本集团年内的关联方交易详情载于本年报合并

财务报表附注38，该等交易均为上市规则所定

义的关连交易或持续关连交易，其中若干交易

构成完全豁免关联交易或持续关联交易。本公

司已遵守上市规则第14A章的披露规定。

有关连交易之详情概述于下文「关连交易及

持续关连交易」一节。

控股东在重大合同中之权益

除下文「关联交易及持续关连交易」一节及本年

报综合财务报表附注38所披露者外，于年末或

年内任何时间，本公司或其任何附属公司与控

股东或其任何附属公司之间并无存续其他重

大合约（不论是由任何控股东或其任何附属

公司向本公司或其任何附属公司提供服务或其

他）。

DIRECTORS’ INTERESTS IN COMPETING

BUSINESES

During the year ended 31 March 2025, none of the Directors nor

any of their respective close asociates (as defined in the Listing

Rules), engaged in any busines that competes or is likely to

compete, either directly or indirectly, with the busines of the

Group, or had any other conflict of interest with the Group.

RELATED PARTY TRANSACTIONS

Details of related party transactions of the Group during the year

are set out in note 38 to the consolidated financial statements

in this anual report, al of which are either a conected

transaction or a continuing conected transaction as defined

under the Listing Rules, in which certain transaction(s) constitute

fuly exempt conected transaction(s) or continuing conected

transaction(s). The Company has complied with the disclosure

requirements in acordance with Chapter 14A of the Listing

Rules.

Details of the conected transactions are sumarised in the

section headed “Conected Transactions and Continuing

Conected Transactions” below.

CONTROLING SHAREHOLDERS’ INTEREST IN

CONTRACTS OF SIGNIFICANCE

Save as disclosed in the section “Conected Transactions and

Continuing Conected Transactions” below and in note 38 to

the consolidated financial statements of this anual report, no

other contracts of significance betwen the Company or any

of its subsidiaries and the controling shareholder or any of its

subsidiaries subsisted at the end of the year or at any time during

the year, whether for the provision of services to the Company or

any of its subsidiaries by any controling shareholder or any of its

subsidiaries or otherwise.

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

关连交易及持续关连交易

出售 EPS Medical

于二零二四年十月二日，EPS Medical

Consultancy Services Limited（本公司的间接全资

附属公司）作为卖方与EPS HD（作为买方）订立

股份转让协议，以1.00日元的代价在出售完成

前出售本公司的全资附属公司EPS Medical的全

部股权，该公司主要从事提供IRO（创新研究组

织）服务。股份转让协议亦规定，买方须于交

易完成时向卖方偿还EPS Medical欠卖方的股东

贷款及应计利息176,181,245日元（约9,549,119港

元）。此次出售于二零二四年十月二日股份转

让协议签署后完成。出售详情进一步载于本公

司日期为二零二四年十月二日及二零二四年十

月八日的公告。

由于EPS HD为本公司控股东，根据《上市规

则》，EPS HD被视为本公司的关连人士。因此，

依《股份转让协议》出售EPS Medical构成本公司

依据《上市规则》第14A章的关连交易。

出售EPS Inovative Group

于二零二五年二月十九日，本公司（作为卖方）

与EPS HD（作为买方）订立买卖协议，据此，

(i)本公司有条件同意出售，而EPS HD有条件同

意收购EPS Inovative全部已发行股本，代价为

1.00日元（约0.049092港元）；及(i)本公司亦有条

件同意出售或有条件促使购买，而有条件促使

购买HDEPSEPS Group拥有的若干集团内贷款，

价格为1,250,000,000日圆（约61,365,000港元）。

出售事项已于二零二五年三月三十一日完成。

有关出售事项的详情进一步载于本公司日期为

二零二五年二月十九日及二零二五年三月三十

一日的公告以及本公司日期为二零二五年三月

十四日的通函。

CONECTED TRANSACTIONS AND CONTINUING

CONECTED TRANSACTIONS

Disposal of EPS Medical

On 2 October 2024, EPS Medical Consultancy Services Limited

(an indirect wholy-owned subsidiary of the Company) as

vendor entered into a share transfer agrement with EPS HD as

purchaser, for the disposal of the entire equity interest of EPS

Medical, a wholy-owned subsidiary of the Company prior to

the completion of the disposal which is principaly engaged in

the provision of IRO (Inovative Research Organisation) services

at a consideration of JPY1.00. The share transfer agrement

also required that the purchaser repay the shareholder loan

and acrued interest owed by EPS Medical to the vendor in

the amount of JPY176,181,245 (equivalent to aproximately

HK$9,549,119) to the vendor at completion. Completion of

the disposal tok place upon the signing of the share transfer

agrement on 2 October 2024. Details of the disposal are further

set out in the anouncements of the Company dated 2 October

2024 and 8 October 2024.

Since EPS HD is a controling shareholder of the Company, EPS

HD is considered a conected person of the Company under

the Listing Rules. As such, the disposal of EPS Medical under the

share transfer agrement constituted a conected transaction of

the Company under Chapter 14A of the Listing Rules.

Disposal of EPS Inovative Group

On 19 February 2025, the Company as vendor entered into

a sale and purchase agrement with EPS HD as purchaser,

pursuant to which (i) the Company conditionaly agred to sel,

and EPS HD conditionaly agred to acquire the entire isued

share capital of EPS Inovative, at a consideration of JPY1.00

(equivalent to aproximately HK$0.049092); and (i) the Company

also conditionaly agred to sel or procure to sel, and EPS HD

conditionaly agred to purchase certain intra-group loans owned

by EPS Inovative Group for a consideration of JPY1,250,000,000

(equivalent to aproximately HK$61,365,000). Completion of the

disposal tok place on 31 March 2025. Details of the disposal are

further set out in the anouncements of the Company dated

19 February 2025 and 31 March 2025 and the circular of the

Company dated 14 March 2025.

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

由于EPS HD为本公司的控股东，因此根据上

市规则，EPS HD被视为本公司的关连人士。因

此，根据上市规则第14A章，买卖协议下出售

EPS Inovative Group构成本公司的关连交易。

本集团与Firenze Aparel Limited（「Firenze」）

之租赁协议

于二零二四年一月八日，本公司附属公司尚捷

（香港）有限公司（「尚捷香港」）就本集团租用位

于本公司香港主要营业地点的物业（「该物业」）

与Firenze订立重续租赁协议（「租赁协议」），月

租为100,000港元，租期为二零二四年二月一日

至二零二六年一月三十一日（包括首尾两日）。

该物业用作本集团于香港的总办事处及主要营

业地点。根据租赁协议，Firenze同意支付管理

费以及政府差饷及政府地租。租赁协议项下之

月租由相关订约方经参考现行市价后公平磋商

厘定。截至二零二五年三月三十一日止年度，

本集团根据租赁协议已支付总租金1,200,000

港元（截至二零二四年三月三十一日止年度：

1,200,000港元）。

由于Firenze由陈永佳先生（「陈先生」）（为本

公司全资附属公司Sped Aparel (BVI) Limited

（「Sped Aparel BVI」）的董事）拥有100%权

益，Firenze根据上市规则，被视为本公司的关

连人士。因此，根据上市规则第14A章，本集

团根据租赁协议自Firenze租赁该物业构成完全

豁免本集团之持续关连交易。

Since EPS HD is a controling shareholder of the Company, EPS

HD is considered a conected person of the Company under

the Listing Rules. As such, the disposal of EPS Inovative Group

under the sale and purchase agrement constituted a conected

transaction of the Company under Chapter 14A of the Listing

Rules.

Tenancy agrement betwen the Group and Firenze

Aparel Limited (“Firenze”)

On 8 January 2024, Sped Aparel (HK) Limited (“Sped Aparel

HK”), a subsidiary of the Company, entered into a renewal

tenancy agrement (the “Tenancy Agrement”) with Firenze

for the leasing of a property located at the principal place of

busines of the Company in Hong Kong (the “Property”) to

the Group for a monthly lease payment of HK$100,000 from

1 February 2024 to 31 January 2026 (both days inclusive). The

Property was used as a head ofice and the principal place of

busines of the Group in Hong Kong. Pursuant to the Tenancy

Agrement, Firenze agred to pay management fe and

government rates and government rent. The monthly lease

payment under the Tenancy Agrement was determined on

an arm’s length basis betwen the parties thereto by reference

to the prevailing market rates. The agregate lease paid by the

Group under the Tenancy Agrement was HK$1,200,000 for the

year ended 31 March 2025 (for the year ended 31 March 2024:

HK$1,200,000).

Since Firenze is owned as to 100% by Mr. Chan Wing Kai (“Mr.

Chan”), being a director of Sped Aparel (BVI) Limited (“Sped

Aparel BVI”), a wholy-owned subsidiary of the Company, Firenze

is considered as a conected person of the Company under the

Listing Rules. As such, the leasing of the Property by the Group

from Firenze under the Tenancy Agrement constituted a fuly

exempted continuing conected transaction of the Group under

Chapter 14A of the Listing Rules.

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

本集团与タマホーム株式会社之租赁协议

此外，于年内，本公司附属公司Sped Aparel

Japan合同会社（「Sped Aparel Japan」）向タ

マホーム株式会社租用一所物业，タマホーム

株式会社是由严浩（最终控股公司的控股东）

委聘的管理公司，而严浩为该物业的最终实

益拥有人。续约租赁协议于二零二三年十二月

二十日签订，自二零二四年一月十一日至二零

二六年一月十日期间，每月租金为1,125,920日

圆。该物业在日本用作营业办公室。租赁协议

项下之月租由相关订约方经参考现行市价后公

平磋商厘定。截至二零二五年三月三十一日止

年度，本集团已支付总租金13,511,040日圆（截

至二零二四年三月三十一日止年度：13,511,040

日圆）。根据上市规则，严浩被视为本集团之

关连人士。因此，根据上市规则第14A章，向

严浩为最终实益拥有人之管理公司租赁物业构

成完全豁免本集团之持续关连交易。

CRO服务安排

于报告年内，本集团三家（二零二四年：三家）

中国附属公司向其最终控股公司的附属公司提

供CRO服务，以及于报告年内该三家（二零二四

年：三家）中国附属公司提供CRO服务相关的总

收入为3.6百万港元（二零二四年：3.8百万港元）。

Tenancy agrement betwen the Group and タマホーム株

式会社

Also, during the year, Sped Aparel Japan 合同会社 (“Sped

Aparel Japan”), a subsidiary of the Company leased a property

from タマホーム株式会社, which is a management company

engaged by Yan Hao (controling shareholder of ultimate

holding company) who is the ultimate beneficial owner of the

property. A renewal of tenancy agrement was entered into on

20 December 2023 for a monthly lease payment of JPY1,125,920

from 11 January 2024 to 10 January 2026. The property was used

as a busines ofice in Japan. The monthly lease payment under

the tenancy agrement was determined on an arm’s length

basis betwen the parties thereto by reference to the prevailing

market rates. The agregate amount of lease payment made by

the Group was JPY13,511,040 for the year ended 31 March 2025

(for the year ended 31 March 2024: JPY13,511,040). Yan Hao is

considered as a conected person of the Group under the Listing

Rules. As such, the leasing of the property from the management

company which Yan Hao is the ultimate beneficial owner

constituted a fuly exempted continuing conected transaction

of the Group under Chapter 14A of the Listing Rules.

CRO services arangement

During the Reporting Year, the thre (2024: thre) PRC

subsidiaries of the Group provided CRO services to its ultimate

holding company’s subsidiaries and the total revenue in relation

to the CRO services provided by the thre (2024: thre) PRC

subsidiaries during the Reporting Year amounted to HK$3.6

milion (2023: HK$3.8 milion).

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

分摊行政服务开支及服务成本安排

于报告年内，本集团五间（二零二四年：五间）

日本附属公司及一家中国附属公司与最终控股

公司及关联公司分摊行政服务费用和服务成

本。年内所产生的行政开支及服务成本为15.4

百万港元（二零二四年：20.6百万港元）。有关

本集团与其最终控股公司及关联公司分摊行政

服务及服务成本之交易按成本基准进行，而有

关成本按本集团所获服务比例可予识别，并已

按公平公正的基准分配至本集团。因此，有关

交易根据上市规则第14A.98条构成获全面豁免

的持续关连交易。

向最终控股公司购买

于报告年度内，本集团旗下一家附属公司向最

终控股公司采购金额为110,000港元（2024年：

无）。此采购相关交易依据《上市规则》构成完

全豁免的持续关连交易。

供应协议

兹提述本公司日期为二零二三年三月二十八

日、二零二三年四月二十七日及二零二三年五

月二十三日的公告，内容有关本集团收购瑞益

股份有限公司（「R&E」）65%股权。在收购完成

之前，R&E已与日本供应商Taiga Industrial Co.,

Ltd（「Taiga」）于二零二三年三月十三日签订了

独家长期供应协议（「供应协议」），以供应日本

保健食品为期10年，以促进其在中国和海外的

分销。每件产品的采购价格不得超过产品成本

的10%。

卖方的最终实益拥有人为R&E余下35%股权的拥

有者（因此属于上市规则所定义的关连人士），

与Taiga为同一人。因此，Taiga为本公司在子

公司层级的关连人士。收购完成后，供应协议

下拟进行的交易依上市规则第14A章构成本公

司的持续关连交易。

Sharing of administrative services expenses and services

costs arangement

During the Reporting Year, five (2024: five) Japanese subsidiaries

and one PRC subsidiary of the Group shared administrative

services expenses and services costs with ultimate holding

company and related Companies. Administrative expenses and

services costs incured during the year amounted to HK$15.4

milion (2024: HK$20.6 milion). The transactions relating to

the sharing of the administrative services and services costs

betwen the Group and its ultimate holding company and

related Companies are on a cost basis, and such costs were

identifiable in proportion to the services received by the Group

and had ben alocated to the Group on a fair and equitable

basis. Acordingly, such transactions constituted fuly exempt

continuing conected transactions under Rule 14A.98 of the

Listing Rules.

Purchase from ultimate holding company

During the Reporting Year, a subsidiary of the Group purchased

from ultimate holding company in the amount of HK$110,000

(2024: Nil). The transactions relating to such purchase constituted

fuly exempt continuing conected transactions under the Listing

Rules.

Suply Agrement

Reference is made to the anouncements of the Company

dated 28 March 2023, 27 April 2023 and 23 May 2023 in

relation to the Group’s acquisition of 65% equity interest in R&E

Corporation Limited (“R&E”). R&E has, prior to the completion

of the acquisition, entered into an exclusive long-term suply

agrement (the “Suply Agrement”) dated 13 March 2023

with Taiga Industrial Co., Ltd (“Taiga”), a Japanese suplier, for

the suply of Japanese health fod for up to 10 years to facilitate

the distribution in the PRC and overseas. The purchase price in

respect of each product shal be no more than 10% markup on

the cost of the product.

The ultimate beneficial owner of the vendor, being the owner of

remaining 35% of R&E’s equity interest (and hence a conected

person within the meaning of the Listing Rules), and Taiga is

the same person. Acordingly, Taiga is a conected person of

the Company at the subsidiary level. Upon completion of the

acquisition, the transactions contemplated under the Suply

Agrement constituted continuing conected transactions of the

Company under Chapter 14A of the Listing Rules.

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

购买商品

于二零二三年七月二十七日，本公司间接全资

附属公司EP Trading Co., Ltd.（「EP Trading」）与

EPS Americas Corp（「EPS USA」）订立框架购买

协议（「框架购买协议」），据此，EP Trading同

意购买，EPS USA同意出售截至二零二六年三

月三十一日止三个财政年度的临床前动物测试

耗材。详情请参阅本公司日期为二零二三年七

月二十七日的公告。

于报告年内，向EPS（美国）采购临床前动物试

验耗材之总额为25.9百万港元（二零二四年：

19.2百万港元）。

EPS USA为EPS HD的全资附属公司，其为本公

司的控股东，因此为本公司的关连人士，

因此依上市规则第14A.07条为本公司的关连人

士。因此，根据上市规则第14A章，采购框架

协议下拟进行的交易构成本公司持续关连的交

易。

聘用CRO服务

于二零二三年十二月十五日，EPS Medical

Consultancy (Japan) Co., Ltd.（「EPSMC」）（本公

司的附属公司于二零二四年十月完成出售其

全部股权之前）与EPS Corporation及EP Mediate

Co., Ltd（「EP Mediate」）订立CRO服务框架协议

（「CRO服务框架协议」），据此，EPS Corporation

及EP Mediate已同意于截至二零二六年三月三

十一日止三个财政年度内向EPSMC提供CRO服

务。详情请参阅本公司日期为二零二三年十二

月十五日的公告。

于报告年内，与EPS Corporation及EP Mediate提

供CRO服务有关的服务费为2.9百万港元（二零

二四年：4.6百万港元）。

Purchase of gods

On 27 July 2023, EP Trading Co., Ltd. (“EP Trading”), an indirect

wholy-owned subsidiary of the Company, entered into the

framework purchase agrement (the “Framework Purchase

Agrement”) with EPS Americas Corp (“EPS USA”), pursuant

to which EP Trading has agred to purchase, and EPS USA has

agred to sel the pre-clinical animal testing consumables for the

thre financial years ending 31 March 2026. For details, please

refer to the anouncement of the Company dated 27 July 2023.

During the Reporting Year, the total purchase of pre-clinical

animal testing consumables from EPS USA amounted to HK$25.9

milion (2024: HK$19.2 milion).

EPS USA is a wholy-owned subsidiary of EPS HD, which is the

controling shareholder of the Company and hence a conected

person of the Company, is therefore a conected person of

the Company under Rule 14A.07 of the Listing Rules. Hence,

the transactions contemplated under the Framework Purchase

Agrement constituted continuing conected transactions of the

Company under Chapter 14A of the Listing Rules.

Engagement for CRO services

On 15 December 2023, EPS Medical Consultancy (Japan) Co.,

Ltd. (“EPSMC”), a subsidiary of the Company imediately prior

to the completion of the disposal of its entire equity interest

in October 2024, EPS Corporation and EP Mediate Co., Ltd (“EP

Mediate”) entered into the CRO services framework agrement

(the “CRO Services Framework Agrement”), pursuant to

which EPS Corporation and EP Mediate have agred to provide

the CRO services to EPSMC for the thre financial years ending 31

March 2026. For details, please refer to the anouncement of the

Company dated 15 December 2023.

During the Reporting Year, the service fe in relation to the

provision of CRO services from EPS Corporation and EP Mediate

amounted to HK$2.9 milion (2024: HK$4.6 milion).

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

EP Mediate为EPS Corporation的全资附属公司，

而EPS Corporation为EPNextS, Inc.的全资附属

公司，而EPNextS, Inc.则为本公司控股东EPS

HD的全资附属公司，因此，根据上市规则第

14A.07条，为本公司的关连人士。因此，在二

零二四年十月完成出售EPSMC之前，根据上市

规则第14A章，CRO服务架构协议下拟进行的交

易构成本公司持续关连的交易。

奖励协议

于二零二四年三月六日，本公司与Sped

Aparel BVI董事陈先生订立奖励协议（「奖励协

议」），据此，陈先生已向本公司承诺会促使

Sped Aparel BVI及其子公司于截至二零二六

年三月三十一日止两个财政年度达致溢利及收

益方面的若干绩效目标，而成功达标后陈先生

将有权收取若干绩效花红。详情请参阅本公司

日期为二零二四年三月六日的公告。

陈先生为本公司全资附属公司Sped Aparel

BVI的董事，因此为本公司附属公司层面的关连

人士。因此，根据上市规则第14A章，激励协

议项下拟进行的交易构成本公司的持续关连交

易。

除上文披露者外，本集团于截至二零二五年三

月三十一日止年度并无订立任何根据上市规则

第14A章项下之规定须予披露之关连交易或持

续关连交易。

独立非执行董事审核并确认，上述非豁免及非

完全豁免的持续关联交易已达成：

(i) 在本集团的日常业务过程中；

(i) 依照正常商业条款或较佳条款；和

(i) 根据本次交易的相关协议，交易条款公平

合理，符合公司股东的整体利益。

EP Mediate is a wholy-owned subsidiary of EPS Corporation,

which is a wholy-owned subsidiary of EPNextS, Inc., which is

in turn a wholy-owned subsidiary of EPS HD, the controling

shareholder of the Company, is therefore a conected person of

the Company under Rule 14A.07 of the Listing Rules. Hence, the

transactions contemplated under the CRO Services Framework

Agrement constituted continuing conected transactions of

the Company under Chapter 14A of the Listing Rules prior to

completion of the disposal of EPSMC in October 2024.

Incentive Agrement

On 6 March 2024, the Company entered into the incentive

agrement (the “Incentive Agrement”) with Mr. Chan, a

director of Sped Aparel BVI, pursuant to which Mr. Chan

has undertaken to the Company to procure to met certain

performance targets in respect of the profits and revenue of

Sped Aparel BVI and its subsidiaries for the two financial years

ending 31 March 2026, the sucesful fulfilment of which would

entitle Mr. Chan to certain performance bonuses. For details,

please refer to the anouncement of the Company dated 6

March 2024.

Mr. Chan is a director of Sped Aparel BVI, a wholy-owned

subsidiary of the Company, and is therefore a conected person

of the Company at subsidiary level. Hence, the transactions

contemplated under the Incentive Agrement constituted

continuing conected transactions of the Company under

Chapter 14A of the Listing Rules.

Save as disclosed above, the Group has not entered into any

conected transaction or continuing conected transaction

during the year ended 31 March 2025 which should be disclosed

pursuant to the requirements under Chapter 14A of the Listing

Rules.

The independent non-executive Directors have reviewed and

confirmed that the above non-exempt and non-fuly exempt

continuing conected transactions have ben entered into:

(i) in the ordinary and usual course of busines of the Group;

(i) on normal comercial terms or beter; and

(i) in acordance with the relevant agrements governing

such transaction on terms that are fair and reasonable and

in the interests of the shareholders of the Company as a

whole.

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

本公司已委聘核数师就本集团依上市规则第

14A.56条揭露的上述非豁免及非完全豁免持续

关连交易出具函件，确认第14A.56条所载事宜

规则。核数师已发出无保留意见函件，载有核

数师根据上市规则第14A.56条就本集团根据本

节披露的持续关连交易的发现及结论，并向董

事会确认了该等事项。

管理合约

截至二零二五年三月三十一日止年度，就本集

团整体或任何环节业务方面并无订立或存有管

理及行政合约。

足够公众持股量

根据本公司可公开取得的资料及就董事所深

知，董事确认，本公司于截至本报告日期符合

上市规则的最低公众持股量规定。

股权融资活动

于二零二四年四月二十二日，根据与各认购人

订立的上述认购协议，(i) 10,080,645股认购股

份已配发及发行予KIRABOSHI CONSULTING CO.,

LTD.，认购价为每股认购股份0.992港元；及

(i) 12,096,774股认购股份已配发及发行予OHMI

LC（合同会社近江），认购价为每股认购股份

0.992港元（统称「认购股份」），其中账面总值约

221,774港元。董事认为，透过认购事项筹集资

金将是对业务合作的长期投资，并将为其营运

资金提供现金资源，有助于增强财务状况，使

本集团能够进一步物色商机。认购详情已于本

公司日期为二零二四年四月九日及二零二四年

四月二十二日的公告中披露。

The Company has engaged the auditor to isue a leter

confirming the maters set out in Rule 14A.56 in respect of

the above non-exempt and non-fuly exempt continuing

conected transactions disclosed by the Group in acordance

with Rule 14A.56 of the Listing Rules. The auditor has isued

their unqualified leter containing the auditor’s findings and

conclusions in respect of the continuing conected transactions

disclosed by the Group under this section in acordance with,

and confirmed to the Board the maters set out in, Rule 14A.56 of

the Listing Rules.

MANAGEMENT CONTRACTS

No contracts concerning the management and administration of

the whole or any part of the busines of the Group were entered

into or existed during the year ended 31 March 2025.

SUFICIENCY OF PUBLIC FLOAT

Based on the information that is publicly available to the

Company and to the best knowledge of the Directors, the

Directors confirm that the Company complies with the minimum

of public float as required under the Listing Rules as at the date

of this report.

EQUITY FUND RAISING ACTIVITIES

On 22 April 2024, (i) 10,080,645 shares were aloted and isued

to KIRABOSHI CONSULTING CO., LTD. at the subscription price of

HK$0.992 per Share; and (i) 12,096,774 shares were aloted and

isued to OHMI LC (合同会社近江) at the subscription price

of HK$0.992 per Share (together, the “Subscription Shares”),

pursuant to the subscription agrements dated 9 April 2024 and

entered into with each subscriber, with an agregate nominal

value of aproximately HK$221,774. The Directors consider that

the raising of funds by the subscription would be a long-term

investment for busines colaboration and would help strengthen

the financial position by providing cash resources to fund its

working capital and to enable the Group to further pursue

busines oportunities. Details of the subscription are disclosed

in the anouncements of the Company dated 9 April 2024 and

22 April 2024.

REPORT OF THE DIRECTORS

董事会报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

发行认购股份所得款项总额为22.0百万港元，

扣除开支后，发行认购股份所得款项净额约

21.8百万港元。股份于认购协议日期在联交所

所报的收市价为每股0.98港元。配发及发行

的每股认购股份净价约为每股认购股份0.98港

元，乃依所得款项净额总额除以认购股份总数

（依认购价每股0.992港元计算）。

截至二零二五年三月三十一日止年度，本公司

日期为二零二四年四月二十二日的公告所披露

的所得款项净额约21.8百万港元已悉数动用。

约18.1百万港元用作本集团内部研发业务中前

期投资类项目的研发费用，以加速该等项目进

程；剩余额用于员工成本、专业费、其他一

般行政及营运开支。

除上述揭露外，报告年度公司并无募集资金、

出售库存股的情况，也不存在先前会计年度发

行股本证券募集资金的情况。

The gros proceds from the isue of Subscription Shares

amounted to HK$22.0 milion, and after deduction of expenses,

the net proceds from the isue of Subscription Shares

amounted to aproximately HK$21.8 milion. The closing price of

the Shares as quoted on the Stock Exchange on the date of the

subscription agrements was HK$0.98 per Share. The net price

per Subscription Share aloted and isued, which is calculated

by dividing the agregate net proceds by the total number of

Subscription Shares based on the subscription price of HK$0.992

per Share, is aproximately HK$0.98 per Subscription Share.

During the year ended 31 March 2025, the net proceds of

aproximately HK$21.8 milion as disclosed in the anouncement

of the Company dated 22 April 2024 were fuly utilised.

Aproximately HK$18.1 milion were aplied for research and

development expenses of the Group on the upfront investment-

type of projects in the in-house research and development

busines in order to acelerate those projects; and the remaining

balances were used for staf costs, profesional fes, other

general administrative and operating expenses.

Save as disclosed above, there was no equity fund raising by

the Company, nor was there any sale of treasury shares by the

Company during the Reporting Year, and there were there no

proceds brought forward from any isue of equity securities

made in previous financial years.

REPORT OF THE DIRECTORS

董事会报告

ANUAL REPORT 2024/2025

2024/2025 年报

核数师

德勤•关黄陈方会计师行辞任本集团外部核数

师，自二零二五年一月二十八日起生效。天

健国际会计师事务所有限公司（「天健国际」）已

获委任为本集团外部核数师，自二零二五年二

月二十八日起生效。截至二零二五年三月三十

一日止年度的综合财务报表皆已获天建国际审

计。

除上文所披露者外，本公司核数师在前三年未

发生其他变动。

续聘天健国际为本公司核数师之决议案将于应

届股东周年大会上提呈。

承董事会命

主席兼执行董事

鹫北健一郎

香港，二零二五年六月二十七日

AUDITOR

Deloite Touche Tohmatsu, Certified Public Acountants

resigned as the external auditor of the Group with efect from 28

January 2025. Confucius International CPA Limited (“Confucius

International”) has ben apointed as the external auditor of

the Group with efect from 28 February 2025. The consolidated

financial statements for the year ended 31 March 2025 was

audited by Confucius International.

Save as disclosed above, there was no other change in the

auditors of the Company in the preceding thre years.

A resolution to re-apoint Confucius International as auditor

of the Company wil be proposed at the forthcoming anual

general meting.

By order of the Board

Washikita Kenichiro

Chairman and executive Director

Hong Kong, 27 June 2025

INDEPENDENT AUDITOR’S REPORT

独立核数师报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

TO THE MEMBERS OF

EPS CREATIVE HEALTH TECHNOLOGY GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

OPINION

We have audited the consolidated financial statements of EPS

Creative Health Technology Group Limited (the “Company”) and

its subsidiaries (colectively refered to as the “Group”) set out on

pages 139 to 255, which comprise the consolidated statement

of financial position as at 31 March 2025, and the consolidated

statement of profit or los, the consolidated statement of profit

or los and other comprehensive income, consolidated statement

of changes in equity and consolidated statement of cash flows

for the year then ended, and notes to the consolidated financial

statements, including material acounting policy information and

other explanatory information.

In our opinion, the consolidated financial statements give a

true and fair view of the consolidated financial position of the

Group as at 31 March 2025, and of its consolidated financial

performance and its consolidated cash flows for the year then

ended in acordance with HKFRS Acounting Standards isued

by the Hong Kong Institute of Certified Public Acountants

(“HKICPA”) and have ben properly prepared in compliance

with the disclosure requirements of the Hong Kong Companies

Ordinance.

BASIS FOR OPINION

We conducted our audit in acordance with Hong Kong

Standards on Auditing (“HKSAs”) isued by the HKICPA. Our

responsibilities under those standards are further described in

the Auditor’s Responsibilities for the Audit of the Consolidated

Financial Statements section of our report. We are independent

of the Group in acordance with the HKICPA’s Code of Ethics for

Profesional Acountants (the “Code”), and we have fulfiled our

other ethical responsibilities in acordance with the Code. We

believe that the audit evidence we have obtained is suficient

and apropriate to provide a basis for our opinion.

独立核数师报告

致EPS创健科技集团有限公司股东

（于开曼群岛注册成立之有限公司）

意见

本核数师（「我们」）已审核列载于第139至255页

之EPS创健科技集团有限公司（「贵公司」）及其

附属公司（统称「贵集团」）之综合财务报表，该

等综合财务报表包括于二零二五年三月三十一

日之综合财务状况表及截至该日止年度之综合

损益表、综合损益及其他全面收益表、综合权

益变动表及综合现金流量表，以及综合财务报

表附注，包括重大会计政策资料及其他说明资

料。

我们认为，该等综合财务报表已根据香港会计

师公会颁布的《香港财务报告准则会计准则》真

实而中肯地反映了贵集团于二零二五年三月

三十一日之综合财务状况及截至该日止年度之

综合财务表现及综合现金流量，并已遵照香港

《公司条例》的披露要求妥为拟备。

意见之基础

我们已根据香港会计师公会颁布之《香港审计

准则》进行审计。我们在该等准则下承担之责

任已在本报告「核数师就审计综合财务报表承

担之责任」部分中作进一步阐述。根据香港会

计师公会颁布的《专业会计师道德守则》（「守

则」），我们独立于贵集团，并已履行该等守

则中的其他专业道德责任。我们相信，我们所

获得之审计凭证能充足及适当地为我们的审计

意见提供基础。

INDEPENDENT AUDITOR’S REPORT

独立核数师报告

ANUAL REPORT 2024/2025

2024/2025 年报

关键审计事项

关键审计事项是根据我们的专业判断，认为对

本期综合财务报表之审计最为重要之事项。这

些事项是在我们审计整体综合财务报表及出具

意见时进行处理。我们不会对这些事项提供单

独之意见。

KEY AUDIT MATERS

Key audit maters are those maters that, in our profesional

judgment, were of most significance in our audit of the

consolidated financial statements of the curent period. These

maters were adresed in the context of our audit of the

consolidated financial statements as a whole, and in forming our

opinion thereon, and we do not provide a separate opinion on

these maters.

Key Audit MaterHow our audit adresed the key audit mater

关键审计事项我们的审计如何处理关键审计事项

Revenue recognition in trading of aparel products

服装产品贸易之收益确认

We identified the ocurence and cut-of of revenue

recognition in trading of aparel products as key audit

mater due to revenue being one of the key performance

indicators of the Group and could be subject to

manipulation to met targets or expectations, such as

profit and revenue guarantes.

我们将服装产品贸易之收益确认识别为关键审计事

项，原因为收益是贵集团的关键绩效指标之一，可

能会受到操纵以实现目标或预期（如溢利及收益保证）。

The Group evaluates the contractual and shiping terms

of each customer contract in order to determine the

apropriate timing for revenue recognition.

贵集团评估各客户合约的合约及运送条款以厘定收益

确认的适当时间。

Revenue from trading of aparel products is recognised

at a point in time when control of the gods has ben

transfered to the customers in acordance with the

contractual arangements and related agred comercial

shiping terms. As detailed in note 5 to the consolidated

financial statements, the revenue from trading of aparel

products amounting to aproximately HK$329,716,000

for the year ended 31 March 2025.

当货品控制权根据合约安排及有关经协定的商业运送

条款转移至客户时，即确认服装产品贸易之收益。诚

如综合财务报表附注5详述，截至二零二五年三月三

十一日止年度，服装产品贸易之收益约为329,716,000

港元。

Our audit procedures in relation to revenue recognition in

trading of knitwear aparel products included:

我们就服装产品贸易之收益确认的发生及截止采取的审

计程序包括下列各项：

– obtaining an understanding and evaluating the

efectivenes of the Group’s key internal controls

over revenue recognition in trading of aparel

products;

了解及评估贵集团对服装产品贸易之收益确认

方面关键内部控制的成效；

– inspecting customer contracts, on a sample basis, to

understand key terms of sale transactions including

the terms of delivery and sale returns and asesing

if the related revenue was properly recognised in

acordance with such contractual terms and with

reference to the requirements of the prevailing

acounting standards;

抽样检查客户合约，了解销售交易的主要条款，

包括交付及销售退货条款，以及评估有关合约条

款是否参照现行会计准则的规定后根据相关销售

合约予以确认；

– testing recorded revenue transactions on a sample

basis, against coresponding customer contracts,

gods delivery notes and shiping documents that

evidenced control of gods have ben transfered;

根据证明货物控制权已移交的相应客户合约、货

物交付单和装运单据，对记录的收入交易进行抽

样测试；

INDEPENDENT AUDITOR’S REPORT

独立核数师报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

关键审计事项（续）KEY AUDIT MATERS (CONTINUED)

Key Audit Mater (Continued)How our audit adresed the key audit mater

(Continued)

关键审计事项（续）我们的审计如何处理关键审计事项（续）

– testing, on a sample basis, whether revenue

transactions recorded around financial year end

date had ben recognised in the apropriate

financial period by tracing sales invoices, shiping

documents and the terms as set out in customer

contracts; and

透过追查销售发票、装运单据及客户合约所载条

款，抽样测试在财政年度结束日期前后记录的收

益交易是否已在适当的财政期间予以确认；及

– performing revenue analysis by products and

customers to ases the reasonablenes of the

revenue recognised.

按产品及客户分类进行收入分析，以评估收益是

否合理确认。

其他事项

贵集团截至二零二四年三月三十一日止年度之

综合财务报表乃经其他核数师审核，该核数师

于二零二四年六月二十七日就该等报表发表无

保留意见。

其他信息

贵公司董事需对其他信息负责。其他信息包括

刊载于年报内之全部信息，但不包括综合财务

报表及我们的核数师报告。

我们对综合财务报表之意见并不涵盖其他信

息，我们亦不对该等其他信息发表任何形式之

鉴证结论。

结合我们对综合财务报表之审计，我们的责任

是阅读其他信息，在此过程中，考虑其他信息

是否与综合财务报表或我们在审计过程中所瞭

解之情况存在重大抵触，或似乎存在重大错误

陈述之情况。基于我们已执行的工作，如果我

们认为其他信息存在重大错误陈述，我们需要

报告该事实。在这方面，我们没有任何报告。

OTHER MATER

The consolidated financial statements of the Group for the year

ended 31 March 2024 were audited by another auditor who

expresed an unmodified opinion on those statements on 27

June 2024.

OTHER INFORMATION

The directors of the Company are responsible for the other

information. The other information comprises the information

included in the anual report, but does not include the

consolidated financial statements and our auditor’s report

thereon.

Our opinion on the consolidated financial statements does not

cover the other information and we do not expres any form of

asurance conclusion thereon.

In conection with our audit of the consolidated financial

statements, our responsibility is to read the other information

and, in doing so, consider whether the other information is

materialy inconsistent with the consolidated financial statements

or our knowledge obtained in the audit or otherwise apears

to be materialy mistated. If, based on the work we have

performed, we conclude that there is a material mistatement

of this other information, we are required to report that fact. We

have nothing to report in this regard.

INDEPENDENT AUDITOR’S REPORT

独立核数师报告

ANUAL REPORT 2024/2025

2024/2025 年报

董事及管理层就综合财务报表须承担之

责任

贵公司董事须负责根据香港会计师公会颁布之

《香港财务报告准则会计准则》及香港《公司条

例》之披露要求拟备真实而中肯之综合财务报

表，并对其认为使综合财务报表的拟备不存

在由于欺诈或错误而导致的重大错误陈述所需

的内部控制负责。

在拟备综合财务报表时，贵公司董事负责评

估贵集团持续经营之能力，并在适用情况下

披露与持续经营有关之事项，以及使用持续经

营为会计基础，除非贵公司董事有意将贵

集团清盘或停止经营，或别无其他实际之替代

方案。

管理层负责监督贵集团的财务报告过程。

核数师就审计综合财务报表承担之责任

我们的目标，是对综合财务报表整体是否不存

在由于欺诈或错误而导致的重大错误陈述取得

合理保证，并出具包括我们意见之核数师报

告。我们根据协定的委聘条款仅向整体股东报

告，除此之外，我们的报告不可用作其他用

途。我们概不就本报告之内容，对任何其他人

士负责或承担法律责任。合理保证是高水平之

保证，但不能保证按照《香港审计准则》进行之

审计，在某一重大错误陈述存在时总能发现。

错误陈述可以由欺诈或错误引起，如果合理预

期它们单独或汇总起来可能影响综合财务报表

使用者依赖财务报表所作出之经济决定，则有

关错误陈述可被视为重大。

RESPONSIBILITIES OF DIRECTORS AND THOSE CHARGED

WITH GOVERNANCE FOR THE CONSOLIDATED FINANCIAL

STATEMENTS

The directors of the Company are responsible for the preparation

of the consolidated financial statements that give a true and fair

view in acordance with HKFRS Acounting Standards isued

by the HKICPA and the disclosure requirements of Hong Kong

Companies Ordinance, and for such internal control as the

directors of the Company determine is necesary to enable the

preparation of consolidated financial statements that are fre

from material mistatement, whether due to fraud or eror.

In preparing the consolidated financial statements, the directors

of the Company are responsible for asesing the Group’s ability

to continue as a going concern, disclosing, as aplicable, maters

related to going concern and using the going concern basis of

acounting unles the directors of the Company either intend to

liquidate the Group or to cease operations, or have no realistic

alternative but to do so.

Those charged with governance are responsible for overseing

the Group’s financial reporting proces.

AUDITOR’S RESPONSIBILITIES FOR THE AUDIT OF

THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable asurance about whether

the consolidated financial statements as a whole are fre from

material mistatement, whether due to fraud or eror, and to

isue an auditor’s report that includes our opinion solely to you,

as a body, in acordance with our agred terms of engagement,

and for no other purpose. We do not asume responsibility

towards or acept liability to any other person for the contents of

this report. Reasonable asurance is a high level of asurance, but

is not a guarante that an audit conducted in acordance with

HKSAs wil always detect a material mistatement when it exists.

Mistatements can arise from fraud or eror and are considered

material if, individualy or in the agregate, they could reasonably

be expected to influence the economic decisions of users taken

on the basis of these consolidated financial statements.

INDEPENDENT AUDITOR’S REPORT

独立核数师报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

核数师就审计综合财务报表承担之责任

（续）

在根据《香港审计准则》进行审计的过程中，我

们运用了专业判断，保持了专业怀疑态度。我

们亦：

• 识别和评估由于欺诈或错误而导致综合

财务报表存在重大错误陈述的风险，设

计及执行审计程序以应对这些风险，以

及获取充足和适当的审计凭证，作为我

们意见的基础。由于欺诈可能涉及串

谋、伪造、蓄意遗漏、虚假陈述，或凌

驾于内部控制之上，因此未能发现因欺

诈而导致的重大错误陈述的风险高于未

能发现因错误而导致的重大错误陈述的

风险。

，以设计适

当的审计程序，但目的并非对贵集团

内部控制的有效性发表意见。

• 评价贵公司董事所采用会计政策的恰

当性及作出会计估计和相关披露的合理

性。

• 对董事采用持续经营会计基础的恰当性

作出结论。根据所获取的审计凭证，确

定是否存在与事项或情况有关的重大不

确定性，从而可能导致对贵集团的持

续经营能力产生重大疑虑。如果我们认

为存在重大不确定性，则有必要在核数

师报告中提请使用者注意综合财务报表

中的相关披露。假若有关的披露不足，

则我们应当发表非无保留意见。我们的

结论是基于核数师报告日止所取得的审

计凭证。然而，未来事项或情况可能导

致贵集团不能持续经营。

AUDITOR’S RESPONSIBILITIES FOR THE AUDIT OF

THE CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

As part of an audit in acordance with HKSAs, we exercise

profesional judgment and maintain profesional skepticism

throughout the audit. We also:

• Identify and ases the risks of material mistatement

of the consolidated financial statements, whether due

to fraud or eror, design and perform audit procedures

responsive to those risks, and obtain audit evidence, that

is suficient and apropriate to provide a basis for our

opinion. The risk of not detecting a material mistatement

resulting from fraud is higher than for one resulting from

eror, as fraud may involve colusion, forgery, intentional

omisions, misrepresentations, or the overide of internal

control.

• Obtain an understanding of internal control relevant to

the audit in order to design audit procedures that are

apropriate in the circumstances, but not for the purpose

of expresing an opinion on the efectivenes of the

Group’s internal control.

• Evaluate the apropriatenes of acounting policies used

and the reasonablenes of acounting estimates and

related disclosures made by the directors of the Company.

’ use of

the going concern basis of acounting and, based on the

audit evidence obtained, whether a material uncertainty

exists related to events or conditions that may cast

significant doubt on the Group’s ability to continue as a

going concern. If we conclude that a material uncertainty

exists, we are required to draw atention in our auditor’s

report to the related disclosures in the consolidated

financial statements or, if such disclosures are inadequate,

to modify our opinion. Our conclusions are based on the

audit evidence obtained up to the date of our auditor’s

report. However, future events or conditions may cause

the Group to cease to continue as a going concern.

INDEPENDENT AUDITOR’S REPORT

独立核数师报告

ANUAL REPORT 2024/2025

2024/2025 年报

核数师就审计综合财务报表承担之责任

（续）

、结

构和内容，包括披露，以及综合财务报

表是否中肯反映交易和事项。

，以就集团内实体

或业务单位的财务信息获取充足、适当

的审计凭证，作为对集团财务报表发表

意见的基础。我们负责贵集团审计的

方向、监督和执行。我们为审计意见承

担全部责任。

除其他事项外，我们与管理层沟通了计划的审

计范围、时间安排、重大审计发现等，包括我

们在审计中识别出内部控制的任何重大缺陷。

我们还向管理层提交声明，说明我们已符合有

关独立性的相关专业道德要求，并与他们沟通

有可能合理地被认为会影响我们独立性的所有

关系和其他事项，以及为消除对独立性的威胁

所采取的行动或防范措施（若适用）。

AUDITOR’S RESPONSIBILITIES FOR THE AUDIT OF

THE CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

, structure and content

of the consolidated financial statements, including the

disclosures, and whether the consolidated financial

statements represent the underlying transactions and

events in a maner that achieves fair presentation.

• Plan and perform the group audit to obtain suficient

apropriate audit evidence regarding the financial

information of the entities or busines units within the

group as a basis for forming an opinion on the group

financial statements. We are responsible for the direction,

supervision and performance of the group audit. We

remain solely responsible for our audit opinion.

We comunicate with those charged with governance

regarding, among other maters, the planed scope and

timing of the audit and significant audit findings, including any

significant deficiencies in internal control that we identify during

our audit.

We also provide those charged with governance with a

statement that we have complied with relevant ethical

requirements regarding independence, and to comunicate with

them al relationships and other maters that may reasonably be

thought to bear on our independence, and where aplicable,

action taken to eliminate threats or safeguards aplied.

INDEPENDENT AUDITOR’S REPORT

独立核数师报告

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

核数师就审计综合财务报表承担之责任

（续）

从与管理层沟通的事项中，我们确定哪些事项

对本期综合财务报表的审计最为重要，因而构

成关键审计事项。我们在核数师报告中描述这

些事项，除非法律法规不允许公开披露这些事

项，或在极端罕见的情况下，如果合理预期在

我们报告中沟通某事项造成的负面后果超过产

生的公众利益，我们决定不应在报告中沟通该

事项。

天健国际会计师事务所有限公司

执业会计师

叶婉雅

执业证书编号：P05908

香港

二零二五年六月二十七日

AUDITOR’S RESPONSIBILITIES FOR THE AUDIT OF

THE CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

From the maters comunicated with those charged with

governance, we determine those maters that are of most

significance in the audit of the consolidated financial statements

of the curent period and are therefore the key audit maters.

We describe these maters in our auditor’s report unles law or

regulation precludes public disclosure about the mater or when,

in extremely rare circumstances, we determine that a mater

should not be comunicated in our report because the adverse

consequences of doing so would reasonably be expected to

outweigh the public interest benefits of such comunication.

Confucius International CPA Limited

Certified Public Acountants

YIP YUEN NGA

Practising Certificate Number: P05908

Hong Kong

27 June 2025

2025
二零二五年
HK$’000
千港元
544,522
(449,944)
94,578
50,169
(18,105)
(35,327)
(49,593)
41,722
(8,306)
33,416
(3,022)
30,394
38,585
(8,191)
30,394
7.41

CONSOLIDATED STATEMENT OF PROFIT OR LOS

综合损益表

FOR the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

二零二四年

NotesHK$’000

附注千港元

Revenue收益5644,615

Cost of sales销售成本(545,358)

Gros profit毛利99,257

Other income, gains and loses其他收入、收益及亏损711,883

Research and development expenses研发开支(24,309)

Seling and distribution expenses销售及分销开支(48,819)

Administrative expenses行政开支(54,994)

Profit (los) from operations经营所得溢利（亏损）(16,982)

Finance costs融资成本9(7,070)

Profit (los) before tax除税前溢利（亏损）8(24,052)

Taxation税项10(2,444)

Profit (los) for the year年内溢利（亏损）(26,496)

Atributable to:以下人士应占：

Owners of the Company本公司拥有人(22,066)

Non-controling interests非控股权益(4,430)

Profit (los) for the year年内溢利（亏损）(26,496)

Earnings (los) per share每股盈利（亏损）12

Basic and diluted (HK cents)基本及摊薄（港仙）(4.41)

2025
二零二五年
HK$’000
千港元
30,394
133
(2,519)
(2,386)
28,008
36,330
(8,322)
28,008

CONSOLIDATED STATEMENT OF PROFIT OR LOS AND OTHER COMPREHENSIVE INCOME

综合损益及其他全面收益表

FOR the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

二零二四年

HK$’000

千港元

Profit (los) for the year年内溢利（亏损）(26,496)

Other comprehensive income (expense)

for the year

年内其他全面收益（开支）

Items that may be reclasified

subsequently to profit or los:

其后可能重新分类至损益之

项目：

Exchange diferences on translation

of foreign operations

换算海外业务之汇兑差额

(1,456)

Release of exchange reserve upon

disposal of subsidiaries

出售附属公司时解除

汇兑储备–

Other comprehensive expense for the year年内其他全面开支(1,456)

Total comprehensive income (expense)

for the year

年内全面收益（开支）总额

(27,952)

Atributable to:以下人士应占：

Owners of the Company本公司拥有人(22,284)

Non-controling interests非控股权益(5,668)

Total comprehensive income (expense)

for the year

年内全面收益（开支）总额

(27,952)

2025
二零二五年
HK$’000
千港元
5,502
3,576
260
19,505
75,207
1,038
105,088
16,648
46
73,732
1,644
4,000
135,691
231,761
31,800
10,669
14,779
–
10,084
2,617
7,376
2,897
80,222
151,539
256,627

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

综合财务状况表

At 31 March 2025

于二零二五年三月三十一日

ANUAL REPORT 2024/2025

2024/2025 年报

二零二四年

NotesHK$’000

附注千港元

Non-curent asets非流动资产

Property, plant and equipment物业、厂房及设备145,561

Right-of-use asets使用权资产154,087

Other financial asets其他金融资产2,977

Godwil商誉1649,040

Intangible asets无形资产17155,310

Refundable rental deposits可退回租金按金20981

217,956

Curent asets流动资产

Inventories存货1815,747

Contract asets合约资产19985

Trade and other receivables贸易及其他应收款项2070,657

Tax recoverable可收回税项–

Pledged bank deposits已抵押银行存款219,000

Cash and cash equivalents现金及现金等价物22115,540

211,929

Curent liabilities流动负债

Trade and other payables and

acruals

贸易及其他应付款项以及

应计费用

52,084

Contract liabilities合约负债253,269

Amounts due to related parties应付关联方款项2678,360

Amount due to ultimate holding

company

应付最终控股公司款项26

45,739

Amount due to non-controling

interests

应付非控股权益款项26

11,759

Lease liabilities租赁负债242,606

Tax payable应付税项3,878

Bank borowings银行借贷297,335

205,030

Net curent asets净流动资产6,899

Total asets les curent liabilities总资产减流动负债224,855

2025
二零二五年
HK$’000
千港元
1,168
50,540
29,987
12,409
94,104
162,523
5,222
115,462
120,684
41,839
162,523

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

综合财务状况表

At 31 March 2025

于二零二五年三月三十一日

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

二零二四年

NotesHK$’000

附注千港元

Non-curent liabilities非流动负债

Lease liabilities租赁负债241,512

Amounts due to a related party应付关联方款项26–

Amount due to non-controling

interests

应付非控股权益款项26

50,204

Defered tax liabilities递延税项负债2834,957

86,673

Net asets净资产138,182

Capital and reserves资本及储备

Share capital股本305,000

Reserves储备60,355

Equity atributable to owners of

the Company

本公司拥有人应占权益

65,355

Non-controling interests非控股权益3572,827

Total equity权益总额138,182

The consolidated financial statements on pages 139 to 255 were

aproved and authorised for isue by the board of directors on

27 June 2025 and are signed on its behalf by:

WASHIKITA KENICHIROMIYANO TSUMORU

鹫北健一郎宫野积

DIRECTORDIRECTOR

董事董事

载于第139至255页的综合财务报表已由董事会

于二零二五年六月二十七日批准及授权刊发，

并由以下董事代表签署：

–	–	–	–	–	–	–	–	38,585	38,585	(8,191)	30,394
–	–	–	–	–	–	–	(2,255)	–	(2,255)	(131)	(2,386)
–	–	–	–	–	–	–	(2,255)	38,585	36,330	(8,322)	28,008
222	21,778	–	–	–	–	–	–	–	22,000	–	22,000
–	–	–	–	877	–	–	–	(877)	–	–	–
–	–	–	–	–	266	–	–	–	266	–	266
–	–	–	–	–	–	(3,267)	–	–	(3,267)	(22,666)	(25,933)
5,222	69,434	17,016	4,000	877	266	37,881	(2,639)	(11,373)	120,684	41,839	162,523

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

综合权益变动表

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

Atributable to owners of the Company

本公司拥有人应占

capital

premium

Special

reserve

Capital

reserve

Statutory

reserve

option

reserve

Other

reserve

Exchange

reserve

Acumulated

losesTotal

Non–

controling

interests

Total

equity

股本股份溢价特别储备资本储备法定储备购股权储备其他储备汇兑储备累计亏损总计非控股权益权益总额

HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元

(Note i)(Note i)(Note i)(Note iv)(Note v)(Note vi)

（附注i）（附注i）（附注i）（附注iv）（附注v）（附注vi）

At 1 April 2023于二零二三年

四月一日5,00047,65617,0164,000–41,148(166)(27,015)87,6394,00591,644

Los for the year年内亏损–(22,066)(22,066)(4,430)(26,496)

Other comprehensive expense其他全面开支–(218)–(218)(1,238)(1,456)

Total comprehensive expense

for the year

年内全面开支

总额–(218)(22,066)(22,284)(5,668)(27,952)

Acquisition of non-wholy

owned subsidiaries

收购非全资拥有附属

公司–74,49074,490

At 31 March 2024 and 1 April

于二零二四年三月三

十一日及二零二四

年四月一日5,00047,65617,0164,000–41,148(384)(49,081)65,35572,827138,182

Profit for the year年内溢利

Other comprehensive expense其他全面开支

Total comprehensive income

(expense) for the year

年内全面收益（开支）

总额

Isue of new shares, net of

share isue expenses

发行新股，扣除股份

发行费用

Profit apropriate to statutory

reserve

拨作法定储备之溢利

Recognition of equity-setled

share-based payment

确认以权益结算以股

份为基础之付款

开支

Release upon disposal of

subsidiaries

出售附属公司时解除

At 31 March 2025于二零二五年

三月三十一日

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

综合权益变动表

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

Notes:

(i) The share premium represents the diference betwen the par

value of the shares of the Company and proceds received from

the isuance of the shares of the Company. The aplication of

share premium is governed by Section 34 of Cayman Companies

Act and the provision of the Company’s memorandum and

articles asociation.

(i) Special reserve represents the coresponding movements in

reserves of the Group as a result of the group reorganisation of

Sped Aparel Limited and Firenze Aparel Limited completed

on 1 February 2016. None of these entities formed part of the

Group but were held and controled by Mr. Chan Wing Kai, the

then controling shareholder of the Company at that time.

(i) Capital reserve represents the diference betwen the nominal

value of the one share of the Company isued as part of the

reorganisation to acquire Knit World International Limited (“Knit

World”), a subsidiary of the Company, from the then controling

shareholder of the Company and the nominal value of the then

isued share capital of Knit World.

(iv) Statutory reserve, which is non-distributable, is apropriated from

the profit after taxation of the Group’s PRC subsidiaries under

the aplicable laws and regulations in the PRC. In acordance

with the relevant laws and regulations in the PRC and Articles

of Asociation of the subsidiaries incorporated in the PRC, these

entities are required to apropriate 10% of the anual statutory

net profits, after ofseting any prior years’ loses as determined

under the PRC acounting standards, to the statutory reserve

before distributing a dividend. When the balance of the statutory

reserve reaches 50% of the share capital of the PRC subsidiaries,

any further apropriation is at the discretion of shareholders.

The statutory surplus reserve fund can be used to ofset prior

years’ loses, if any, and may be converted into share capital

by isuing new shares to shareholders in proportion to their

existing shareholding or by increasing the par value of the shares

curently held by them, provided that the remaining balance of

the statutory reserve after such isue is no les than 25% of share

capital.

(v) Other reserve represents (i) the shareholder contribution for

providing an interest fre borowings to the Company in

conection with sales and purchase agrement; (i) the efect

arising from the busines combination involving entities under

comon control on 26 April 2021; (i) the total consideration

for the acquisition of the combining entities of HK$8,842,000

which was setled through the curent acounts with the

related parties and acounted for a demed distribution; and (iv)

demed contribution arising from the wavier of amount due to a

related company of HK$14,354,000 in the bok of the combining

entities during the year ended 31 March 2023. In adition, during

the year ended 31 March 2023, there is dividend recognised

as distribution by a subsidiary under busines combination

under comon control before completion of acquisition of

HK$3,965,000, which was setled through curent acount with a

related company.

(vi) The exchange reserve comprises al foreign exchange diferences

arising from the translation of the financial statements of foreign

operations.

附注：

(i) 股份溢价指本公司股份面值与发行本公司股

份之所得款项之间之差额。股份溢价之应用

受开曼群岛公司法第34条及本公司组织章程

大纲及细则之条文所规管。

(i) 特别储备指因Sped Aparel Limited及Firenze

Aparel Limited之集团重组于二零一六年二

月一日完成而导致本集团储备产生之相应变

动。该等实体并非本集团之组成部分，惟均

由本公司当时之控股东陈永启先生持有及

控制。

(i) 资本储备指作为重组一部分而发行以向本公

司当时之控股东收购本公司附属公司Knit

World International Limited（「Knit World」）之本

公司一股份之面值与Knit World当时已发行

股本面值之差额。

(iv) 法定储备指不可分派之储备，乃根据中国适

用法律及法规拨自本集团中国附属公司之除

税后溢利。根据中国相关法律及法规以及于

中国注册成立之附属公司的组织章程细则，

该等实体于分派股息前，须划拨年度法定纯

利（抵销按中国会计准则厘定之任何过往年

度亏损后）10%至法定储备。当法定储备结余

达至中国附属公司股本50%时，可由股东酌

情厘定是否再作任何划拨。法定盈余储备金

可用于抵销过往年度亏损（如有），并可透过

按股东当前持股比例向其发行新股份或增加

其当前所持股份的面值转换为股本，前提是

在该发行后，法定储备余下结余不少于股本

25%。

(v) 其他储备指(i)股东就买卖协议向本公司提供

免息借贷而作出的注资；(i)于二零二一年四

月二十六日涉及共同控制实体的业务合并产

生的影响；(i)收购合并实体的总代价8,842,000

港元，已透过与关联方的现有账户拨付并按

视作分派入账处理；及(iv)于合并实体截至二

零二三年三月三十一日止年度的账簿内豁免

应付关联公司款项14,354,000港元而产生的视

作注资。此外，于截至二零二三年三月三十

一日止年度，股息3,965,000港元于收购完成

前确认为受共同控制的业务合并的附属公司

所作分派，已透过与关联公司的现有账户拨

付。

(vi) 汇兑储备包括换算海外业务财务报表产生之

所有汇兑差额。

2025
二零二五年
HK$’000
千港元
33,416
2,938
2,974
9,900
(1)
(43,247)
(2,136)
(11)
291
266
8,306
4
(20,217)
18,050
(538)
9,995
(947)
(14,295)
(17,017)
(745)
7,712
(15,297)
(2,626)
(17,923)

CONSOLIDATED STATEMENT OF CASH FLOWS

综合现金流量表

For the year ended 31 MARCH 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

二零二四年

HK$’000

千港元

OPERATING ACTIVITIES经营活动

Profit (los) before tax除税前溢利（亏损）(24,052)

Adjustments for:就下列各项所作调整：

Depreciation of property, plant and

equipment

物业、厂房及设备折旧

2,585

Depreciation of right-of-use asets使用权资产折旧3,450

Amortisation of intangible asets无形资产摊销7,984

(Gain) los on disposal of property, plant and

equipment

出售物业、厂房及设备之

（收益）亏损35

Gain on disposals of subsidiaries出售附属公司产生的收益–

Gain on waiver of amount due to a related

party

豁免应付关联方款项产生的

收益–

Gain on deregistration of subsidiaries注销附属公司产生的收益–

Los on early termination of lease

arangement

提前终止租赁安排产生的亏损

–

Equity-setled share-based payment expenses以权益结算以股份为基础之

付款开支–

Finance costs融资成本7,070

Fair value los on financial liabilities at FVTPL按公平值计入损益之金融

负债之公平值亏损–

Fair value gain on promisory note due to

non-controling interests

非控股权益产生的承兑票据

公平值收益(16,059)

Impairment los on godwil商誉减值亏损–

Interest income利息收入(1,090)

Operating cash flows before working capital

changes

营运资金变动前经营现金流量

(20,077)

(Increase) decrease in inventories存货（增加）减少8,608

Increase in trade and other receivables贸易及其他应收款项增加(11,777)

Decrease in trade and other payables and

acruals

贸易及其他应付款项以及

应计费用减少(3,341)

(Increase) decrease in contract asets合约资产（增加）减少1,801

Increase (decrease)in contract liabilities合约负债增加（减少）(2,379)

Cash used in operations经营所用现金(27,165)

Income tax paid已缴所得税(1,400)

NET CASH USED IN OPERATING ACTIVITIES经营活动所用现金净额(28,565)

2025
二零二五年
HK$’000
千港元
(5,707)
(260)
2,829
5,000
538
–
54,805
57,205
2,897
(7,335)
22,000
(8,731)
(19,478)
(3,024)
(3,113)
(16,784)
22,498
115,540
(2,347)
135,691

CONSOLIDATED STATEMENT OF CASH FLOWS

综合现金流量表

For the year ended 31 MARCH 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

二零二四年

HK$’000

千港元

INVESTING ACTIVITIES投资活动

Purchase of property, plant and equipment购买物业、厂房及设备(5,037)

Purchase of other financial asets购买其他金融资产–

Proceds from sale of property, plant and

equipment

销售物业、厂房及设备所得款项

–

Release of pledged bank deposit解除已抵押银行存款–

Interest received已收利息1,090

Net cash outflow on acquisition of subsidiaries收购附属公司之现金流出净额(16,456)

Net cash inflow on disposals of subsidiaries出售附属公司之现金流入净额–

NET CASH FROM (USED IN) INVESTING

ACTIVITIES

投资活动产生（所用）现金净额

(20,403)

FINANCING ACTIVITIES融资活动

Proceds from bank borowings银行借贷所得款项7,335

Repayment of bank borowings偿还银行借贷–

Proceds from isuance of shares发行股份所得款项–

Repayment to related parties, net向关联方还款净额(12,294)

(Repayment to) advance from ultimate holding

company, net

最终控股公司（还款）垫款净额

46,427

Repayment of lease liabilities偿还租赁负债(3,367)

Interest paid已付利息(4,442)

NET CASH (USED IN) FROM FINANCING

ACTIVITIES

融资活动（所用）产生现金净额

33,659

NET INCREASE (DECREASE) IN CASH AND CASH

EQUIVALENTS

现金及现金等价物增加（减少）

净额(15,309)

CASH AND CASH EQUIVALENTS AT BEGINING

OF THE YEAR

年初的现金及现金等价物

131,471

EFECT OF FOREIGN EXCHANGE RATE CHANGES汇率变动之影响(622)

CASH AND CASH EQUIVALENTS AT END OF THE

YEAR

年末的现金及现金等价物

115,540

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

1. GENERAL INFORMATION

EPS Creative Health Technology Group Limited (the

“Company”) was incorporated in the Cayman Islands as

an exempted company and registered in the Cayman

Islands with limited liability under the Companies Act,

Cap. 22 (Act 3 of 1961, as consolidated and revised) of the

Cayman Islands on 19 November 2015. The adres of the

Company’s registered ofice is Cricket Square, Hutchins

Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman

Islands and the principal place of busines of the Company

is Flat A, 17/F., Gemstar Tower, 23 Man Lok Stret, Hung

Hom, Kowlon, Hong Kong.

The Company is an investment holding company and its

subsidiaries (colectively refered to as the “Group”) are

principaly engaged in trading of aparel products to its

customers, trading of healthcare and medicated products

and leasing of medical devices, specialised contract

research organisation (“CRO”) and inovative research

organisation (“IRO”) services performing in Japan and

the People’s Republic of China (“PRC”). The Group is also

engaged in in-house drug discovery and development.

The principal activities of the subsidiaries are set out in

note 35.

The imediate and ultimate holding company is EPS

Holdings, Inc., a company incorporated in Japan with

limited liability, the isued shares of which were listed

on the Tokyo Stock Exchange until its subsequent

privatisation on 17 September 2021.

The consolidated financial statements are presented in

Hong Kong dolars (“HK$”), which is also the functional

curency of the Company.

1. 一般资料

EPS创健科技集团有限公司（「本公司」）

于二零一五年十一月十九日根据开曼群

岛法例第22章公司法（一九六一年第3号

法例，经综合及修订）在开曼群岛注册

成立为获豁免公司并在开曼群岛登记为

有限公司。本公司之注册办事处地址为

Cricket Square, Hutchins Drive, P.O. Box

2681, Grand Cayman, KY1-1111, Cayman

Islands，而本公司之主要营业地点为香

港九龙红磡民乐街23号骏升中心17楼A

室。

本公司为一间投资控股公司，与其附属

公司（统称「本集团」）主要从事向其客户

进行服装产品贸易、保健产品及药品

贸易以及医疗器械租赁及提供日中专业

受托研究机构（「CRO」）、创新研究机构

（「IRO」）服务。本集团亦从事内部药物

发现及开发。附属公司之主要业务载于

附注35。

直接及最终控股公司为EPS Holdings,

Inc.，其为一间于日本注册成立之有限公

司，其已发行股份在东京证券交易所上

市，直至其后于二零二一年九月十七日

私有化。

综合财务报表以本公司之功能货币港元

（「港元」）呈列。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

2. 应用新订香港财务报告准则会计

准则及准则之修订本

于本年度强制生效的香港财务报告准则

会计准则之修订本

于本年度，本集团首次应用由香港会计

师公会（「香港会计师公会」）颁布的下列

香港财务报告准则会计准则之修订本，

其于二零二四年四月一日开始的本集团

年度期间强制生效，以编制综合财务报

表：

香港财务报告准则

第16号之修订本

售后租回之租赁

负债

香港会计准则第1号

之修订本

负债分类为流动或

非流动及香港诠

释第5号（二零二

零年）之相关修订

香港会计准则第1号

之修订本

附有契约之非流动

负债

香港会计准则第7号

及香港财务报告准

则第7号之修订本

供应商融资安排

于本年度应用香港财务报告准则会计准

则之修订本对本集团本年度及过往年度

的财务状况及表现及╱或本综合财务报

表所载披露并无重大影响。

2. APLICATION OF NEW AND AMENDMENTS

TO HKFRS ACOUNTING STANDARDS

Amendments to HKFRS Acounting Standards that

are mandatorily efective for the curent year

In the curent year, the Group has aplied the folowing

amendments to HKFRS Acounting Standards isued by

the Hong Kong Institute of Certified Public Acountant

(“HKICPA”) for the first time, which are mandatorily

efective for the Group’s anual period begining on 1

April 2024 for the preparation of the consolidated financial

statements:

Amendments to HKFRS 16Lease Liability in a Sale and

Leaseback

Amendments to HKAS 1Clasification of Liabilities as

Curent or Non-curent and

related amendments to

Hong Kong Interpretation 5

(2020)

Amendments to HKAS 1Non-curent Liabilities with

Covenants

Amendments to HKAS 7

and HKFRS 7

Suplier Finance

Arangements

The aplication of the amendments to HKFRS Acounting

Standards in the curent year has had no material impact

on the Group’s financial positions and performance for the

curent and prior years and/or on the disclosures set out

in these consolidated financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

2. 应用新订香港财务报告准则会计

准则及准则之修订本（续）

已颁布但尚未生效的新订香港财务报告

准则会计准则及准则之修订本

本集团并无提早采纳以下已颁布但尚未

生效的新订香港财务报告准则会计准则

及准则之修订本：

香港财务报告准则

第9号及香港财务

报告准则第7号之

修订本

金融工具之分类与

计量之修订

香港财务报告准则

第10号及香港会

计准则第28号之

修订本

投资者与其联营公

司或合营公司之

间的资产出售或

注入

香港财务报告准则

会计准则之

修订本

香港财务报告准则

会计准则年度改

进－第11册

香港会计准则

第21号之修订本

缺乏可兑换性

香港财务报告准则

第18号

财务报表之呈列及

披露

香港财务报告准则

第19号

非公共受托责任附

属公司：披露

于二零二五年四月一日或之后开始的

年度期间生效。

于二零二六年四月一日或之后开始的

年度期间生效。

于二零二七年四月一日或之后开始的

年度期间生效。

于待定日期或之后开始的年度期间生

效。

除下文所述新订香港财务报告准则会计

准则外，本公司董事预计应用所有新订

香港财务报告准则会计准则及准则之修

订本于可见将来将不会对综合财务报表

构成重大影响。

2. APLICATION OF NEW AND AMENDMENTS

TO HKFRS ACOUNTING STANDARDS

(CONTINUED)

New and amendments to HKFRS Acounting Standards

in isue but not yet efective

The Group has not early aplied the folowing new and

amendments to HKFRS Acounting Standards that have

ben isued but are not yet efective:

Amendments to HKFRS 9

and HKFRS 7

Amendments to the

Clasification and

Measurement of Financial

Instruments

Amendments to HKFRS 10

and HKAS 28

Sale or Contribution of

Asets betwen an Investor

and its Asociate or Joint

Venture

Amendments to HKFRS

Acounting Standards

Anual Improvements

to HKFRS Acounting

Standards – Volume 11

Amendments to HKAS 21Lack of Exchangeability

HKFRS 18Presentation and Disclosure

in Financial Statements

HKFRS 19Subsidiaries without Public

Acountability: Disclosures

Efective for anual periods begining on or after 1 April

2025.

Efective for anual periods begining on or after 1 April

2026.

Efective for anual periods begining on or after 1 April

2027.

Efective for anual periods begining on or after a date

to be determined.

Except for the new HKFRS Acounting Standards

mentioned below, the directors of the Company anticipate

that the aplication of al other new and amendments

to HKFRS Acounting Standards wil have no material

impact on the consolidated financial statements in the

foreseable future.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

2. 应用新订香港财务报告准则会计

准则及准则之修订本（续）

已颁布但尚未生效的新订香港财务报告

准则会计准则及准则之修订本（续）

香港财务报告准则第18号「财务报表之呈

列及披露」

香港财务报告准则第18号「财务报表之呈

列及披露」载列财务报表之呈列及披露规

定，将取代香港会计准则第1号「财务报

表之呈列」。本新订香港财务报告准则会

计准则在延续香港会计准则第1号中众多

规定的同时，引入于损益表中呈列指定

类别及定义小计的新规定；就财务报表

附注中管理层界定之表现计量提供披露

及改进于财务报表中将予披露之合并及

分类资料。此外，香港会计准则第1号

之部分段落已移至香港会计准则第8号及

香港财务报告准则第7号。香港会计准则

第7号「现金流量表」及香港会计准则第33

号「每股盈利」亦作出细微修订。

香港财务报告准则第18号及其他香港财

务报告准则会计准则之修订本将于二零

二七年四月一日或之后开始的年度期间

生效，并允许提早应用。应用新准则预

期将会影响损益表之呈列以及未来财务

报表之披露。本集团正在评估香港财务

报告准则第18号对本集团综合财务报表

之详细影响。

2. APLICATION OF NEW AND AMENDMENTS

TO HKFRS ACOUNTING STANDARDS

(CONTINUED)

New and amendments to HKFRS Acounting Standards

in isue but not yet efective (Continued)

HKFRS 18 Presentation and Disclosure in Financial

Statements

HKFRS 18 Presentation and Disclosure in Financial

Statements, which sets out requirements on presentation

and disclosures in financial statements, wil replace HKAS

1 Presentation of Financial Statements. This new HKFRS

Acounting Standard, while carying forward many of the

requirements in HKAS 1, introduces new requirements

to present specified categories and defined subtotals in

the statement of profit or los; provide disclosures on

management-defined performance measures in the notes

to the financial statements and improve agregation

and disagregation of information to be disclosed in the

financial statements. In adition, some HKAS 1 paragraphs

have ben moved to HKAS 8 and HKFRS 7. Minor

amendments to HKAS 7 Statement of Cash Flows and

HKAS 33 Earnings per Share are also made.

HKFRS 18, and amendments to other HKFRS Acounting

Standards, wil be efective for anual periods begining

on or after 1 April 2027, with early aplication permited.

The aplication of the new standard is expected to afect

the presentation of the statement of profit or los and

disclosures in the future financial statements. The Group is

in the proces of asesing the detailed impact of HKFRS

18 on the Group’s consolidated financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料

3.1 综合财务报表之编制基准

本公司之综合财务报表已根据香

港会计师公会颁布之香港财务报

告准则会计准则编制。就编制综

合财务报表而言，倘有关资料合

理预期会影响主要使用者作出的

决定，则有关资料被视为重大。

此外，综合财务报表包括香港联

合交易所有限公司证券上市规则

及香港公司条例规定之适用披露

事项。

于批准综合财务报表时，本公司

董事合理预期本集团有足够资源

于可预见将来继续经营。因此，

彼等在编制综合财务报表时继续

采用持续经营会计基准。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION

3.1 Basis of preparation of the consolidated

financial statements

The consolidated financial statements of the

Company have ben prepared in acordance with

HKFRS Acounting Standards isued by the HKICPA.

For the purpose of preparation of the consolidated

financial statements, information is considered

material if such information is reasonably expected

to influence decisions made by primary users. In

Adition, the consolidation financial statements

include aplicable disclosure required by the Rules

Governing the Listing of Securities on The Stock

Exchange of Hong Kong Limited and by the Hong

Kong Companies Ordinance.

The directors of the Company have, at the time of

aproving the consolidated financial statements, a

reasonable expectation that the Group has

adequate resources to continue in operational

existence for the foreseable future. Thus they

continue to adopt the going concern basis of

acounting in preparing the consolidated financial

statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料

合并基准

综合财务报表包括本公司以及受

本公司及其附属公司所控制实体

之财务报表。在下列情况下，本

公司对该被投资方具有控制权：

• 具有承担或享有参与有关被

投资方所得之可变回报的风

险或权利；及

• 能使用其权力影响该等回

报，

如果事实和情况表明上述三项控

制要素中的一项或多项发生变

化，本集团将重新评估其是否控

制被投资方。

附属公司由本集团获得其控制权

之时起合并计算，而当本集团失

去其控制权时则停止合并计算。

具体而言，本年度收购或出售的

附属公司的收入和费用自本集团

取得控制权之日起至本集团不再

控制该附属公司之日止计入综合

损益表。

损益及其他全面收益各项目归属

于本公司拥有人及非控股权益。

附属公司的全面收益总额归属于

本公司拥有人及非控股权益，即

使会导致非控股权益出现亏损结

余。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

Basis of consolidation

The consolidated financial statements incorporate

the financial statements of the Company and

entities controled by the Company and its

subsidiaries. Control is achieved when the

Company:

;

, or has rights, to variable returns

from its involvement with the investe; and

• has the ability to use its power to afect its

returns.

The Group reaseses whether or not it controls an

investe if facts and circumstances indicate that

there are changes to one or more of the thre

elements of control stated above.

Consolidation of a subsidiary begins when the

Group obtains control over the subsidiary and

ceases when the Group ceases to control the

subsidiary. Specificaly, income and expenses of a

subsidiary acquired or disposed of during the year

are included in the consolidated statement of profit

or los from the date the Group gains control until

the date when the Group ceases to control the

subsidiary.

Profit or los and each item of other comprehensive

income are atributed to the owners of the

Company and to the non-controling interests. Total

comprehensive income of subsidiaries is atributed

to the owners of the Company and to the non-

controling interests even if this results in the non-

controling interests having a deficit balance.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

合并基准（续）

附属公司所呈报金额已按需要作

出调整，以确保与本集团之政策

保持一致。

与本集团成员公司间之交易有关

的所有集团内公司间资产及负

债、权益、收益、开支及现金流

量于合并时全数对销。

附属公司的非控股权益与本集团

在其中的权益分开列报，代表现

有的所有权益，其持有人在清

算时有权按比例分享相关附属公

司的净资产。

业务合并

业务乃一组集成活动及资产，包

括相结合能够显著促进产出能力

的投入及实质性的过程。倘所获

得的过程对持续产出的能力（包括

具备执行相关流程所需技能、知

识或经验的组织劳动力，或对持

续生产出的能力有重大贡献，

则被认为属独特或稀缺，或在无

重大成本、努力或持续生产出

能力出现延迟的情况下不可取代）

至关重要，则其被视为具实质性。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Basis of consolidation (Continued)

When necesary, amounts reported by subsidiaries

have ben adjusted to conform with the Group’s

acounting policies.

Al intragroup asets and liabilities, equity, income,

expenses and cash flows relating to transactions

betwen members of the Group are eliminated in

ful on consolidation.

Non-controling interests in subsidiaries are

presented separately from the Group’s equity

therein, which represent present ownership

interests entitling their holders to a proportionate

share of net asets of the relevant subsidiaries upon

liquidation.

Busines combinations

A busines is an integrated set of activities and

asets which includes an input and a substantive

proces that together significantly contribute to the

ability to create outputs. The acquired proceses

are considered substantive if they are critical to the

ability to continue producing outputs, including

an organised workforce with the necesary skils,

knowledge, or experience to perform the related

proceses or they significantly contribute to the

ability to continue producing outputs and are

considered unique or scarce or canot be replaced

without significant cost, efort, or delay in the ability

to continue producing outputs.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

业务合并（续）

收购业务（受共同控制的业务合并

除外）以收购方式入账。在业务合

并中转让的代价按公平值计量，

而公平值乃按本集团所转让资

产、本集团向被收购方前拥有人

所承担负债及本集团为交换被收

购方控制权所发行股权于收购日

期的公平值总和计算。收购相关

成本通常于产生时于损益中确认。

所收购的可识别资产及所承担的

负债必须符合财务报告概念框架

（「概念框架」）内资产及负债的定

义，惟香港会计准则第37号「拨

备、或然负债及或然资产」或香

港财务报告诠释委员会诠释第21

号「征费」范围内的交易及事件除

外，于该情况下，本集团应用香

港会计准则第37号或香港财务报

告诠释委员会诠释第21号而非概

念框架以识别其于业务合并中所

承担的负债。或然资产不予确认。

于收购日期，所收购已识别资产

及所承担负债按其公平值确认，

惟下列者除外：与被收购方以股

份为基础的付款安排有关之负债

或股本工具或以本集团订立以股

份为基础的付款安排取代被收购

方以股份为基础的付款安排，乃

于收购日期根据香港财务报告准

则第2号「以股份为基础的付款」计

量。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Busines combinations (Continued)

Acquisitions of busineses, other than busines

combination under comon control are acounted

for using the acquisition method. The consideration

transfered in a busines combination is measured

at fair value, which is calculated as the sum of the

acquisition-date fair values of the asets transfered

by the Group, liabilities incured by the Group to

the former owners of the acquire and the equity

interests isued by the Group in exchange for

control of the acquire. Acquisition-related costs are

generaly recognised in profit or los as incured.

The identifiable asets acquired and liabilities

asumed must met the definitions of an aset and

a liability in the Conceptual Framework for Financial

Reporting (the “Conceptual Framework”) except

for transactions and events within the scope of

HKAS 37 Provisions, Contingent Liabilities and

Contingent Asets or HK(IFRIC)-Int 21 Levies, in

which the Group aplies HKAS 37 or HK(IFRIC)-

Int 21 instead of the Conceptual Framework to

identify the liabilities it has asumed in a busines

combination. Contingent asets are not recognised

At the acquisition date, the identifiable asets

acquired and the liabilities asumed are recognised

at their fair value, except that liabilities or equity

instruments related to share-based payment

arangements of the acquire or share-based

payment arangements of the Group entered into

to replace share-based payment arangements

of the acquire are measured in acordance with

HKFRS 2 Share-based Payment at the acquisition

date.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

业务合并（续）

商誉乃以所转让代价、任何非控

股权益于被收购方中所占金额及

收购方先前所持被收购方股本权

益的公平值（如有）的总和，超

逾所收购已识别资产及所承担负

债于收购日期的净额计量。倘重

新评估后，所收购已识别资产及

所承担负债的净额超出所转让代

价、任何非控股权益于被收购方

中所占金额及收购方先前所持被

收购方股本权益的公平值（如有）

的总和，则超逾差额立即于损益

内确认为议价收购收益。

属现时所有权益且于清盘时让

持有人有权按比例分占相关附属

公司资产净值之非控股权益，会

初步或非控股权益应占被收购方

已识别资产净值的已确认金额或

公平值计量。

当本集团于一项业务合并中所转

让的代价包含或然代价安排时，

或然代价按收购日期之公平值计

量，并作为于业务合并中转让的

代价的一部分入账。符合计量期

间调整的或然代价公平值变动会

作出追溯调整。计量期调整为于

「计量期」（不得超过收购日期起计

一年）内所获得与于收购日期已存

在的事实及情况有关的额外资料

所产生的调整。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Busines combinations (Continued)

Godwil is measured as the exces of the sum

of the consideration transfered, the amount of

any non-controling interests in the acquire, and

the fair value of the acquirer’s previously held

equity interest in the acquire (if any) over the net

amount of the identifiable asets acquired and the

liabilities asumed as at acquisition date. If, after

re-asesment, the net amount of the identifiable

asets acquired and liabilities asumed exceds the

sum of the consideration transfered, the amount

of any non-controling interests in the acquire

and the fair value of the acquirer’s previously

held interest in the acquire (if any), the exces

is recognised imediately in profit or los as a

bargain purchase gain.

Non-controling interests that are present

ownership interests and entitle their holders to a

proportionate share of the relevant subsidiary’s

net asets in the event of liquidation are initialy

measured at the non-controling interests’

proportionate share of the recognised amounts of

the acquire’s identifiable net asets or at fair value.

When the consideration transfered by the Group

in a busines combination includes a contingent

consideration arangement, the contingent

consideration is measured at its acquisition-date

fair value and included as part of the consideration

transfered in a busines combination. Changes

in the fair value of the contingent consideration

that qualify as measurement period adjustments

are adjusted retrospectively. Measurement

period adjustments are adjustments that arise

from aditional information obtained during the

“measurement period” (which canot exced one

year from the acquisition date) about facts and

circumstances that existed at the acquisition date.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

业务合并（续）

不符合计量期调整的或然代价的

其后会计处理则取决于或然代价

的分类作出。分类为权益的或

然代价不会于其后的报告日期重

新计量，而其后结算于权益内入

账。分类为资产或负债的或然代

价会于其后的报告日期重新计量

至其公平值，相应的盈亏于损益

中确认。

倘业务合并分阶段完成，则本集

团先前所持被收购方的股本权益

会重新计量至收购日期（即本集团

获得控制权当日）的公平值，而所

产生的盈亏（如有）会于损益或其

他全面收益（如适用）确认。如本

集团已直接出售先前持有的股本

权益，先前已于其他全面收益确

认并根据香港财务报告准则第9号

「金融工具」（「香港财务报告准则

第9号」）计量的在收购日期前于被

收购方的权益所产生的金额，将

须按相同基准入账。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Busines combinations (Continued)

The subsequent acounting for the contingent

consideration that do not qualify as measurement

period adjustments depends on how the

contingent consideration is clasified. Contingent

consideration that is clasified as equity is not

remeasured at subsequent reporting dates and

its subsequent setlement is acounted for within

equity. Contingent consideration that is clasified as

an aset or a liability is remeasured to fair value at

subsequent reporting dates, with the coresponding

gain or los being recognised in profit or los.

When a busines combination is achieved in

stages, the Group’s previously held equity interest

in the acquire is remeasured to fair value at the

acquisition date (i.e. the date when the Group

obtains control), and the resulting gain or los,

if any, is recognised in profit or los or other

comprehensive income, as apropriate. Amounts

arising from interests in the acquire prior to

the acquisition date that have previously ben

recognised in other comprehensive income and

measured under HKFRS 9 Financial Instruments

(“HKFRS 9”) would be acounted for on the same

basis as would be required if the Group had

disposed directly of the previously held equity

interest.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

本集团于现有附属公司之权益变

动

倘本集团于附属公司之权益变动

并无导致本集团失去对该等附属

公司的控制权，则入账列作股本

交易。本集团之权益相关组成部

分及非控股权益之账面值乃作出

调整，以反映彼等于附属公司之

相关权益变动，包括根据本集团

及非控股权益之间的占比权益于

本集团及非控股权益之间重新归

属相关储备。

非控股权益作调整之金额与已支

付或已收取代价之公平值间之任

何差额乃直接于权益确认，并归

属于本公司拥有人。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Changes in the Groups interests in existing

subsidiaries

Changes in the Groups interests in subsidiaries

that do not result in the Group losing control

over the subsidiaries are acounted for as equity

transactions. The carying amounts of the Groups

relevant components of equity and the non-

controling interests are adjusted to reflect the

changes in their relative interests in the subsidiaries,

including re-atribution of relevant reserves

betwen the Group and the non-controling

interests acording to the Groups and the non-

controling interests proportionate interests.

Any diference betwen the amount by which the

non-controling interests are adjusted, and the

fair value of the consideration paid or received

is recognised directly in equity and atributed to

owners of the Company.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

本集团于现有附属公司之权益变

动（续）

当本集团失去对一间附属公司之

控制权时，该附属公司之资产及

负债以及非控股权益（如有）将终

止入账。收益或亏损于损益确

认，并按(i)已收取代价公平值及

任何保留权益公平值之总额与(i)

本公司拥有人应占附属公司之资

产（包括商誉）及负债账面值间之

差额计算。先前于其他全面收益

确认之与该附属公司相关之所有

金额将会以犹如本集团已直接出

售该附属公司之相关资产及负债

的方式入账（即按适用香港财务报

告准则会计准则所订明╱允许而

重新分类至损益或转拨至另一权

益类别）。于失去控制权当日仍保

留于前附属公司之任何投资的公

平值，则根据香港财务报告准则

第9号「金融工具」于其后入账时视

为初步确认之公平值，或（如适

用）于联营公司或合营公司之投资

的初步确认成本。

商誉

收购业务所产生的商誉按收购业

务当日确定的成本（见上文会计政

策）减累计减值亏损（如有）入账。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Changes in the Groups interests in existing

subsidiaries (Continued)

When the Group loses control of a subsidiary, the

asets and liabilities of that subsidiary and non-

controling interests (if any) are derecognised.

A gain or los is recognised in profit or los and

is calculated as the diference betwen (i) the

agregate of the fair value of the consideration

received and the fair value of any retained

interest and (i) the carying amount of the

asets (including godwil), and liabilities of the

subsidiary atributable to the owners of the

Company. Al amounts previously recognised

in other comprehensive income in relation to

that subsidiary are acounted for as if the Group

had directly disposed of the related asets or

liabilities of the subsidiary (i.e. reclasified to

profit or los or transfered to another category

of equity as specified/permited by aplicable

HKFRS Acounting Standards). The fair value of

any investment retained in the former subsidiary

at the date when control is lost is regarded as the

fair value on initial recognition for subsequent

acounting under HKFRS 9 Financial Instruments or,

when aplicable, the cost on initial recognition of

an investment in an asociate or a joint venture.

Godwil

Godwil arising on an acquisition of a busines

is caried at cost as established at the date of

acquisition of the busines (se the acounting

policy above) les acumulated impairment loses,

if any.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

商誉（续）

就减值测试而言，商誉乃分配至

预期将自合并协同效益获益的本

集团各现金产生单位（或现金产生

单位组别），即就内部管理目的监

控商誉的最低水平且不超过经营

分部。

获分配商誉的现金产生单位（或现

金产生单位组别）会每年进行减值

测试，或于有迹象显示该单位可

能出现减值时更频密地进行减值

测试。就于报告期间因收购产生

的商誉而言，获分配商誉的现金

产生单位（或现金产生单位组别）

于该报告期末前进行减值测试。

倘可收回金额低于其账面值，则

首先分配减值亏损以减少任何商

誉的账面值，然后根据该单位（或

现金产生单位组别）内各资产的账

面值按比例分配至其他资产。

于出售相关现金产生单位或现金

产生单位组别内的任何现金产生

单位时，会于厘定出售损益金额

时计及商誉的应占金额。当本集

团出售现金产生单位（或现金产生

单位组别内的一个现金产生单位）

内的业务时，所出售商誉金额按

所出售业务（或现金产生单位）与

所保留现金产生单位（或现金产生

单位组别）部分的相对价值计量，

除非本集团可证明部分其他方法

能更好地反映与所出售业务相关

的商誉，则作别论。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Godwil (Continued)

For the purposes of impairment testing, godwil is

alocated to each of the Group’s CGUs (“CGUs”) (or

group of CGUs) that is expected to benefit from the

synergies of the combination, which represent the

lowest level at which the godwil is monitored for

internal management purposes and not larger than

an operating segment.

A CGU (or group of CGUs) to which godwil has

ben alocated is tested for impairment anualy or

more frequently when there is indication that the

unit may be impaired. For godwil arising on an

acquisition in a reporting period, the CGU (or group

of CGUs) to which godwil has ben alocated

is tested for impairment before the end of that

reporting period. If the recoverable amount is les

than its carying amount, the impairment los is

alocated first to reduce the carying amount of any

godwil and then to the other asets on a pro-rata

basis based on the carying amount of each aset

in the unit (or group of CGUs).

On disposal of the relevant CGU or any of the CGU

within the group of CGUs, the atributable amount

of godwil is included in the determination of

the amount of profit or los on disposal. When the

Group disposes of an operation within the CGU

(or a CGU within a group of CGUs), the amount

of godwil disposed of is measured on the basis

of the relative values of the operation (or the

CGU) disposed of and the portion of the CGU (or

the group of CGUs) retained, unles the Group

can demonstrate that some other method beter

reflects the godwil asociated with the operation

disposed of.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

客户合约收益

本集团有关客户合约收益的会计

政策资料载于附注5、19及25。

租赁

本集团会于合约开始时根据香港

财务报告准则第16号「租赁」项下

的定义评估合约是否为租赁或包

含租赁。除非该合约的条款及条

件随后有更改，否则不会重新评

估。

本集团作为承租人

短期租赁及低价值资产租赁

本集团将短期租赁确认豁免应用

于自开始日期起租期为12个月或

以下之办公室物业及办公室设备

租赁且不包含购买选择权。其亦

适用于低价值资产租赁的确认。

短期租赁低价值资产租赁的租赁

付款在租赁期内按直线法或另一

系统基准确认为费用。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Revenue from contracts with customers

Information about the Group’s acounting policies

relating to contract with customer is provided in

note 5, 19 and 25.

Leases

The Group aseses whether a contract is or

contains a lease based on the definition under

HKFRS 16 Leases at inception of the contract. Such

contract wil not be reasesed unles the terms

and conditions of the contract are subsequently

changed.

The Group as a lese

Short-term leases and leases of low-value asets

The Group aplies the short-term lease recognition

exemption to leases of ofice premises and ofice

equipment that have a lease term of 12 months

or les from the comencement date and do

not contain a purchase option. It also aplies the

recognition exemption for lease of low-value asets.

Lease payments on short-term leases and leases of

low-value asets are recognised as expense on a

straight-line basis or another systematic basis over

the lease term.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

租赁（续）

本集团作为承租人（续）

使用权资产

使用权资产之成本包括：

• 于开始日期或之前作出之任

何租赁付款，减任何已收

租赁优惠；

• 本集团产生之任何初步直接

成本；及

• 本集团拆卸及移除相关资

产、复原相关资产所在场

地或复原相关资产至租赁条

款及条件所规定之状况之过

程中所产生的估计成本。

使用权资产按成本减任何累计折

旧及减值亏损计量，并就租赁负

债的任何重新计量进行调整。

使用权资产按直线基准于估计可

使用年期与租期之间之较短者计

提折旧。

本集团将租赁资产作为单独项目

于综合财务状况表内呈列。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Leases (Continued)

The Group as a lese (Continued)

Right-of-use asets

The cost of right-of-use asets includes:

• the amount of the initial measurement of

the lease liability;

• any lease payments made at or before

the comencement date, les any lease

incentives received;

;

and

• an estimate of costs to be incured by the

Group in dismantling and removing the

underlying asets, restoring the site on which

it is located or restoring the underlying aset

to the condition required by the terms and

conditions of the lease.

Right-of-use asets are measured at cost, les any

acumulated depreciation and impairment loses,

and adjusted for any remeasurement of lease

liabilities.

Right-of-use asets are depreciated on a straight-

line basis over the shorter of its estimated useful

life and the lease term.

The Group presents right-of-use asets as a separate

line item on the consolidated statement of financial

position.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

租赁（续）

本集团作为承租人（续）

可退还的租赁按金

已支付的可退还租赁按金根据香

港财务报告准则第9号入账，并初

步按公平值计量。初始确认时对

公平值的调整被视为额外的租赁

付款，并包括在使用权资产成本

中。

租赁负债

于租赁开始日，本集团按当时尚

未支付的租赁付款的现值确认并

计量租赁负债。在计算租赁付款

的现值时，如果租赁中隐含的利

率难以确定，则本集团在租赁开

始日使用增量借款利率。

租赁付款包括固定付款。

于开始日期后，租赁负债乃透过

增计利息及租赁付款进行调整。

倘租期有所变动发生变化，本集

团会重新计量租赁负债（并对相关

使用权资产作出相应调整），在此

情况下，相关租赁负债透过使用

重新评估日期之经修订贴现率贴

现经修订租赁付款而重新计量。

本集团将租赁负债作为单独项目

于综合财务状况表内呈列。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Leases (Continued)

The Group as a lese (Continued)

Refundable rental deposits

Refundable rental deposits paid are acounted

under HKFRS 9 and initialy measured at fair value.

Adjustments to fair value at initial recognition

are considered as aditional lease payments and

included in the cost of right-of-use asets.

Lease liabilities

At the comencement date of a lease, the Group

recognises and measures the lease liability at the

present value of lease payments that are unpaid

at that date. In calculating the present value of

lease payments, the Group uses the incremental

borowing rate at the lease comencement date if

the interest rate implicit in the lease is not readily

determinable.

The lease payments include fixed payments.

After the comencement date, lease liabilities are

adjusted by interest acretion and lease payments.

The Group remeasures lease liabilities (and makes

a coresponding adjustment to the related right-

of-use asets) whenever the lease term has

changed, in which case the related lease liability

is remeasured by discounting the revised lease

payments using a revised discount rate at the date

of reasesment.

The Group presents lease liabilities as a separate

line item on the consolidated statement of financial

position.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

物业、厂房及设备

物业、厂房及设备有持作生产或

供应货品或服务或行政用途的有

形资产（下文所述的在建物业工程

除外），乃于综合财务状况表按成

本减其后累计折旧及累计减值亏

损（如有）后列账。

折旧乃根据资产（在建工程除外）

之估计可使用年期减其剩余价值

后以直线法确认撇销之成本。估

计可使用年期、剩余价值及折旧

方法会在各报告期末检讨，并按

未来基准法将任何估计变更之影

响入账。

物业、厂房及设备项目于出售或

当预期持续使用该资产将不会产

生未来经济利益时终止确认。出

售物业、厂房及设备项目或将有

关项目报废所产生之任何收益或

亏损乃以销售所得款项与该资产

之账面值之差额厘定，并于损益

内确认。

于业务合并中收购之无形资产

业务合并中收购之无形资产与商

誉分开确认，初步按其于收购日

期之公平值（被视作其成本）确认。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Property, plant and equipment

Property, plant and equipment are tangible

asets that are held for use in the production or

suply of gods or services, or for administrative

purposes other than properties construction in

progres as described below, are stated in the

consolidated statement of financial position at cost

les subsequent acumulated depreciation and

acumulated impairment loses, if any.

Depreciation is recognised so as to write of the

cost of asets, other than construction in progres

les their residual values, over their estimated useful

lives, using the straight-line method. The estimated

useful lives, residual values and depreciation

method are reviewed at the end of each reporting

period, with the efect of any changes in estimate

acounted for on a prospective basis.

An item of property, plant and equipment is

derecognised upon disposal or when no future

economic benefits are expected to arise from

the continued use of the aset. Any gain or los

arising on the disposal or retirement of an item of

property, plant and equipment is determined as

the diference betwen the sales proceds and the

carying amount of the aset and is recognised in

profit or los.

Intangible asets acquired in a busines

combination

Intangible asets acquired in a busines

combination are recognised separately from

godwil and are initialy recognised at their fair

value at the acquisition date (which is regarded as

their cost).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

于业务合并中收购之无形资产（续）

于初步确认后，于业务合并中收

购之具有限可使用年期之无形资

产按与单独收购之无形资产相同

之基准，以成本减累计摊销及任

何累计减值亏损呈报。于业务合

并中收购之具无限可使用年期之

无形资产按成本减任何其后累计

减值亏损列账。

无形资产于出售时或预计使用或

出售该资产并无未来经济利益时

取消确认。取消确认无形资产所

产生之收益及亏损，按该资产之

出售所得款项净额与其账面值之

差额计量，在资产取消确认时于

损益确认。

物业、厂房及设备、使用权资产

以及无形资产（商誉除外）之减值

于报告期末，本集团检讨其物

业、厂房及设备、使用权资产以

及具有限可使用年期之无形资产

以外的资产之账面值，以厘定有

否迹象显示该等资产出现减值亏

损。倘出现任何有关迹象，则须

估计相关资产之可收回金额，以

厘定减值亏损（如有）之程度。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Intangible asets acquired in a busines

combination (Continued)

Subsequent to initial recognition, intangible asets

acquired in a busines combination with finite

useful lives are reported at costs les acumulated

amortisation and any acumulated impairment

loses, on the same basis as intangible asets that

are acquired separately. Intangible asets acquired

in a busines combination with indefinite useful

lives are caried at cost les any subsequent

acumulated impairment loses.

An intangible asets is derecognised on disposal,

or when no future economic benefits are expected

from use or disposal. Gains and loses arising from

derecognition of an intangible aset, measured as

the diference betwen the net disposal proceds

and carying amount of the aset, are recognised in

profit or los when the aset is derecognised.

Impairment on property, plant and equipment

and right-of-use asets and intangible asets

other than godwil

At the end of the reporting period, the Group

reviews the carying amounts of its property, plant

and equipment, right-of-use asets and intangible

asets with finite useful lives to determine whether

there is any indication that these asets have

sufered an impairment los. If any such indication

exists, the recoverable amount of the relevant aset

is estimated in order to determine the extent of the

impairment los (if any).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

物业、厂房及设备、使用权资产

以及无形资产（商誉除外）之减值

（续）

金融资产以外的资产的可收回金

额可单独估计。倘无法个别估计

可收回金额，则本集团会估计该

资产所属现金产生单位之可收回

金额。

于测试现金产生单位的减值时，

倘可设立合理及一致的分配基

准，则公司资产分配至相关现金

产生单位，或分配至现金产生单

位内可设立合理及一致分配基准

的最小组别。可收回金额按公司

资产所属现金产生单位或现金产

生单位组别厘定，并与相关现金

产生单位或现金产生单位组别的

账面值相比较。

可收回金额为公平值（减出售成

本）与使用价值两者中之较高值。

于评估使用价值时，乃以反映目

前市场对金钱时间价值及资产（或

现金产生单位）于估计未来现金流

量调整前之独有风险之税前贴现

率贴现估计未来现金流量至其现

值。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Impairment on property, plant and equipment

and right-of-use asets and intangible asets

other than godwil (Continued)

The recoverable amount of asets other than

financial asets are estimated individualy. When it

is not posible to estimate the recoverable amount

individualy, the Group estimates the recoverable

amount of the CGU to which the aset belongs.

In testing a CGU for impairment, corporate

asets are alocated to the relevant CGU when a

reasonable and consistent basis of alocation can

be established, or otherwise they are alocated to

the smalest group of CGUs for which a reasonable

and consistent alocation basis can be established.

The recoverable amount is determined for the CGU

or group of CGUs to which the corporate aset

belongs, and is compared with the carying amount

of the relevant CGU or group of CGUs.

Recoverable amount is the higher of fair value les

costs of disposal and value in use. In asesing

value in use, the estimated future cash flows are

discounted to their present value using a pre-

tax discount rate that reflects curent market

asesments of the time value of money and the

risks specific to the aset (or a CGU) for which

the estimates of future cash flows have not ben

adjusted.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

物业、厂房及设备、使用权资产

以及无形资产（商誉除外）之减值

（续）

倘估计资产（或现金产生单位）之

可收回金额少于其账面值，资产

（或现金产生单位）之账面值被削

减至其可收回金额。就未能按合

理一致的基准分配至现金产生单

位的企业资产或部分企业资产，

本集团会比较一个组别的现金产

生单位账面值（包括已分配至该

组现金产生单位的企业资产或部

分企业资产的账面值）与该组现

金产生单位的可收回金额。于分

配减值亏损时，减值亏损首先分

配以扣减任何商誉（如适用）的账

面值，然后按该单位或一组现金

产生单位各项资产的账面值所占

比例分配至其他资产。资产的账

面值不会被调低至低于其公平值

减出售成本（如可计量）、其使用

价值（如可厘定）及零（以最高者

为准）。其他已分配至资产的减值

亏损金额则按比例分配至该单位

或该组现金产生单位内的其他资

产。减值亏损即时于损益确认。

倘减值亏损于其后拨回，则该项

资产（或现金产生单位或一组现金

产生单位）之账面值会增加至其经

修订之估计可收回金额，惟增加

后之账面值不得超出假设过往年

度并无就该项资产（或现金产生单

位或一组现金产生单位）确认减值

亏损原应厘定之账面值。减值亏

损拨回即时于损益确认。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Impairment on property, plant and equipment

and right-of-use asets and intangible asets

other than godwil (Continued)

If the recoverable amount of an aset (or a CGU) is

estimated to be les than its carying amount, the

carying amount of the aset (or a CGU) is reduced

to its recoverable amount. For corporate asets

or portion of corporate asets which canot be

alocated on a reasonable and consistent basis to a

CGU, the Group compares the carying amount of

a group of CGUs, including the carying amounts

of the corporate asets or portion of corporate

asets alocated to that group of CGUs, with the

recoverable amount of the group of CGUs. In

alocating the impairment los, the impairment los

is alocated first to reduce the carying amount of

any godwil (if aplicable) and then to the other

asets on a pro-rata basis based on the carying

amount of each aset in the unit or the group

of CGUs. The carying amount of an aset is not

reduced below the highest of its fair value les

costs of disposal (if measurable), its value in use

(if determinable) and zero. The amount of the

impairment los that would otherwise have ben

alocated to the aset is alocated pro rata to the

other asets of the unit or the group of CGUs. An

impairment los is recognised imediately in profit

or los.

Where an impairment los subsequently reverses,

the carying amount of the aset (or CGU or a

group of CGUs) is increased to the revised estimate

of its recoverable amount, but so that the increased

carying amount does not exced the carying

amount that would have ben determined had no

impairment los ben recognised for the aset (or

a CGU or a group of CGUs) in prior years. A reversal

of an impairment los is recognised imediately in

profit or los.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

存货

存货按成本及可变现净值两者的

较低者列报。存货的成本乃按照

先进先出方法厘定。可变现净值

指存货的估计售价减所有估计完

成本及进行销售所需的成本。

进行销售的所需成本包括直接归

属于销售的增量成本及本集团为

进行销售而必需产生的非增量成

本。

借贷成本

由于本集团概无合资格产品，

故所有借贷成本均于产生期间确

认，并计入损益。

外币

于编制各集团实体之财务报表

时，以该实体之功能货币以外货

币（外币）进行之交易按交易日期

之通用汇率确认。于报告期末，

以外币列值之货币项目按该日之

通用汇率重新换算。按公平值列

账及以外币计值之非货币项目按

厘定公平值当日之通用汇率重新

换算。以外币及按历史成本计量

之非货币项目不会重新换算。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Inventories

Inventories are stated at the lower of cost and net

realisable value. Cost of inventories are determined

on a first-in, first-out method. Net realisable

value represents the estimated seling price for

inventories les al estimated seling price for

inventories les al estimated costs of completion

and costs necesary to make the sale. Costs

necesary to make the sale include incremental

costs directly atributable to the sale and non-

incremental costs which the Group must incur to

make the sale.

Borowing costs

Al borowing costs are recognised as and included

in profit or los in the period in which they are

incured as the Group does not have any qualifying

asets.

Foreign curencies

In preparing the financial statements of each

individual group entity, transactions in curencies

other than the functional curency of that entity

(foreign curencies) are recognised at the rates of

exchange prevailing on the dates of transactions.

At the end of the reporting period, monetary items

denominated in foreign curencies are retranslated

at the rates prevailing at that date. Non-monetary

items caried at fair value that are denominated

in foreign curencies are retranslated at the rates

prevailing on the date when the fair value was

determined. Non-monetary items that are measured

in terms of historical cost in a foreign curency are

not retranslated.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

外币（续）

结算货币项目及货币项目之重新

换算产生之汇兑差额于产生期间

之损益内确认。

就呈列综合财务报表而言，本集

团之海外业务资产及负债使用于

报告期末之通用汇率换算为本集

团之呈列货币（即港元）。收入及

开支项目按该年度之平均汇率换

算，惟倘期内之汇率大幅波动，

则使用交易当日之汇率换算。所

产生之汇兑差额（如有）于其他全

面收入中确认及于汇兑储备中的

权益累计（计入非控股权益（如适

用）。

于出售海外业务（即出售本集团于

海外业务之全部权益，或涉及失

去对包括海外业务之附属公司之

控制权之出售，或部分出售包括

保留权益成为金融资产之海外业

务之合营企业或联营公司之权益）

时，就本公司拥有人应占该业务

于权益累计之所有汇兑差额重新

分类至损益。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Foreign curencies (Continued)

Exchange diferences arising on the setlement

of monetary items, and on the retranslation of

monetary items, are recognised in profit or los in

the period in which they arise.

For the purposes of presenting the consolidated

financial statements, the asets and liabilities of

the Group’s foreign operations are translated into

the presentation curency of the Group (i.e. HK$)

using exchange rate prevailing at the end of the

reporting period. Income and expenses items are

translated at the average exchange rates for the

year, unles exchange rates fluctuate significantly

during the period, in which case, the exchange

rates at the dates of transactions are used.

Exchange diferences arising, if any, are recognised

in other comprehensive income and acumulated

in equity under the heading of the exchange

reserve (atributable to non-controling interests as

apropriate).

On the disposal of a foreign operation (that is, a

disposal of the Group’s entire interest in a foreign

operation, or a disposal involving los of control

over a subsidiary that includes a foreign operation,

or a partial disposal of an interest in a joint

arangement or an asociate that includes a foreign

operation of which the retained interest becomes

a financial aset), al of the exchange diferences

acumulated in equity in respect of that operation

atributable to the owners of the Company are

reclasified to profit or los.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

退休福利成本

定额供款退休福利计划、国家管

理退休福利计划及强制性公积金

计划（「强积金计划」）之供款均于

雇员提供服务而使其有权享有供

款时确认为开支。

短期雇员福利

短期雇员福利按预期于雇员提供

服务时支付的福利的未贴现金额

确认。除非另一项香港财务报告

准则规定或允许将福利计入一项

资产的成本中，否则所有短期雇

员福利会确认为开支。

负债于扣除任何已付金额后就雇

员的累计福利（如工资及薪金以及

年假）确认。

金融工具

当某集团实体成为工具合约条文

之一方时，会确认金融资产及金

融负债。所有以正规途径购入或

销售之金融资产乃按交易日期基

准确认及取消确认。正规途径购

入或销售乃按市场所在地法规或

惯例所确定之时间框架内交付资

产之金融资产购入或销售。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Retirement benefit costs

Payments to defined contribution retirement

benefits scheme, state-managed retirement benefit

scheme and Mandatory Provident Fund Scheme

(“MPF Scheme”) are recognised as an expense

when employes have rendered service entitling

them to the contributions.

Short-term employe benefits

Short-term employe benefits are recognised at

the undiscounted amount of the benefits expected

to be paid as and when employes rendered the

services. Al short-term employe benefits are

recognised as an expense unles another HKFRS

requires or permits the inclusion of the benefit in

the cost of an aset.

A liability is recognised for benefits acruing to

employes (such as wages and salaries and anual

leave) after deducting any amount already paid.

Financial instruments

Financial asets and financial liabilities are

recognised when a group entity becomes a party

to the contractual provisions of the instruments. Al

regular way purchases or sales of financial asets

are recognised and derecognised on a trade date

basis. Regular way purchases or sales are purchases

or sales of financial asets that require delivery

of asets within the time frame established by

regulation or convention in the market place.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融资产及金融负债在初始时以

公平值计量，惟客户合约所产生

的贸易应收款项乃根据香港财务

报告准则第15号「客户合约收益」

（「香港财务报告准则第15号」）初

步计量。购置或发行金融资产及

金融负债（按公平值计入损益之金

融资产或金融负债除外）直接应占

之交易成本在初始确认时计入或

扣自各金融资产或金融负债（倘适

用）之公平值。购置按公平值计入

损益之金融资产或金融负债直接

应占之交易成本即时在损益中确

认。

实际利率法为一种计算相关期间

内金融资产或金融负债之摊销成

本及利息收入及利息开支分配之

方法。实际利率乃于金融资产或

金融负债预期年期或（如适用）更

短期间将估计未来现金收款及付

款（包括构成实际利率不可或缺部

分的所有已付或已收费用、交易

成本及其他溢价或折让）准确贴现

至初步确认时账面净值的利率。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial asets and financial liabilities are initialy

measured at fair value except for trade receivables

arising from contracts with customers which are

initialy measured in acordance with HKFRS 15

“Revenue from Contracts with Customers” (“HKFRS

15”). Transaction costs that are directly atributable

to the acquisition or isue of financial asets and

financial liabilities (other than financial asets

or financial liabilities at FVTPL) are aded to or

deducted from the fair value of the financial asets

or financial liabilities, as apropriate, on initial

recognition. Transaction costs directly atributable

to the acquisition of financial asets or financial

liabilities at FVTPL are recognised imediately in

profit or los.

The efective interest method is a method of

calculating the amortised cost of a financial asets

or financial liabilities and of alocating interest

income and interest expense over the relevant

period. The efective interest rate is the rate that

exactly discounts estimated future cash receipts

and payments (including al fes paid or received

that form an integral part of the efective interest

rate, transaction costs and other premiums or

discounts) through the expected life of the financial

asets or financial liabilities, or, where apropriate, a

shorter period to the net carying amount on initial

recognition.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融资产

金融资产的分类及其后计量

符合下列条件之金融资产其后按

摊销成本计量：

• 金融资产乃于以收取合约现

金流量为目标的业务模式中

持有；及

• 合约条款会导致于指定日期

产生之现金流量纯粹为支付

本金及未偿还本金额的利

息。

所有其他金融资产其后按公平值

计入损益计量。

摊销成本及利息收入

利息收入就其后按摊销成本计量

之金融资产采用实际利率法确

认。利息收入透过将实际利率用

于金融资产总账面值来计算，惟

其后已变为信贷减值的金融资产

（见下文）除外。就其后已变为信

贷减值的金融资产而言，利息收

入透过将实际利率用于自下个报

告期起计的金融资产摊销成本来

确认。倘信贷减值金融工具的信

贷风险降低令金融资产不再维持

信贷减值，则利息收入在断定资

产不再维持信贷减值后，透过将

实际利率用于自报告期开始起计

的金融资产总账面值来确认。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial asets

Clasification and subsequent measurement of

financial asets

Financial asets that met the folowing conditions

are subsequently measured at amortised cost:

• the financial aset is held within a busines

model whose objective is to colect

contractual cash flows; and

• the contractual terms give rise on specified

dates to cash flows that are solely payments

of principal and interest on the principal

amount outstanding.

Al other financial asets are subsequently measured

at FVTPL.

Amortised cost and interest income

Interest income is recognised using the efective

interest method for financial asets measured

subsequently at amortised cost. Interest income is

calculated by aplying the efective interest rate

to the gros carying amount of a financial aset,

except for financial asets that have subsequently

become credit-impaired (se below). For financial

asets that have subsequently become credit-

impaired, interest income is recognised by aplying

the efective interest rate to the amortised cost of

the financial aset from the next reporting period.

If the credit risk on the credit-impaired financial

instrument improves so that the financial aset

is no longer credit-impaired, interest income is

recognised by aplying the efective interest

rate to the gros carying amount of the financial

aset from the begining of the reporting period

folowing the determination that the aset is no

longer credit-impaired.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融资产（续）

按公平值计入损益之金融资产

按公平值计入损益的金融资产按

于报告期末的公平值计量，而任

何公平值收益或亏损均于损益内

确认。于损益内确认的净收益或

亏损不包括就金融资产赚取的任

何股息或利息，并计入「其他收

入、收益及亏损」项目。

须根据香港财务报告准则第9号进

行减值评估的金融资产及其他项

目之减值

本集团根据预期信贷亏损模式就

金融资产（包括贸易及其他应收款

项、已抵押银行存款以及现金及

现金等价物）及须根据香港财务报

告准则第9号进行减值评估的合约

资产进行减值评估。预期信贷亏

损金额于各报告日期更新，以反

映自初始确认起的信贷风险变动。

全期预期信贷亏损指在相关工具

预期年期内所有可能出现的违约

事件所产生的预期信贷亏损。相

反，12个月预期信贷亏损指预期

自可能于报告日期后十二个月内

出现的违约事件所产生的全期预

期信贷亏损的部分。有关评估乃

根据本集团过往的信用损失经验

作出，并就债务人的特定因素、

整体经济环境，以及对于报告日

期的当前情况及未来情况的预测

所作出的评估作出调整。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial asets (Continued)

Financial asets at FVTPL

Financial asets at FVTPL are measured at fair value

at the end of the reporting period, with any fair

value gains or loses recognised in profit or los.

The net gain or los recognised in profit or los

excludes any dividend or interest earned on the

financial aset and is included in the “other income,

gains and loses” line item.

Impairment of financial asets and other item

subject to impairment asesment under HKFRS 9

The Group performs impairment asesment

under expected credit los (“ECL”) model on

financial asets (including trade and other

receivables, pledged bank deposit and cash and

cash equivalents) and contract asets which are

subject to impairment asesment under HKFRS 9.

The amount of ECL is updated at each reporting

date to reflect changes in credit risk since initial

recognition.

Lifetime ECL represents the ECL that wil result from

al posible default events over the expected life

of the relevant instrument. In contrast, 12-month

ECL represents the portion of lifetime ECL that is

expected to result from default events that are

posible within 12 months after the reporting

date. Asesment are done based on the Group’s

historical credit los experience, adjusted for factors

that are specific to the debtors, general economic

conditions and an asesment of both the curent

conditions at the reporting date as wel as the

forecast of future conditions.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融资产（续）

须根据香港财务报告准则第9号进

行减值评估的金融资产及其他项

目之减值（续）

本集团一直就贸易应收款项及合

约资产确认全期预期信贷亏损。

至于所有其他工具，本集团计算

的亏损拨备与12个月预期信贷亏

损相同，除非自初步确认以来信

用风险大幅增加，则本集团在有

关情况下会确认全期预期信贷亏

损。评估是否需要确认全期预期

信贷亏损乃以自初步确认以来出

现违约的可能性或风险是否大幅

上升而定。

信贷风险大幅增加

于评估信贷风险自初步确认以来

是否大幅增加时，本集团会将报

告日期金融工具的违约风险与初

步确认日期金融工具的违约风险

进行比较。于作出有关评估时，

本集团会考虑合理及有理据支持

的定量及定性资料，包括无须不

必要的成本或努力即可获得的过

往经验及前瞻性资料。

尤其是，于评估信贷险是否已大

幅增加时，会考虑下列资料：

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial asets (Continued)

Impairment of financial asets and other item

subject to impairment asesment under HKFRS 9

(Continued)

The Group always recognises lifetime ECL for trade

receivables and contract asets.

For al other instruments, the Group measures the

los alowance equal to 12-month ECL, unles when

there has ben a significant increase in credit risk

since initial recognition, in which case the Group

recognises lifetime ECL. The asesment of whether

lifetime ECL should be recognised is based on

significant increases in the likelihod or risk of a

default ocuring since initial recognition.

Significant increase in credit risk

In asesing whether the credit risk has increased

significantly since initial recognition, the Group

compares the risk of a default ocuring on the

financial instrument as at the reporting date with

the risk of a default ocuring on the financial

instrument as at the date of initial recognition. In

making this asesment, the Group considers both

quantitative and qualitative information that is

reasonable and suportable, including historical

experience and forward-loking information that is

available without undue cost or efort.

In particular, the folowing information is taken into

acount when asesing whether credit risk has

increased significantly:

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融资产（续）

信贷风险大幅增加（续）

（如有）或内

部信用评级出现或预期出现

重大恶化；

• 外部市场的信贷风险指标重

大恶化，如信用息差大幅

扩大、应收款项的信用违

约掉期价格大幅上升；

、财务或经济状况现

时或预期的不利变动，预

期会令债务人履行其债务责

任的能力大幅下跌；

• 债务人的营运业绩出现或预

期出现重大恶化；

、经济

或科技环境出现或预期出现

重大不利变动，导致债务

人履行其债务责任的能力大

幅下跌。

不论上述评估的结果，当合约付

款已逾期超过30日，本集团会假

定信用风险自初步确认以来已大

幅增加，除非本集团具有合理及

有理据支持的资料显示情况并非

如此。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial asets (Continued)

Significant increase in credit risk (Continued)

• an actual or expected significant deterioration

in the financial instrument’s external (if

available) or internal credit rating;

• significant deterioration in external market

indicators of credit risk, e.g. a significant

increase in the credit spread, the credit

default swap prices for the debtor;

• existing or forecast adverse changes in

busines, financial or economic conditions

that are expected to cause a significant

decrease in the debtor’s ability to met its

debt obligations;

• an actual or expected significant deterioration

in the operating results of the debtor;

• an actual or expected significant adverse

change in the regulatory, economic, or

technological environment of the debtor

that results in a significant decrease in the

debtor’s ability to met its debt obligations.

Irespective of the outcome of the above asesment,

the Group presumes that the credit risk has

increased significantly since initial recognition

when contractual payments are more than 30

days past due, unles the Group has reasonable

and suportable information that demonstrates

otherwise.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融资产（续）

信贷风险大幅增加（续）

本集团定期监控用以识别信贷风

险有否大幅增加的标准之有效

性，且修订标准（如适当）来确保

标准能在金额逾期前识别信贷风

险大幅增加。

违约定义

就内部信贷风险管理而言，本集

团认为，违约事件在内部制订或

得自外界来源的资料显示债务人

不大可能悉数向债权人（包括本集

团）还款（未计及本集团所持任何

抵押品）时发生。

无论上述情形如何，本集团认

为，当工具逾期超过90天，则发

生违约，除非本集团有合理且可

支持的资料证明更滞后的违约标

准属更合适。

信贷减值金融资产

当一项或多项对金融资产估计未

来现金流量产生有害影响的事件

发生时，金融资产会被视为出现

「信贷减值」。金融资产出现信贷

减值的证据包括以下事件的可观

察数据：

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial asets (Continued)

Significant increase in credit risk (Continued)

The Group regularly monitors the efectivenes

of the criteria used to identify whether there has

ben a significant increase in credit risk and revises

them as apropriate to ensure that the criteria are

capable of identifying significant increase in credit

risk before the amount becomes past due.

Definition of default

For internal credit risk management, the Group

considers an event of default ocurs when

information developed internaly or obtained from

external sources indicates that the debtor is unlikely

to pay its creditors, including the Group, in ful

(without taking into acount any colaterals held by

the Group).

Irespective of the above, the Group considers

that default has ocured when the instrument

is more than 90 days past due unles the Group

has reasonable and suportable information to

demonstrate that a more laging default criterion is

more apropriate.

Credit-impaired financial asets

A financial aset is “credit-impaired” when one or

more events that have a detrimental impact on the

estimated future cash flows of the financial asets

have ben ocured. Evidence that a financial aset

is credit-impaired includes observable data about

the folowing events:

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融资产（续）

信贷减值金融资产（续）

• 借款人之发行人面临重大财

政困难；

，例如拖欠或逾期还

款；

• 借款人之放款人因与借款人

有关之经济或合约原因，

向借款人授出放款人在其他

情况下不会考虑授出之优

惠；或

• 借款人可能将会破产或进行

其他财务重组。

撇销政策

当本集团并无合理预期收回全部

或部分金融资产，则会撇销相关

金融资产。撇销构成取消确认事

项。倘有资料显示对手方面对严

重财务困难，且实际上并无收回

款项的前景（如对手方被清盘或进

入破产程序，或（如为贸易应收款

项）金额已逾期超过一年（以较早

发生者为准），本集团一般会进

行撇销。于适当时，在考虑法律

意见后，本集团可能仍会根据收

款程序处理被撇销的金融资产。

所收回的任何款项于损益中确认。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial asets (Continued)

Credit-impaired financial asets (Continued)

• significant financial dificulty of the isuer of

the borower;

, such as a default or

past due event;

, for economic

or contractual reasons relating to the

borower’s financial dificulty, having granted

to the borower a concesion(s) that the

lender(s) would not otherwise consider; or

• it is becoming probably that the borower

wil enter bankruptcy or other financial

reorganisation.

Write-of policy

The Group writes of a financial aset when the Group

has no reasonable expectations of recovering the

relevant financial aset in its entirety or a portion

thereof. A write-of constitutes a derecognition

event. The Group usualy writes of when there is

information indicating that the counterparty is in

severe financial dificulty and there is no realistic

prospect of recovery, e.g. when the counterparty

has ben placed under liquidation or has entered

into bankruptcy procedings, or in the case of trade

receivables when the amounts are over one year

past due, whichever ocurs soner. Financial asets

writen of may stil be subject to enforcement

activities under the Group’s recovery procedures,

taking into acount legal advice when apropriate.

Any recoveries are recognised in profit or los.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融资产（续）

预期信贷亏损的计量及确认

预期信贷亏损的计量为违约概

率、违约损失率（即违约损失程

度）及违约风险的函数。违约概

率及违约损失率乃基于历史数据

及前瞻性资料评估。预期信贷亏

损的预估乃无偏概率加权平均金

额，以发生违约的风险为权重确

定。

一般而言，预期信贷亏损按本集

团根据合约应收的所有合约现金

流量与本集团预计收取的现金流

量之间的差额估计，并按初始确

认时厘定的实际利率贴现。

经计及过往逾期资料及相关信贷

资料（如前瞻性宏观经济资料），

若干贸易应收款项及合约资产的

全期预期信贷亏损乃按集体基准

予以考虑。

为进行集体评估，本集团制定分

组时考虑以下特点：

、规模及行

业；及

（倘可获得）。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial asets (Continued)

Measurement and recognition of ECL

The measurement of ECL is a function of the

probability of default, los given default (i.e. the

magnitude of the los if there is a default) and

the exposure at default. The asesment of the

probability of default and los given default is based

on historical data and forward-loking information.

Estimation of ECL reflects an unbiased and

probability-weighted amount that is determined

with the respective risks of default ocuring as the

weights.

Generaly, the ECL is the diference betwen al

contractual cash flows that are due to the Group in

acordance with the contract and the cash flows

that the Group expects to receive, discounted at

the efective interest rate determined at initial

recognition.

Lifetime ECL for certain trade receivables and

contract asets are considered on a colective basis

taking into consideration past due information and

relevant credit information such as forward loking

macroeconomic information.

For colective asesment, the Group takes into

consideration the folowing characteristics when

formulating the grouping:

;

, size and industry of debtors; and

• External credit ratings where available.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融资产（续）

预期信贷亏损的计量及确认（续）

分组工作经管理层定期检讨，以

确保各组别成分继续具备类似信

贷风险特性。

利息收入按金融资产的总账面值

计算，惟倘金融资产信贷减值，

则利息收入按金融资产的摊销成

本计算。

本集团通过调整所有金融工具的

账面值于损益确认彼等之减值收

益或亏损，惟贸易应收款项乃透

过亏损拨备账确认相应调整。

外汇收益及亏损

以外币计值金融资产的账面值以

相关外币厘定，并于各报告期末

按即期汇率换算。

• 就并非为指定对冲关系一部

分之按摊销成本计量的金融

资产而言，汇兑差额于损

益中「其他收入、收益及亏

损」项目中确认（附注7）为外

汇收益╱（亏损）净额部份。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial asets (Continued)

Measurement and recognition of ECL (Continued)

The grouping is regularly reviewed by management

to ensure the constituents of each group continue

to share similar credit risk characteristics.

Interest income is calculated based on the gros

carying amount of the financial aset unles the

financial aset is credit-impaired, in which case

interest income is calculated based on amortised

cost of the financial aset.

The Group recognises an impairment gain or los

in profit or los for al financial instruments by

adjusting their carying amount, with the exception

of trade receivables where the coresponding

adjustment is recognised through a los alowance

acount.

Foreign exchange gains and loses

The carying amount of financial asets that are

denominated in a foreign curency is determined

in that foreign curency and translated at the spot

rate at the end of each reporting period.

• For financial asets measured at amortised

cost that are not part of a designated

hedging relationship, exchange diferences

are recognised in profit or los in the ‘Other

income, gains and loses’ line item (note 7)

as part of the net foreign exchange gains/

(loses).

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融资产（续）

金融资产终止确认

仅当自资产收取现金流量之合约

权利届满或当其转移金融资产及

该资产的绝大部分风险及所有权

回报转移予另一实体时，本集团

方会终止确认金融资产。

于终止确认按摊销成本计量的金

融资产时，该资产账面值与已收

及应收代价总和之差额于损益内

确认。

金融负债及股本

分类为债务或股本

债务及股本工具按照合约安排之

实质内容以及金融负债及股本工

具之定义归类为金融负债或权益。

股本工具

股本工具指能证明拥有本集团在

减除其所有负债后之资产中之剩

余权益之任何合约。本公司发行

的股本工具按已收所得款项扣除

直接发行成本确认。

金融负债

所有金融负债其后以实际利率法

按摊销成本计量。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial asets (Continued)

Derecognition of financial aset

The Group derecognises a financial aset only

when the contractual rights to the cash flows from

the aset expire or when it transfers the financial

aset and substantialy al the risks and rewards of

ownership of the aset to another entity.

On derecognition of a financial aset measured at

amortised cost, the diference betwen the aset’s

carying amount and the sum of the consideration

received and receivable is recognised in profit or

los.

Financial liabilities and equity

Clasification as debt or equity

Debt and equity instruments are clasified as either

financial liabilities or as equity in acordance with

the substance of the contractual arangements and

the definitions of a financial liability and an equity

instrument.

Equity instruments

An equity instrument is any contract that evidences

a residual interest in the asets of the Group after

deducting al of its liabilities. Equity instruments

isued by the Company are recognised at the

proceds received, net of direct isue costs.

Financial liabilities

Al financial liabilities are subsequently measured at

amortised cost, using the efective interest method.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融负债及股本（续）

按公平值计入损益之金融负债

倘金融负债为香港财务报告准则

第3号适用之业务合并中收购方的

或然代价，则金融负债分类为按

公平值计入损益。

按摊销成本计量之金融负债

金融负债（包括贸易及其他应付款

项、应付关联方款项及应付最终

控股公司款项）其后以实际利率法

按摊销成本计量。

外汇收益及亏损

就以外币计值及于各报告期末按

摊销成本计量的金融负债而言，

外汇收益及亏损根据该等工具的

摊销成本厘定。就不构成指定对

冲关系一部分的金融负债而言，

外汇收益及亏损于损益中「其他收

入、收益及亏损」项目中确认（附

注7）为外汇收益╱（亏损）净额部

份。

终止确认金融负债

本集团仅会在本集团之责任解

除、取消或到期时，方会终止确

认金融负债。已终止确认之金融

负债账面值与已付及应付代价两

者间之差额会于损益中确认。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial liabilities and equity (Continued)

Financial liabilities at FVTPL

Financial liabilities are clasified as at FVTPL when

the financial liability is contingent consideration

of an acquirer in a busines combination to which

HKFRS 3 aplies.

Financial liabilities at amortised cost

Financial liabilities including trade and other

payables, amounts due to related parties and

ultimate holding company are subsequently

measured at amortised cost, using the efective

interest method.

Foreign exchange gains and loses

For financial liabilities that are denominated in a

foreign curency and are measured at amortised

cost at the end of each reporting period, the

foreign exchange gains and loses are determined

based on the amortised cost of the instruments.

These foreign exchange gains and loses are

recognised in the ‘Other income, gains and loses’

line item in profit or los (note 7) as part of net

foreign exchange gains/(loses) for financial

liabilities that are not part of a designated hedging

relationship.

Derecognition of financial liabilities

The Group derecognises financial liabilities

when, and only when, the Group’s obligations

are discharged, canceled or have expired.

The diference betwen the carying amount

of the financial liability derecognised and the

consideration paid and payable is recognised in

profit or los.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

金融工具（续）

金融负债及股本（续）

抵销金融资产及金融负债

当及仅当本集团现时拥有抵销已

确认金额之合法可强制执行权

利，并有意按净额基准结算或同

时变现资产及结算负债，方会抵

销金融资产及金融负债，并于综

合财务状况报表呈列净额。

税项

所得税开支指当期应缴税项及递

延税项两者的总和。

当期税项乃根据年内应课税溢利

计算。由于其他年度应课税或可

扣税收入及开支项目以及毋须课

税或不可扣税的项目，应课税溢

利与综合损益及其他全面收益表

所报「除税前亏损」不同。本集团

的当期应交税项乃按报告期末颁

布或实质上颁布之税率计算。

递延税项就综合财务报表中资产

及负债之账面金额与计算应课税

溢利时所采用之相应税基的暂时

差额确认。递延应交税项通常就

所有应课税之暂时差额确认。递

延税项资产通常就可能会获得可

用作抵销可扣税暂时差额之应课

税溢利就所有可扣税暂时差额确

认。倘该暂时差额源自初始确认

（业务合并除外）不影响应课税溢

利或会计溢利之交易中资产及负

债，则该等递延税项资产及负债

不予确认。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Financial instruments (Continued)

Financial liabilities and equity (Continued)

Ofseting a financial aset and a financial liability

A financial aset and a financial liability are ofset

and the net amount presented in the consolidated

statement of financial position when, and only

when, the Group curently has a legaly enforceable

right to set of the recognised amounts; and

intends either to setle on a net basis, or to realise

the aset and setle the liability simultaneously.

Taxation

Income tax expense represents the sum of the tax

curently payable and defered tax.

The tax curently payable is based on taxable profit

for the year. Taxable profit difers from los before

taxation because of income or expense that are

taxable or deductible in other years and items that

are never taxable or deductible. The Group’s liability

for curent tax is calculated using tax rates that

have ben enacted or substantively enacted by the

end of the reporting period.

Defered tax is recognised on temporary diferences

betwen the carying amounts of asets and

liabilities in the consolidated financial statements

and the coresponding tax base used in the

computation of taxable profit. Defered tax liabilities

are generaly recognised for al taxable temporary

diferences. Defered tax asets are generaly

recognised for al deductible temporary diferences

to the extent that it is probable that taxable profits

wil be available against which those deductible

temporary diferences can be utilised. Such

defered tax asets and liabilities are not recognised

if the temporary diference arises from the initial

recognition (other than in a busines combination)

of asets and liabilities in a transaction that afects

neither the taxable profit nor the acounting profit.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

税项（续）

递延应交税项就与于附属公司之

投资相关的应课税暂时差额予以

确认，惟本集团可控制暂时差额

之拨回及暂时差额可能于可见将

来不会拨回除外。与该等投资及

权益相关的可扣税暂时差额所产

生之递延税项资产，仅于可能有

足够应课税溢利可以使用暂时差

额之利益且预计于可见将来可以

拨回时予以确认。

递延税项资产账面值于各报告期

末作出检讨，并于不再可能有足

够应课税溢利以供收回全部或部

分资产时作调减。

递延税项资产及负债乃根据报告

期末已颁布或实质颁布订之税率

（及税法）按清偿负债或变现资产

期间预期适用之税率计量。

递延应交税项及资产之计量反映

按照本集团预期方式于报告期末

收回或结清其资产及负债的账面

金额之税务结果。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Taxation (Continued)

Defered tax liabilities are recognised for taxable

temporary diferences asociated with investments

in subsidiaries, except where the Group is able to

control the reversal of the temporary diference

and it is probable that the temporary diference

wil not reverse in the foreseable future. Defered

tax asets arising from deductible temporary

diferences asociated with such investments and

interests are only recognised to the extent that

it is probable that there wil be suficient taxable

profits against which to utilise the benefits of the

temporary diferences and they are expected to

reverse in the foreseable future.

The carying amount of a defered tax aset is

reviewed at the end of the reporting period and

reduced to the extent that it is no longer probable

that suficient taxable profit wil be available to

alow al or part of the aset to be recovered.

Defered tax asets and liabilities are measured

at the tax rates that are expected to aply in the

period in which the liability is setled or the aset is

realised, based on tax rate (and tax laws) that have

ben enacted or substantively enacted by the end

of the reporting period.

The measurement of defered tax liabilities and

asets reflects the tax consequences that would

folow from the maner in which the Group

expects, at the end of the reporting period, to

recover or setle the carying amount of its asets

and liabilities.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

税项（续）

倘若出现可依法执行之权利将当

期税项资产与当期应交税项抵

销，且该等税项涉及同一税务

机关向同一纳税实体征收之所得

税，即可抵销递延税项资产及负

债。

当期及递延税项于损益内确认，

惟若其有关之项目于其他全面收

益中确认或直接计入权益，则当

期税项与递延税项也会于其他全

面收益中确认或直接计入权益。

现金及现金等价物

现金及现金等价物于综合财务状

况表呈列，包括现金（其包括手头

现金及活期存款，不包括受监管

限制而导致有关结余不再符合现

金定义的银行结余）。

以股份为基础之付款

以权益结算以股份为基础之付款交易

向雇员授出之购股权

向雇员及提供类似服务的其他人

士所作出以权益结算以股份为基

础之付款，乃按股本工具于授出

日期之公平值计量。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Taxation (Continued)

Defered tax asets and liabilities are ofset when

there is a legaly enforceable right to set of curent

tax asets against curent tax liabilities and when

they relate to income taxes levied to the same

taxable entity by the same taxation authority.

Curent and defered tax are recognised in profit

or los, except when they relate to items that

are recognised in other comprehensive income

or directly in equity, in which case, the curent

and defered tax are also recognised in other

comprehensive income or directly in equity

respectively.

Cash and cash equivalents

Cash and cash equivalents presented on the

consolidated statement of financial position

include cash, which comprises of cash on hand and

demand deposits, excluding bank balances that are

subject to regulatory restrictions that result in such

balances no longer meting the definition of cash.

Share-based payments

Equity-setled share-based payment transactions

Share options granted to employes

Equity-setled share-based payments to employes

and others providing similar services are measured

at the fair value of the equity instruments at the

grant date.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

3. 综合财务报表之编制基准及重大

会计政策资料（续）

3.2 重大会计政策资料（续）

以股份为基础之付款（续）

以权益结算以股份为基础之付款

交易（续）

向雇员授出之购股权（续）

于授出日期厘定（所有非市场归属

条件均不予考虑）的以权益结算以

股份为基础之付款的公平值，于

归属期内根据本集团对最终将会

归属的股本工具之估计按直线法

支销，并在股本（以股份为基础

之付款储备）内作出相应增加。于

各报告期末，本集团根据对所有

相关非市场归属条件之评估，修

订其对预期归属股本工具数目之

估计。修订原先估计之影响（如

有）于损益确认，致使累计开支反

映经修订估计，并对以股份为基

础之付款储备作出相应调整。就

于授出日期即时归属之购股权而

言，所授出购股权之公平值即时

于损益支销。

于购股权获行使时，过往于以股

份为基础之付款储备中确认之金

额将转拨至累计亏损。当购股权

于归属日期后被没收或于届满日

期仍未获行使，过往于以股份为

基础之付款储备中确认之金额将

转拨至累计亏损。

于授出之购股权归属时，过往于

以股份为基础之付款储备中确认

之金额将转拨至股本及股份溢价。

3. BASIS OF PREPARATION OF THE CONSOLIDATED

FINANCIAL STATEMENTS AND MATERIAL

ACOUNTING POLICY INFORMATION (CONTINUED)

3.2 Material acounting policy information

(Continued)

Share-based payments (Continued)

Equity-setled share-based payment transactions

(Continued)

Share options granted to employes (Continued)

The fair value of the equity-setled share-based

payments determined at the grant date without

taking into consideration al non-market vesting

conditions is expensed on a straight-line basis over

the vesting period, based on the Group’s estimate

of equity instruments that wil eventualy vest,

with a coresponding increase in equity (share-

based payments reserve). At the end of each

reporting period, the Group revises its estimate of

the number of equity instruments expected to vest

based on asesment of al relevant non-market

vesting conditions. The impact of the revision

of the original estimates, if any, is recognised in

profit or los such that the cumulative expense

reflects the revised estimate, with a coresponding

adjustment to the share -based payments reserve.

For share options that vest imediately at the date

of grant, the fair value of the share options granted

is expensed imediately to profit or los.

When share options are exercised, the amount

previously recognised in share-based payments

reserve wil be transfered to acumulated loses.

When the share options are forfeited after the

vesting date or are stil not exercised at the expiry

date, the amount previously recognised in share-

based payments reserve wil be transfered to

acumulated loses.

When shares granted are vested, the amount

previously recognised in share-based payments

reserve wil be transfered to share capital and

share premium.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

4. 估计不确定因素之主要来源

在应用附注3所述本集团之会计政策期

间，本公司董事须对不可随时从其他来

源取得之资产及负债账面值作出判断、

估计及假设。该等估计乃基于过往经验

及其他视为相关之因素作出。实际结果

可能与该等估计不同。

有关估计会持续予以检讨。倘会计估计

之修订仅影响作出修订之期间，则于修

订估计期间确认有关修订；倘修订同时

影响当前及未来期间，则于修订期间及

未来期间确认有关修订。

本集团对未来作出估计及假设。由于未

来存在不确定性，实际结果可能与该等

估计存在差异。下文讨论涉及重大风险

导致下一个财务年度资产及负债的账面

值须作出重大调整的估计及假设。

独家分销权及商誉之估计减值

于二零二五年三月三十一日，独家分销

权及商誉的账面值分别约为75,207,000

港元及19,505,000港元（二零二四年：

85,196,000港元及49,040,000港元）。商

誉须每年进行减值测试，具有限可使用

年期之无形资产则于出现减值迹象时进

行减值测试。于厘定该组资产是否减值

时，本集团须对该组资产所属现金产生

单位的账面值能否获可收回金额（乃根据

使用价值计算得出）支持作出判断及估

算。建立相关假设及其输入数据需要作

出判断及估算。有关该等因素的事实、

情况或估算出现任何变动，可导致对可

收回金额作出重大调整。

有关可收回金额计算的详情于附注16及

17披露。

4. KEY SOURCES OF ESTIMATION UNCERTAINTY

In the aplications of the Group’s acounting policies,

which are described in note 3, the directors of the

Company are required to make judgements, estimates and

asumptions about the carying amounts of asets and

liabilities that are not readily aparent from other sources.

The estimates are based on the historical experience and

other factors that are considered to be relevant. Actual

results may difer from these estimates.

The estimates are reviewed on an ongoing basis. Revisions

to acounting estimates are recognised in the period in

which the estimate is revised if the revision afects only

that period, or in the period of the revision and future

periods if the revision afects both curent and future

periods.

The Group makes estimates and asumptions concerning

the future. As the future is inherently uncertain, actual

results may difer from these estimates. The estimates

and asumptions that have a significant risk of causing

a material adjustment to the carying amounts of asets

and liabilities within the next financial year are adresed

below.

Estimated impairment of exclusive distribution

rights and godwil

As at 31 March 2025, the carying amounts of exclusive

distribution rights and godwil were aproximately

HK$75,207,000 and HK$19,505,000 (2024: HK$85,196,000

and HK$49,040,000), respectively. Godwil is required to

be tested for impairment anualy and intangible asets

with definite life whenever there is an indication that

the intangible asets may be impaired. In determining

whether the group of asets are impaired, the Group has

to exercise judgement and make estimation on whether

the carying value of CGU to which the group of asets

belong can be suported by a recoverable amount,

which is based on its value in use calculation. Judgement

and estimation are required in establishing the relevant

asumptions and inputs thereof. Changes in facts,

circumstances or estimations relating to these factors

could result in material adjustments to the recoverable

amounts.

Details of the recoverable amount calculations are

disclosed in notes 16 and 17.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（续）

按公平值计入损益之金融负债之公平值

乃使用多种估值技术厘定。本集团利用

其判断选择各种方法之合适基准及作出

假设，其中包括贴现率、对被收购附属

公司之表现所作估计及达成其溢利目标

的或然率。其后于各报告期末重新计量

至公平值。所采用假设之变动可能对结

余之公平值造成重大影响，因而影响本

集团之财务状况及经营业绩。于二零二

五年三月三十一日，计入应付关联方款

项及应付非控股权益款项的按公平值计

入损益之金融负债的账面值分别为4,000

港元及29,987,000港元（二零二四年：零

港元及50,204,000港元）。

4. KEY SOURCES OF ESTIMATION UNCERTAINTY

(CONTINUED)

Fair value of financial liabilities at FVTPL

The fair value of financial liabilities at FVTPL was

determined by using valuation techniques. The Group

uses its judgement to select an apropriate basis from

a variety of methods and makes asumptions, including

the discount rates, estimation of performance of the

subsidiaries and the probability of meting their profit

targets. They are subsequently remeasured to fair value at

the end of each reporting period. Changes in asumptions

used could materialy afect the fair value of the balances

and as a result afect the Group’s financial position and

results of operation. The carying amount of financial

liabilities at FVTPL included in amounts due to related

parties and amount due to non-controling interests as

at 31 March 2025 were HK$4,000 and HK$29,987,000,

respectively (2024: nil and HK$50,204,000).

2025
二零二五年
HK$’000
千港元
286,080
39,320
4,316
329,716
162,574
45,214
537,504
7,018
544,522
52,231
492,291
544,522

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

5. 收益

来自货品及服务之收益

本集团的主要活动为从事服装以及保健

及医药产品及药品贸易以及提供保健服

务。

按主要产品划分的客户合约收益分拆如

下：

5. REVENUE

Revenue from gods and services

The principal activities of the Group are engaged in

trading of aparel and healthcare and medicated products

and provision of healthcare services.

Disagregation of revenue from contracts with customers

by major products is as folows:

二零二四年

HK$’000

千港元

Trading of aparel products服装产品贸易

– Womenswear－女装338,604

– Menswear－男装117,833

– Kidswear－童装10,541

466,978

Trading of healthcare and medicated

products

保健产品及药品贸易

133,198

Provision of IRO and CRO services提供IRO及CRO服务38,149

Revenue from contracts with customers客户合约收益638,325

Leasing of medical devices医疗器械租赁6,290

Total总计644,615

Timing of revenue recognition:收益确认时间：

Over time于一段时间内44,439

A point in time于某个时间点600,176

644,615

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（续）

来自货品及服务之收益（续）

与客户合约之履约责任

来自服装以及保健产品及药品贸易之

收益

来自服装以及保健产品及药品贸易之收

益于产品之控制权转移至客户，即货品

运送至客户指定之目的地时确认。在客

户取得相关货品控制权前进行的交通及

其他相关活动被视为履约活动。本集团

于货品交付予客户时确认应收款项，原

因为待付款到期前仅须时间过去，此

代表收取代价之权利成为无条件之时间

点。一般信贷期限为产品交付时开具发

票后30至90日。

本集团要求若干客户按合约总金额的

5%至10%提供预付订金。当本集团于服

装╱保健产品交付前收到订金，则此将

于合约开始时产生合约负债，直至就指

定合约确认的收益超过订金额。

来自提供IRO及CRO服务之收益

本集团向客户提供IRO及CRO服务。有

关收益于有关履约责任随时间履行时确

认，原因为本集团的履约并无创造对本

集团而言具替代用途的资产，且本集团

对迄今完成的履约的付款有强制执行的

权利。

5. REVENUE (CONTINUED)

Revenue from gods and services (Continued)

Performance obligations for contracts with customers

Revenue from trading of aparel, healthcare and

medicated products

Revenue from trading of aparel, healthcare and

medicated products is recognised when the control of the

products has ben transfered to the customers, being

at the point the gods are delivered to the customer’s

specific location. Transportation and other related activities

that ocur before customers obtains control of the related

god are considered as fulfilment activities. A receivable is

recognised by the Group when the gods are delivered to

the customers as this represents the point in time at which

the right to consideration becomes unconditional, as only

the pasage of time is required before the payment is due.

The normal credit term is 30 to 90 days upon isuance of

invoice at product delivery.

The Group requires certain customers to provide upfront

deposits ranging from 5% to 10% of total contract sum,

when the Group receives a deposit before the aparel/

healthcare products delivery, this wil give rise to contract

liabilities at the start of a contract, until the revenue

recognised on the specific contract exceds the amount

of deposit.

Revenue from provision of IRO and CRO services

The Group provides IRO and CRO services to the

customers. Such revenue are recognised as this

performance obligation is satisfied over time because

the Group’s performance does not create an aset with

an alternative use to the Group and the Group has an

enforceable right to payment for performance completed

to date.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

来自货品及服务之收益（续）

与客户合约之履约责任（续）

来自提供IRO及CRO服务之收益（续）

完成履约责任的进度按输入法计量，即

根据本集团完成履约责任时就输入数据

所付出的努力（即所产生的直接员工成本

及其他直接的经常性开支）对完成履约责

任预期所需的输入确认收益，此方法能

最有效地反映本集团于转让商品控制权

时的履约情况。当本集团有权就完成有

关合约的履约责任收取代价，且该权利

的条件为随时间流逝以外的因素时，即

产生合约资产。合约资产在有关权利成

为无条件（随时间流逝除外）时重新分类

至贸易应收款项。于里程碑完成后向客

户开发票。一般信贷期限为向客户开发

票后60至120日。与本集团有良好业务关

系且财务状况良好之客户可享有180日之

信贷期。本集团要求若干客户按合约总

金额的10%至20%提供预付订金。当本集

团于保健服务开始前收到订金，则此将

于合约开始时产生合约负债，直至就指

定合约确认的收益超过订金额。

5. REVENUE (CONTINUED)

Revenue from gods and services (Continued)

Performance obligations for contracts with customers

(Continued)

Revenue from provision of IRO and CRO services (Continued)

The progres towards completing satisfaction of a

performance obligation is measured based on input

method, which is to recognise revenue on the basis of the

Group’s efort in terms of inputs (i.e. direct staf costs and

other direct overhead costs incured) to the satisfaction

of a performance obligation relative to the total expected

inputs to the satisfaction of that performance obligation,

the best depicts the Group’s performance in transfering

control of products. Contract asets arise when the Group

has right to consideration for satisfaction of a performance

obligation under the relevant contracts, and the right

is conditioned on factors other than pasage of time.

Contract asets are reclasified to trade receivables when

such right become unconditional other than the pasage

of time. Invoices to the customers are isued upon the

milestones completed to date. The normal credit term

is 60 to 120 days upon the isuance of invoices to the

customers. Credit period of 180 days is granted to a

customer with whom the Group has a god relationship

and who is in sound financial condition. The Group

requires certain customers to provide upfront deposits

ranging from 10% to 20% of total contract sum, when the

Group receives a deposit before the comencement of

healthcare services, this wil give rise to contract liabilities

at the start of a contract, until the revenue recognised on

the specific contract exceds the amount of the deposit.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（续）

来自货品及服务之收益（续）

与客户合约之履约责任（续）

来自医疗器械租赁之收益

本集团从事医疗器械租赁业务。租金收

入按直线基准于租期内确认。

分配至剩余履约责任的交易价格

本集团所有未完成履约责任的客户合约

收益的预期限为一年或以下。根据香

港财务报告准则第15号所批准，并无披

露于二零二五年及二零二四年三月三十

一日分配至余下履约责任（未履行或已履

行）的交易价。

6. 分部资料

就资源分配及分部表现评估而向本公司

执行董事（即主要经营决策者）报告之资

料，主要按所交付货品或所提供服务类

型划分。

因此，本集团之可报告及经营分部如下：

(a) 服装产品贸易（「服装业务」）

(b) 保健产品及药品贸易以及医疗器

械租赁（「保健产品业务」）

受托研究机构（「CRO」）服务和内

部研发业务（「IRO及CRO和内部研

发业务」）

5. REVENUE (CONTINUED)

Revenue from gods and services (Continued)

Performance obligations for contracts with customers

(Continued)

Revenue from leasing of medical devices

The Group engaged in medical device leasing. Rental

income is recognised on a straight-line basis over the

lease term.

Transaction price alocated to the remaining performance

obligations

Al the Group’s contracts with customers with unsatisfied

performance obligations have expected duration of one

year or les. As permited under HKFRS 15, the transaction

price alocated to the remaining performance obligations

(unsatisfied or satisfied) as at 31 March 2025 and 2024 is

not disclosed.

6. SEGMENT INFORMATION

Information reported to the executive directors of the

Company, being the chief operating decision maker, for

the purposes of resources alocation and asesment

of segment performance focuses on types of gods or

services delivered or provided.

The Group’s reportable and operating segments are

therefore as folows:

(a) Trading of aparel products (“Garment Busines”)

(b) Trading of healthcare and medicated products and

leasing of medical devices (“Healthcare Products

Busines”)

R&D Busines (“IRO with CRO and In-House R&D

Busines”)

2025		2025
二零二五年		二零二五年
HK$’000		HK$’000
千港元		千港元
329,716	466,978 139,488 38,149	2,190
169,592		18,187
45,214		(34,232)
644,615
544,522		(13,855)
11
47,300
(40)
33,416

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

本集团按经营及可呈报分部划分之收益

及业绩分析如下。

6. SEGMENT INFORMATION (CONTINUED)

The folowing is an analysis of the Group’s revenue and

results by operating and reportable segment.

RevenueSegment profit (los)

收益分部溢利（亏损）

二零二四年

HK$’000

千港元

Garment busines服装业务7,069

Healthcare Products Busines保健产品业务7,711

IRO with CRO and In-House

R&D Busines

IRO及CRO和内部研

发业务(36,403)

Total总计(21,623)

Bank interest income银行利息收入39

Unalocated corporate income

(expenses)

未分配企业收入

（开支）(2,330)

Finance costs on lease liabilities租赁负债之融资

成本(138)

Profit (los) before tax除税前溢利（亏损）(24,052)

Al of the segment revenue reported above is from

external customers.

The acounting policies of the operating and reportable

segments are the same as the Group’s acounting policy

described in note 3. Segment profit (los) represents the

profit earned/los incured by each segment without

alocation of bank interest income, unalocated corporate

income (expenses) and finance costs on lease liabilities.

This is the measure reported to the Group’s management

for the purpose of resources alocation and performance

asesment.

上文所报告之所有分部收益均来自外部

客户。

经营及可报告分部之会计政策与附注3所

述本集团会计政策相同。分部溢利（亏

损）指各分部赚取之溢利╱产生之亏损，

当中并无分配银行利息收入、未分配企

业收入（开支）及租赁负债之融资成本。

此为就资源分配及表现评估向本集团管

理层报告之计量方法。

Garment Business	Healthcare Products business	IRO with CRO and In-House R&D Business	Consolidated
服装业务	保健产品业务	IRO及CRO和内部研发业务	综合
HK$’000	HK$’000	HK$’000	HK$’000
千港元	千港元	千港元	千港元
73,278	175,150	21,599	270,027
			66,822
			336,849
20,662	77,618	21,465	119,745
			54,581
			174,326

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

6. SEGMENT INFORMATION (CONTINUED)

Segment asets and liabilities

The folowing is an analysis of the Group’s asets and

liabilities by operating and reportable segment:

As at 31 March 2025

Segment asets分部资产

Other asets其他资产

Consolidated asets综合资产

Segment liabilities分部负债

Other liabilities其他负债

Consolidated liabilities综合负债

（续）

分部资产及负债

本集团按经营及可报告分部划分之资产

及负债分析如下：

于二零二五年三月三十一日

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

分部资产及负债（续）

于二零二四年三月三十一日

6. SEGMENT INFORMATION (CONTINUED)

Segment asets and liabilities (Continued)

As at 31 March 2024

Garment

Busines

Healthcare

Products

Busines

IRO with CRO

and In-House

R&D BusinesConsolidated

服装业务保健产品业务

IRO及CRO和

内部研发业务综合

HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元

Segment asets分部资产118,001164,011142,313424,325

Other asets其他资产5,560

Consolidated asets综合资产429,885

Segment liabilities分部负债88,44699,277100,654288,377

Other liabilities其他负债3,326

Consolidated liabilities综合负债291,703

For the purpose of monitoring segment performance and

alocating resources among segments:

– Al asets are alocated to operating and reportable

segments other than certain property, plant and

equipment, right-of-use asets, other financial

asets, certain other receivables and deposits and

cash and cash equivalents.

– Al liabilities are alocated to operating and

reportable segments other than certain other

payables and amounts due to related parties.

就监察分部表现及于分部间分配资源而

言：

－除若干物业、厂房及设备、使用

权资产、其他金融资产、若干其

他应收款项及按金以及现金及现

金等价物外，所有资产会分配至

经营及可报告分部。

－除若干其他应付款项及应付关联

方款项外，所有负债会分配至经

营及可报告分部。

Garment Business	Healthcare Products business	IRO with CRO and In-House R&D Business	Segment total	Unallocated	Consolidated
服装业务	保健产品业务	IRO及CRO和内部研发业务	分部总计	未分配	综合
HK$’000	HK$’000	HK$’000	HK$’000	HK$’000	HK$’000
千港元	千港元	千港元	千港元	千港元	千港元
440	70	17	527	11	538
3,276	–	414	3,690	4,616	8,306
203	2,576	152	2,931	7	2,938
1,751	–	680	2,431	543	2,974
–	9,544	356	9,900	–	9,900
54	5,619	34	5,707	–	5,707
–	–	1,684	1,684	1,086	2,770

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（续）

其他分部资料

于二零二五年三月三十一日

6. SEGMENT INFORMATION (CONTINUED)

Other Segment information

As at 31 March 2025

Amounts included in the measure of

segment profit (los) or segment asets

计算分部溢利（亏损）或分部资产时

计入之金额

Results or segment asets:业绩或分部资产：

Interest income利息收入

Interest expenses利息开支

Depreciation of property, plant and

equipment

物业、厂房及设备折旧

Depreciation of right-of-use asets使用权资产折旧

Amortisation of intangible asets无形资产摊销

Aditions to property, plant and

equipment

添置物业、厂房及设备

Aditions to right-of-use asets添置使用权资产–1,6841,6841,0862,770

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

6. SEGMENT INFORMATION (CONTINUED)

Other Segment information (Continued)

As at 31 March 2024

Garment

Busines

Healthcare

Products

Busines

IRO with CRO

and In-House

R&D BusinesSegment totalUnalocatedConsolidated

服装业务保健产品业务

IRO及CRO和

内部研发业务分部总计未分配综合

HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元千港元千港元

Amounts included in the measure of

segment profit (los) or segment asets

计算分部溢利（亏损）或分部资产时

计入之金额

Results or segment asets:业绩或分部资产：

Interest income利息收入96670151,051391,090

Interest expenses利息开支6,932–6,9321387,070

Depreciation of property, plant and

equipment

物业、厂房及设备折旧

5121,9201482,58052,585

Depreciation of right-of-use asets使用权资产折旧2,258–6492,9075433,450

Amortisation of intangible asets无形资产摊销–7,984–7,984–7,984

Aditions to property, plant and

equipment

添置物业、厂房及设备

1434,887–5,03075,037

Aditions to right-of-use asets添置使用权资产3,545–1,4364,981–4,981

Aditions to intangible asets添置无形资产–94,49771,869166,366–166,366

Aditions to godwil商誉增加–19,91930,14850,067–50,067

（续）

其他分部资料（续）

于二零二四年三月三十一日

2025		2025
二零二五年		二零二五年
HK$’000		HK$’000
千港元		千港元
29,444	30,602 214,703 134,383 71,688 191,125 2,114	96,486
186,662		5,478
151,171		1,826
90,498		–
84,535		–
2,212		–
644,615
544,522		103,790

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

6. SEGMENT INFORMATION (CONTINUED)

Geographic information

The Group’s operation of Garment Busines, Healthcare

Products Busines and IRO with CRO and In-House R&D

Busines are located in Hong Kong, Japan and the PRC.

The Group’s revenue from external customers and

information about non-curent asets by geographical

location of the customers and asets respectively are set

out below:

Revenues from external

customersNon-curent asets

来自外部客户之收益非流动资产

二零二四年

HK$’000

千港元

Hong Kong香港107,338

Japan日本105,376

The PRC中国1,284

Europe欧洲–

United States美国–

Other countries其他国家–

213,998

Note: Non-curent asets exclude financial asets.

（续）

地区资料

本集团之服装业务、保健产品业务以及

IRO及CRO和内部研发业务在香港、日本

及中国经营。

本集团来自外部客户之收益及有关非流

动资产之资料分别按客户及资产所在地

区载列如下：

附注：非流动资产不包括金融资产。

2025
二零二五年
HK$’000
千港元
148,485

2025
二零二五年
HK$’000
千港元
538
1,658
2,604
67
1
20,217
(4)
2,136
11
43,247
(18,050)
(1,943)
(313)
50,169

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

6. SEGMENT INFORMATION (CONTINUED)

Geographic information (Continued)

Revenue from major customers:

Revenue from customers individualy contributed over

10% of the total revenue of the Group for the year are as

folows:

二零二四年

HK$’000

千港元

Customer A (from Garment Busines)客户A（来自服装业务）242,753

7. OTHER INCOME, GAINS AND LOSES

Interest income利息收入

Sample sales income样本销售收入

Sundry income杂项收入

Government grants政府补助

Gain (los) on disposal of property, plant

and equipment

出售物业、厂房及设备之

收益（亏损）

Fair value gain on promisory note due

to non-controling interests

(note 26(c)

非控股权益产生的承兑票据

公平值收益（附注26(c)）

Fair value los on financial liabilities at

fair value through profit or los

(note 38(b)

按公平值计入损益之金融

负债之公平值亏损（附注

38(b)）

Gain on waiver of amount due to

related parties (note 38(b)

豁免应付关联方款项产生的

收益（附注38(b)）

Gain on deregistration of subsidiaries注销附属公司产生的收益

Gain on disposals of subsidiaries (note

34)

出售附属公司产生的收益

（附注34）

Impairment los on godwil (note 16)商誉减值亏损（附注16）

Los on exchange diference, net汇兑亏损净额

Others其他

（续）

地区资料（续）

来自主要客户之收益：

年内为本集团之总收益个别贡献10%以

上之客户收益如下：

、收益及亏损

2025
二零二五年
HK$’000
千港元
1,400
42,500
2,695
266
45,461
412,106
(43,247)
2,938
2,974
9,900

2025
二零二五年
HK$’000
千港元
2,441
418
4,795
398
254
8,306

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（亏损）

除税前溢利（亏损）乃于扣除（计入）下列

各项后得出：

8. PROFIT (LOS) BEFORE TAX

Profit (los) before tax is arived at after charging (crediting):

二零二四年

HK$’000

千港元

Auditor’s remuneration核数师酬金2,000

Staf costs (including directors’

emoluments)

员工成本（包括董事薪酬）

– Salaries, wages and other benefits－薪金、工资及其他福利52,252

– Contributions to retirement benefits

schemes

－退休福利计划供款

2,088

– Share-based payment expenses－以股份为基础之付款

开支–

Total staf costs员工成本总额54,340

Cost of inventories recognised as an

expense

确认为开支的存货成本

508,455

Gain on disposals of subsidiaries

(note 34)

出售附属公司产生的收益

（附注34）–

Depreciation of property, plant and

equipment

物业、厂房及设备折旧

2,585

Depreciation of right-of-use asets使用权资产折旧3,450

Amortisation of intangible asets无形资产摊销7,984

9. FINANCE COSTS

二零二四年

HK$’000

千港元

Interest expenses on:下列各项的利息开支：

Factoring of trade receivables贸易应收款项保理3,991

Bank borowings银行借贷313

Amounts due to related parties应付关联方款项2,628

Amounts due to ultimate holding

company

应付最终控股公司款项

–

Lease liabilities租赁负债138

7,070

9. 融资成本

2025
二零二五年
HK$’000
千港元
3,218
(5)
157
(160)
1,498
(111)
4,597
(1,575)
3,022

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

10. 税项

综合损益表内之税项为：

10. TAXATION

Taxation in the consolidated statement of profit or los

represents:

二零二四年

HK$’000

千港元

The taxation comprises:税项包括：

Curent tax:即期税项：

Hong Kong Profits Tax香港利得税

Charge for the year年内支出4,964

Overprovision in respect of prior years过往年度超额拨备(36)

PRC Enterprise Income Tax中国企业所得税

Charge for the year年内支出23

Overprovision in respect of prior years过往年度超额拨备(105)

Japan Corporate Income Tax日本企业所得税

Charge for the year年内支出67

Overprovision in respect of prior years过往年度超额拨备(1,152)

3,761

Defered tax credit for the year (note

28)

年内递延税项抵免（附注28）

(1,317)

2,444

For the years ended 31 March 2025 and 2024, Hong

Kong Profits Tax is calculated at 8.25% on the first HK$2

milion of the estimated asesable profits of one of

the subsidiaries of the Company and at 16.5% on the

estimated asesable profits above HK$2 milion under the

two-tiered profits tax rates regime. The asesable profits

of group entities not qualified for the two-tier profit tax

regime wil continue to be taxed at a flat rate of 16.5%.

根据两级利得税率制度，截至二零

二五年及二零二四年三月三十一日止年

度，香港利得税乃按本公司其中一家附

属公司估计应课税溢利之首2,000,000港

元按8.25%计算，而超过2,000,000港元的

估计应课税溢利则按16.5%计算。不符合

两级利得税率制度的集团实体的应课

税溢利，将继续划一按16.5%征税。

2025
二零二五年
HK$’000
千港元
33,416
5,514
5,272
(11,305)
7,265
(1,550)
(276)
(1,898)
–
3,022

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

10. TAXATION (CONTINUED)

Under the Law of PRC on Enterprise Income Tax (the “EIT

Law”) and Implementation Regulation of the EIT Law, the

tax rate of the PRC subsidiaries is 25% for both years.

Under the rule of Japan Corporate Income Tax, the tax

rate of the Japan subsidiaries is 34.59% for both years.

Reconciliation betwen tax expense and profit (los)

before tax per the consolidated statement of profit or los

at aplicable tax rates:

二零二四年

HK$’000

千港元

Profit (los) before tax除税前溢利（亏损）(24,052)

Tax at the income tax rate of 16.5%

(2024: 16.5%)

按所得税率16.5%（二零二

四年：16.5%）计算之税项(3,969)

Tax efect of expenses not deductible

for tax purpose

不可扣税开支的税务影响

1,856

Tax efect of income not taxable for tax

purpose

毋须课税收入之税务影响

(2,995)

Tax efect of tax los not recognised尚未确认之税项亏损之税务

影响15,878

Utilisation of tax los previously not

recognised

动用先前未确认之税项亏损

(808)

Overprovision in prior years过往年度超额拨备(1,293)

Efect of diferent tax rates of

subsidiaries operating in other

jurisdictions

于其他司法权区经营之附属

公司不同税率之影响

(6,060)

Tax efect of profit two-tiered tax rate两级税率之税务影响(165)

Income tax expense所得税开支2,444

（续）

根据中国企业所得税法（「企业所得税

法」）及企业所得税法实施条例，中国附

属公司于两个年度之税率均为25%。

根据日本企业所得税法，日本附属公司

于两个年度之税率均为34.59%。

综合损益表内按适用税率计算之税项开

支与除税前溢利（亏损）之对账：

Fee	Salaries and other benefits	Retirement Benefits scheme contributions	Equity– settled share–based expense	Total
袍金	薪金及其他福利	退休福利计划供款	以权益结算以股份为基础之付款开支	总计
HK$’000	HK$’000	HK$’000	HK$’000	HK$’000
千港元	千港元	千港元	千港元	千港元
–	88	–	–	88
–	189	–	–	189
–	79	–	–	79
–	119	–	–	119
–	1,007	24	237	1,268
–	45	–	–	45
–	39	–	–	39
–	39	–	–	39
–	40	–	–	40
35	–	–	–	35
60	–	–	–	60
17	–	–	–	17
–	–	–	–	–
120	–	–	–	120
120	–	–	–	120
117	–	–	–	117
91	–	–	–	91
38	–	–	–	38
598	1,645	24	237	2,504

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

11. DIRECTORS’ CHIEF EXECUTIVE’S AND

EMPLOYE’S EMOLUMENTS

Directors’ and chief executive’s remuneration

The emoluments paid or payable of the seventen (2024:

fiften) directors are as folows:

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

Executive Directors执行董事

Mr. Washikita Kenichiro

(1)

鹫北健一郎先生

(1)

Mr. Miyano Tsumoru宫野积先生

Mr. Maezaki Masahiro

(2)

前崎匡弘先生

(2)

Mr. Shimada Tatsuji

(3)

岛田达二先生

(3)

Mr. Chiu Chun Tak赵俊德先生

Mr. Miyazato Hiroki

(2)

宫里启晖先生

(2)

Mr. Narumi Shoichi

(4)

呜海尚一先生

(4)

Ms. Du Yao

(4)

杜垚女士

(4)

Mr. Liang Fei

(4)

梁非先生

(4)

Non-executive Directors非执行董事

Mr. Kusaba Takuya

(5)

草场拓也先生

(5)

Mr. Yan Ping严平先生

Mr. Uematsu Takahiro

(6)

植松高宏先生

(6)

Independent non-executive

Directors

独立非执行董事

Mr. Taguchi Junichi

(7)

田口淳一先生

(7)

Mr. Choi Kon Ming蔡冠明先生

Mr. Chan Cheuk Ho陈卓豪先生

Mr. Saito Hironobu斋藤宏畅先生

Mr. Taniguchi Yasuhiko

(8)

谷口恭彦先生

(8)

Ms. Zhang Cuiping

(9)

张翠萍女士

(9)

、最高行政人员及雇员薪酬

董事及最高行政人员薪酬

已付或应付予十七名（二零二四年：十五

名）的董事薪酬如下：

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

、最高行政人员及雇员薪酬

（续）

董事及最高行政人员薪酬（续）

附注：

(1) 自二零二四年十一月八日起获委任为

执行董事、主席及行政总裁。

(2) 自二零二四年十二月二日起辞任执行

董事。

(3) 自二零二四年十一月八日起辞任执行

董事、主席及行政总裁。

(4) 自二零二四年十二月二日起获委任为

执行董事。

(5) 自二零二四年十二月二日起辞任非执

行董事。

(6) 自二零二四年十二月二日起获委任为

非执行董事。

(7) 自二零二四年四月一日起辞任独立非

执行董事。

(8) 自二零二四年四月一日起获委任为独

立非执行董事。自二零二五年一月十

日起辞任独立非执行董事。

(9) 自二零二四年十二月二日起获委任为

独立非执行董事。

11. DIRECTORS’ CHIEF EXECUTIVE’S AND

EMPLOYE’S EMOLUMENTS (CONTINUED)

Directors’ and chief executive’s remuneration

(Continued)

Notes:

, the Chairman and

the Chief Executive Oficer with efect from 8 November

2024.

(2) Resigned as an Executive Director with efect from 2

December 2024.

, the Chairman and

the Chief Executive Oficer with efect from 8 November

2024.

(4) Apointed as an Executive Director with efect from 2

December 2024.

(5) Resigned as a Non-executive Director with efect from 2

December 2024.

(6) Apointed as a Non-executive Director with efect from 2

December 2024.

(7) Resigned as Independent non-executive Director with

efect from 1 April 2024.

(8) Apointed as Independent non-executive Director with

efect from 1 April 2024. Resigned as Independent non-

executive Director with efect from 10 January 2025.

(9) Apointed as Independent non-executive Director with

efect from 2 December 2024.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

11. DIRECTORS’ CHIEF EXECUTIVE’S AND

EMPLOYE’S EMOLUMENTS (CONTINUED)

Directors’ and chief executive’s remuneration

(Continued)

For the year ended 31 March 2024

截至二零二四年三月三十一日止年度

Salaries

and other

benefits

Retirement

Benefits

scheme

contributionsTotal

袍金

薪金及

其他福利

退休福利

计划供款总计

HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元

Executive Directors执行董事

Mr. Okoso Satoshi

(1)

大社聡先生

(1)

–407–407

Mr. Gao Feng

(2)

高峰先生

(2)

–3528360

Mr. Haribayashi Keikyo

(3)

张林庆桥先生

(3)

–242–242

Mr. Miyano Tsumoru宫野积先生–357–357

Mr. Maezaki Masahiro前崎匡弘先生–182–182

Mr. Shimada Tatsuji

(4)

岛田达二先生

(4)

–84–84

Mr. Chiu Chun Tak

(5)

赵俊德先生

(5)

–1,194211,215

Mr. Miyazato Hiroki

(5)

宫里启晖先生

(5)

–25–25

Non-executive Directors非执行董事

Mr. Xia Xiang Ming

(6)

夏向明先生

(6)

60–60

Mr. Kusaba Takuya

(7)

草场拓也先生

(7)

24–24

Mr. Yan Ping

(7)

严平先生

(7)

25–25

Independent non-

executive Directors

独立非执行董事

Mr. Taguchi Junichi

(8)

田口淳一先生

(8)

120–120

Mr. Choi Kon Ming蔡冠明先生120–120

Mr. Chan Cheuk Ho陈卓豪先生120–120

Mr. Saito Hironobu

(9)

斋藤宏畅先生

(9)

55–55

5242,843293,396

、最高行政人员及雇员薪酬

（续）

董事及最高行政人员薪酬（续）

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

、最高行政人员及雇员薪酬

（续）

董事及最高行政人员薪酬（续）

附注：

(1) 自二零二三年十一月一日起辞任本公

司执行董事及行政总裁。

(2) 自二零二三年十一月一日起辞任执行

董事。

(3) 自二零二四年三月二十日起辞任执行

董事。

(4) 自二零二三年十一月一日起获委任为

执行董事。

(5) 自二零二三年十一月一日起获委任为

执行董事。赵俊德先生于获委任为执

行董事前，曾在本集团一间附属公司

担任雇员，上述金额为其年薪。

(6) 自二零二三年十一月一日起辞任非执

行董事。

(7) 自二零二三年十一月一日起获委任为

非执行董事。

(8) 自二零二四年四月一日起辞任独立非

执行董事。

(9) 自二零二三年十一月一日起获委任为

独立非执行董事。

11. DIRECTORS’ CHIEF EXECUTIVE’S AND

EMPLOYE’S EMOLUMENTS (CONTINUED)

Directors’ and chief executive’s remuneration

(Continued)

Notes:

(1) Resigned as Executive Director and the chief executive of

the Company with efect from 1 November 2023.

(2) Resigned as Executive Director with efect from 1

November 2023.

(3) Resigned as Executive Director with efect from 20 March

2024.

(4) Apointed as Executive Director with efect from 1

November 2023.

(5) Apointed as Executive Director with efect from 1

November 2023. Mr. Chiu Chun Tak serves the Group as

employe under a subsidiary before being apointed

as Executive Director, the amount above represents his

anual salary package.

(6) Resigned as Non-executive Director with efect from 1

November 2023.

(7) Apointed as Non-executive Director with efect from 1

November 2023.

(8) Resigned as Independent non-executive Director with

efect from 1 April 2024.

(9) Apointed as Independent non-executive Director with

efect from 1 November 2023.

2025
二零二五年
HK$’000
千港元
4,201
79
19
4,299

2025
二零二五年
3
1

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

、最高行政人员及雇员薪酬

（续）

五名最高薪酬人士

在最高薪酬的五名人士中，一名（二零二

四年：一名）为董事，其薪酬于上文披

露。其他四名（二零二四年：四名）个人

的薪酬总额如下：

11. DIRECTORS’ CHIEF EXECUTIVE’S AND

EMPLOYE’S EMOLUMENTS (CONTINUED)

Five highest paid individual

Of the five individuals with the highest emoluments, one

(2024: one) is a director whose emoluments are set out

above. The agregate of the emoluments in respect of the

other four (2024: four) individuals are as folows:

二零二四年

HK$’000

千港元

Salary and other emoluments薪金及其他酬金4,012

Retirement scheme contributions退休计划供款77

Equity-setled share-based expense以权益结算以股份为基础之

付款开支–

4,089

The emoluments of the four (2024: four) individuals with

the highest emoluments are within the folowing bands:

Number of individuals

人数

二零二四年

Nil to HK$1,000,000零至1,000,000港元3

HK$1,500,001 to HK$2,000,0001,500,001港元至2,000,000港元1

During the year ended 31 March 2025, no emoluments

(2024: nil) were paid by the Group to any of the directors

or the highest paid individuals as an inducement to join

or upon joining the Group or as compensation for los of

ofice.

薪酬最高的四名（二零二四年：四名）个

人的薪酬在下列范围内：

截至二零二五年三月三十一日止年度，

本集团并无（二零二四年：无）向任何董

事或最高薪酬人士支付任何酬金，作为

加入本集团或加入本集团后之奖励或离

职补偿。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（亏损）

每股基本盈利（亏损）

每股基本盈利（亏损）乃基于本公司拥

有人应占年内溢利约38,585,000港元

（二零二四年：本公司拥有人应占年

内亏损22,066,000港元）及年内已发行

520,901,458股（二零二四年：500,000,000

股）普通股之加权平均数计算。

每股摊薄盈利（亏损）

截至二零二五年三月三十一日止年度之

每股摊薄盈利之计算并无假设本公司授

出之若干购股权获行使，原因为该等购

股权之行使价高于期内之股份平均市价。

截至二零二四年三月三十一日止年度，

由于本公司并无任何发行在外的潜在摊

薄普通股，故并无呈列每股摊薄亏损。

13. 股息

于报告期末后，本公司董事已建议派

付截至二零二五年三月三十一日止年

度之末期股息每股普通股1.0港仙（合计

5,221,774港元），惟须于应届股东大会上

取得股东批准。拟派末期股息并未于综

合财务报表内确认为应付股息。

截至二零二四年三月三十一日止年度，

概无派付或建议派付股息。

12. EARNINGS (LOS) PER SHARE

Basic earnings (los) per share

The calculation of basic earnings (los) per share is based

on the profit for the year atributable to owners of the

Company of aproximately HK$38,585,000 (2024: los

for the year atributable to owners of the Company

HK$22,066,000) and the weighted average number of

ordinary shares of 520,901,458 (2024: 500,000,000) in isue

during the year.

Diluted earnings (los) per share

The computation of diluted earnings per share for the

year ended 31 March 2025 did not asume the exercise

of certain of share options granted by the Company since

the exercise price of those share options was higher than

the average market price of the shares for the period.

No diluted los per share is presented as the Company did

not have any dilutive potential ordinary share outstanding

during the year ended 31 March 2024.

13. DIVIDENDS

Subsequent to the end of the reporting period, a final

dividend in respect of the year ended 31 March 2025 of

HK1.0 cent per ordinary share, in an agregate amount of

HK$5,221,774, has ben proposed by the directors of the

Company and is subject to aproval by the shareholders

in the forthcoming general meting. The proposed final

dividend have not ben recognised as dividend payables

in the consolidated financial statements.

No dividend was paid or proposed for the year ended 31

March 2024.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

14. PROPERTY, PLANT AND EQUIPMENT

Leasehold

improvement

Furniture

and ofice

equipment

Medical

devicesTotal

租赁物业装修

家具及

办公设备医疗器械总计

HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元

COST成本

At 1 April 2023于二零二三年四月一日2,5589,434–11,992

Transfer转拨–(2,310)2,310–

Aditions添置–3094,7285,037

Disposals出售–(70)–(70)

Exchange diference汇兑差额–(132)(282)(414)

At 31 March 2024 and 1 April 2024于二零二四年三月三十一日及

二零二四年四月一日2,5587,2316,75616,545

Aditions添置–1125,5955,707

Disposals/write-of出售╱撇销–(137)(4,802)(4,939)

Disposal of subsidiaries出售附属公司–(59)–(59)

Exchange diference汇兑差额–(9)5748

At 31 March 2025于二零二五年三月三十一日2,5587,1387,60617,302

ACUMULATED DEPRECIATION累计折旧

At 1 April 2023于二零二三年四月一日2,5586,047–8,605

Transfer转拨–(435)435–

Charge for the year年内扣除–7381,8472,585

Disposals出售–(35)–(35)

Exchange diference汇兑差额–(80)(91)(171)

At 31 March 2024 and 1 April 2024于二零二四年三月三十一日及

二零二四年四月一日2,5586,2352,19110,984

Charge for the year年内扣除–4202,5182,938

Disposals/write-of出售╱撇销–(137)(1,974)(2,111)

Eliminated upon disposal of

subsidiaries

出售附属公司时撇销

–(26)–(26)

Exchange diference汇兑差额–(8)2315

At 31 March 2025于二零二五年三月三十一日2,5586,4842,75811,800

NET BOK VALUE账面值

At 31 March 2025于二零二五年三月三十一日–6544,8485,502

At 31 March 2024于二零二四年三月三十一日–9964,5655,561

The above items of property, plant and equipment, after

taking into acount the residual values, are depreciated on

a straight-line basis at the folowing rates per anum:

Leasehold improvementOver the period of the relevant

lease or 5 years, whichever is

shorter

Furniture and ofice

equipment

20% per anum

Medical devicesOver the lease term

The Group leases out a number of medical devices under

operating leases. The leases typicaly run for an initial

period of one to ten years. None of the leases includes

variable lease payments.

、厂房及设备

上述物业、厂房及设备项目之折旧经考

虑剩余价值后，乃采用以下年率按直线

法计算：

租赁物业装修按相关租赁期或5年

（以较短者为准）

家具及办公设备每年20%

医疗器械按租赁期

本集团根据经营租赁出租若干医疗器

械。初步租期通常为一至十年。所有租

赁均不包括变动租金。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

15. RIGHT-OF-USE ASETS

Ofice premises

leased for own use

自用租赁

办公室场所

HK$’000

千港元

COST成本

At 1 April 2023于二零二三年四月一日6,271

Aditions添置4,981

Eliminated upon lease expired租赁届满时撇销(4,895)

Exchange diferences汇兑差额(260)

At 31 March 2024 and 1 April 2024于二零二四年三月三十一日及

二零二四年四月一日6,097

Aditions添置2,770

Early terminated提前终止(1,431)

Eliminated upon lease expired租赁届满时撇销(1,087)

Exchange diferences汇兑差额(3)

At 31 March 2025于二零二五年三月三十一日6,346

ACUMULATED DEPRECIATION累计折旧

At 1 April 2023于二零二三年四月一日3,605

Charge for the year年内扣除3,450

Eliminated upon lease expired租赁届满时撇销(4,895)

Exchange diferences汇兑差额(150)

At 31 March 2024 and 1 April 2024于二零二四年三月三十一日及

二零二四年四月一日2,010

Charge for the year年内扣除2,974

Early terminated提前终止(1,140)

Eliminated upon lease expired租赁届满时撇销(1,087)

Exchange diferences汇兑差额13

At 31 March 2025于二零二五年三月三十一日2,770

NET BOK VALUE账面净值

At 31 March 2025于二零二五年三月三十一日3,576

At 31 March 2024于二零二四年三月三十一日4,087

The ofice premises leased for own use are depreciated

over the terms of the lease.

15. 使用权资产

自用租赁办公室场所于租赁期内折旧。

2025
二零二五年
HK$’000
千港元
2,974
254
743
10
3,777

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

15. RIGHT-OF-USE ASETS (CONTINUED)

The analysis of expense items in relation to leases

recognised in profit or los is as folows:

二零二四年

HK$’000

千港元

Depreciation charge折旧费用

– Ofice premises leased for own use－自用租赁办公室场所3,450

Interest on lease relating liabilities租赁相关负债利息138

Expense to short-term leases短期租赁之开支1,148

Expense relating to leases of low-value

asets, excluding short-term leases of

low-value asets

与低价值资产租赁（不包括低

价值资产的短期租赁）有关

的开支5

Total cash outflow for leases租赁的现金流出总额4,871

During the year, aditions to right-of-use asets and

lease liabilities were aproximately HK$2,770,000 (2024:

HK$4,981,000) and HK$2,740,000 (2024: HK$4,967,000)

respectively.

For both years, the Group leases various ofices for its

operations. Lease contracts are entered into for fixed term

from two to thre years.

16. GODWIL

HK$’000

千港元

Cost and carying values成本及账面值

At 1 April 2023于二零二三年四月一日–

Arising on acquisition of subsidiaries收购附属公司所产生50,067

Exchange diference汇兑差额(1,027)

At 31 March 2024 and 1 April 2024于二零二四年三月三十一日及

二零二四年四月一日49,040

Impairment los recognised for the year年内确认之减值亏损(18,050)

Eliminated upon disposal of subsidiaries出售附属公司时撇销(11,549)

Exchange diference汇兑差额64

At 31 March 2025于二零二五年三月三十一日19,505

（续）

于损益内确认与租赁相关的开支项目分

析如下：

年内，使用权资产添置及租赁负债分

别约为2,770,000港元（二零二四年：

4,981,000港元）及2,740,000港元（二零二

四年：4,967,000港元）。

于两个年度，本集团为其营运租赁若干

办公室。租赁合约按固定期限两至三年

订立。

16. 商誉

2025		2025
二零二五年		二零二五年
HK$’000		HK$’000
千港元		千港元
19,505	19,629 29,411	–
–		–
49,040
19,505		–

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（续）

就减值测试目的而言，商誉及附注17

所载具无限可使用年期之非专利技术

已分配至两个现金产生单位内，即(i)

瑞益股份有限公司及其附属公司（「大

河集团」）；及(i) Biotube Co., Limited

（「Biotube」）。

分配至该等单位的商誉及具无限可使用

年期之非专利技术的账面值（扣除累计减

值亏损）如下：

16. GODWIL (CONTINUED)

For the purpose of impairment testing, godwil and

unpatented technology with indefinite lives set out in

note 17 have ben alocated to two individual CGUs,

comprising (i) R&E Corporation Limited and its subsidiary

(“Taiga Group”); and (i) Biotube Co., Limited (“Biotube”).

The carying amounts of godwil and unpatented

technology with indefinite useful lives (net of acumulated

impairment loses) alocated to these units are as folows:

GodwilUnpatented technology

商誉非专利技术

二零二四年

HK$’000

千港元

Taiga Group大河集团–

BiotubeBiotube68,256

68,256

In adition to godwil and unpatented technology above,

property, plant and equipment (including alocation of

corporate asets) that generate cash flows together with

the related godwil and unpatented technology and

other intangible asets are also included in the respective

CGU for the purpose of impairment asesment.

The recoverable amount of Taiga Group has ben

determined based on a value in use calculation. That

calculation uses cash flow projections based on financial

budgets aproved by management covering a five-year

period, and pre-tax discount rate of 19.96% (2024: 19.34%).

Taiga Group’s cash flows beyond the five-year period are

extrapolated using a steady 2.00% long-term growth rate

(2024: 2.00%).This growth rate does not exced the long-

term growth rate for the PRC market in which Taiga Group

operates.

就减值评估目的而言，除上述商誉及非

专利技术外，产生现金流量的物业、厂

房及设备（包括获分配的企业资产），连

同有关商誉及非专利技术以及其他无形

资产亦计入相关现金产生单位内。

大河集团的可收回金额乃按使用价值计

算方法厘定。该计算采用的现金流量预

测乃根据管理层批准的五年期财务预算

及19.96%（二零二四年：19.34%）税前贴

现率得出。大河集团超过五年期的现

金流量采用稳定的2.00%（二零二四年：

2.00%）长期增长率推算。该增长率并无

超过大河集团经营所在的中国市场的长

期增长率。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

截至二零二五年及二零二四年三月三十

一日止年度，经参考独立专业估值师澋

锋评估有限公司（「澋锋」）作出之估值，

本集团管理层厘定大河集团现金产生单

位并无减值。本集团管理层认为，该等

假设出现任何合理可能变动均不会导致

大河集团现金产生单位的账面值超过其

可收回金额。管理层认为，该等假设出

现任何合理可能变动均不会导致减值。

Biotube的可收回金额乃按使用价值计算

方法厘定。该计算采用的现金流量预测

乃根据管理层批准的五年期财务预算及

23.78%（二零二四年：22.05%）税前贴现

率得出。Biotube超过五年期的现金流量

采用稳定的2.00%（二零二四年：1.60%）

长期增长率推算。该增长率并无超过

Biotube经营所在的日本市场的长期增长

率。

于二零二五年三月三十一日，经参考独

立专业估值师澋锋作出之估值，本集团

管理层厘定分配至Biotube现金产生单位

之商誉产生减值亏损约18,050,000港元

（二零二四年：无）。

16. GODWIL (CONTINUED)

During the years ended 31 March 2025 and 2024, with

reference to the valuation performed by an independent

profesional valuer, Peak Vision Apraisals Limited

(“Peak Vision”), management of the Group determined

that there was no impairment on Taiga Group CGU.

Management of the Group believes that any reasonably

posible change in any of these asumptions would not

cause the carying amount of Taiga Group CGU to exced

its recoverable amount. Management believes that any

reasonably posible change in any of these asumptions

would not result in impairment.

The recoverable amount of Biotube has ben determined

based on a value in use calculation. That calculation

uses cash flow projections based on financial budgets

aproved by management covering a five-year period, and

pre-tax discount rate of 23.78% (2024: 22.05%). Biotube

cash flows beyond the five-year period are extrapolated

using a steady 2.00% long-term growth rate (2024: 1.60%).

This growth rate does not exced the long-term growth

rate for the Japan market in which Biotube operates.

As at 31 March 2025, with reference to the valuation

performed by an independent profesional valuer, Peak

Vision, the management of the Group has determined that

an impairment los of aproximately HK$18,050,000 (2024:

nil) arose in relation to godwil alocated to Biotube CGU.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

17. INTANGIBLE ASETS

Exclusive

distribution

rightsPatent

Unpatented

technologyTotal

独家分销权专利非专利技术总额

HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元

COST成本

At 1 April 2023于二零二三年四月一日–

Acquisition of subsidiaries收购附属公司94,4971,90469,965166,366

Exchange diference汇兑差额(1,376)(46)(1,709)(3,131)

At 31 March 2024 and 1

April 2024

于二零二四年三月三十一日

及二零二四年四月一日93,1211,85868,256163,235

Disposal of subsidiaries出售附属公司–(1,870)(68,690)(70,560)

Exchange diference汇兑差额(589)12434(143)

At 31 March 2025于二零二五年三月三十一日92,532–92,532

AMORTISATION AND

IMPAIRMENT

摊销及减值

At 1 April 2023于二零二三年四月一日–

Charged for the year年内扣除7,984–7,984

Exchange diference汇兑差额(59)–(59)

At 31 March 2024 and

1 April 2024

于二零二四年三月三十一日

及二零二四年四月一日7,925–7,925

Charged for the year年内扣除9,544356–9,900

Eliminated upon disposal

of subsidiaries

出售附属公司时撇销

–(356)–(356)

Exchange diference汇兑差额(144)–(144)

At 31 March 2025于二零二五年三月三十一日17,325–17,325

CARYING VALUES账面净值

At 31 March 2025于二零二五年三月三十一日75,207–75,207

At 31 March 2024于二零二四年三月三十一日85,1961,85868,256155,310

17. 无形资产

2025
二零二五年
HK$’000
千港元
3,041
1,855
11,752
16,648

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

无形资产按直线基准于下列期间内摊销：

独家分销权 10年

专利 17年

非专利技术不予摊销

独家分销权指与一家供应商订立10年期

间于中国进行独家保健产品贸易的权利。

非专利技术乃于收购一间附属公司时所

收购。除非其可使用年期被认定为有限

（验证性临床试验完成后开始计算），否

则非专利技术不予摊销。

有关无形资产的减值测试详情于附注16

披露。

18. 存货

17. INTANGIBLE ASETS (CONTINUED)

Intangible asets are amortised on a straight-line basis

over the folowing periods:

Exclusive distribution rights 10 years

Patents 17 years

Unpatented technology Not amortised

Exclusive distribution rights represent an exclusive rights

with a suplier to trade healthcare products in the PRC for

10 years.

Unpatented technology is acquired during the acquisition

of a subsidiary. The unpatented technology wil not be

amortised until their useful life is determined to be finite,

initiating by the completion of confirmatory clinical trial.

Particulars regarding impairment testing of intangible

asets are disclosed in note 16.

18. INVENTORIES

二零二四年

HK$’000

千港元

Raw materials原材料1,836

Work-in-progres在制品1,984

Finished gods制成品11,927

15,747

2025
二零二五年
HK$’000
千港元
46

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

19. CONTRACT ASETS

二零二四年

HK$’000

千港元

Contract asets from provision of IRO

and CRO services

提供IRO及CRO服务的合约

资产985

As at 1 April 2023, there are contract asets amounted to

aproximately HK$2,786,000.

The contract asets primarily relate to the Group’s right

to consideration from the customers for the tailoring

provision of IRO and CRO services. Contract asets arise

when the Group has right to consideration for the work

completed under relevant contracts and their right is

conditioned on factors other than pasage of time. The

contract asets are transfered to trade receivables upon

the delivery and aceptance of products by customers.

Typical payment terms are 60 to 120 days upon delivery.

The Group clasifies these contract asets as curent asets

because the Group expects to realise them in its normal

operating cycle which is within 12 months after the end

of the reporting period.

Details of the impairment asesment are set out in note

33.

19. 合约资产

于二零二三年四月一日，合约资产价值

约2,786,000港元。

合约资产主要有关本集团就提供特定制

造的IRO及CRO服务向客户收取代价之权

利。合约资产于本集团有权取得根据有

关合约所完成工作的代价，且彼等的权

利须以时间流逝以外的因素为条件时产

生。合约资产于客户交付及接纳产品时

转拨至贸易应收款项。

一般付款期限为交付后60至120日。

本集团将该等合约资产分类为流动资

产，原因为本集团预期于正常营运周期

（即报告期末后十二个月内）将该等资产

变现。

有关减值评估的详情载于附注33。

2025
二零二五年
HK$’000
千港元
29,984
2,242
12,979
29,565
74,770
73,732
1,038
74,770

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

20. TRADE AND OTHER RECEIVABLES

二零二四年

HK$’000

千港元

Trade debtors, net of los alowance应收账款（扣除亏损拨备）46,835

Bils receivable应收票据947

Deposits and other receivables按金及其他应收款项16,948

Prepayments预付款项6,908

71,638

Analysed for reporting purpose as:就报告用途分析为：

Curent asets 流动资产70,657

Non-curent asets 非流动资产981

71,638

As at 1 April 2023, the carying amount of trade receivables

from contracts with customers was HK$34,593,000.

As at 31 March 2025, trade debtors of HK$29,984,000 (2024:

HK$46,835,000) comprised receivables from contracts with

customers and lease receivables of HK$28,248,000 (2024:HK

$46,325,000) and HK$1,736,000 (2024: HK$510,000)

respectively.

The Group’s credit terms on Garment Busines and

Healthcare Products Busines generaly range from 30

to 90 days, while alows an average credit period of 60

to 120 days to its customers of the provision of IRO and

CRO services. Credit period of 180 days is granted to a

customer for the IRO and CRO services with whom the

Group has a god busines relationship and who is in

sound financial condition.

20. 贸易及其他应收款项

于二零二三年四月一日，客户合约产生

之贸易应收款项的账面值为34,593,000港

元。

于二零二五年三月三十一日，应收账款

29,984,000港元（二零二四年：46,835,000

港元）包括客户合约产生之应收款项

28,248,000港元（二零二四年：46,325,000

港元）及应收租赁款项1,736,000港元（二

零二四年：510,000港元）。

本集团服装业务及保健产品业务之信贷

期限一般介乎30至90日，给予其IRO及

CRO服务客户之信贷期限平均为60至120

日。与本集团有良好业务关系且财务状

况良好之IRO及CRO服务客户可享有180

日之信贷期。

2025
二零二五年
HK$’000
千港元
14,194
2,697
11,985
1,108
29,984

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

20. TRADE AND OTHER RECEIVABLES (CONTINUED)

Ageing analysis

As of the end of the reporting period, the ageing analysis

of trade debtors based on the invoice date and net of los

alowance, is as folows:

二零二四年

HK$’000

千港元

1 – 30 days1至30日21,858

31 – 60 days31至60日5,749

61 – 90 days61至90日7,254

Over 90 days90日以上11,974

46,835

As at 31 March 2025, included in the Group’s trade

receivables balance are debtors with agregate

carying amount of aproximately HK$8,133,000 (2024:

HK$5,344,000) which are past due as at the reporting

date. Out of the past due balances, HK$99,000 (2024:

HK$1,234,000) has ben past due 90 days or more and

is not considered as in default. With reference to the

historical records, past experience and also available

reasonable and suportive forward-loking information

to those customers, the directors of the Company do not

consider these receivables as credit-impaired as these

customers have a god busines relationship with the

Group and recuring overdue records of these customers

with satisfactory setlement history.

Included in prepayments, prepayment of inventories

of aproximately HK$18,674,000 (2024: Nil) is related to

Healthcare Products Busines, which are expected to be

realised within one year as at 31 March 2025.

Details of impairment asesment of trade and other

receivables for the years ended 31 March 2025 and 2024

are set out in note 33.

（续）

账龄分析

截至报告期末，按发票日期呈列并扣除

亏损拨备之应收账款之账龄分析如下：

于二零二五年三月三十一日，本集团之

贸易应收款项及应收票据结余中，包括

账面总额约8,133,000港元（二零二四年：

5,344,000港元）之应收账款，该等应收账

款于报告日期已逾期。在逾期结余中，

99,000港元（二零二四年：1,234,000港元）

已逾期90日或以上，且并非视为违约。

经参考该等客户的历史记录、过往经

验以及可获得的合理及有依据前瞻性资

料，本公司董事并不认为该等应收款项

已出现信贷减值，原因为该等客户与本

集团维持良好业务关系，且该等客户的

经常逾期记录显示其还款记录理想。

于二零二五年三月三十一日，预付款项

中的存货预付款项约18,674,000港元（二

零二四年：无）与保健产品业务有关，预

期于一年内变现。

截至二零二五年及二零二四年三月三十

一日止年度，贸易及其他应收款项的减

值评估详情载于附注33。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

21. 已抵押银行存款

于二零二五年三月三十一日，本集团

订立银行融资协议，总金额最高约为

7,800,000港元（二零二四年：20,000,000

港元）。于二零二五年三月三十一日，

银行存款4,000,000港元（二零二四年：

9,000,000港元）已作抵押，以抵押该等融

资。

已抵押银行存款按0.4%（二零二四年：

1.0%至4.2%）的年利率计息。

已抵押银行存款的减值评估详情载于附

注33。

22. 现金及现金等价物

现金及现金等价物包括用于满足本集团

短期现金需求之活期存款及短期存款。

于二零二五年三月三十一日，为数约

27,172,000港元（二零二四年：25,105,000

港元）、64,875,000港元（二零二四年：

2,561,000港元）、21,000港元（二零二四

年：36,000港元）及5,000港元（二零二四

年：17,000港元）之银行结余分别以港

元、日圆、美元及人民币计值，而有关

货币均非各集团实体之功能货币。

银行结余按介乎0.01%至0.39%（二零二四

年：0.10%至4.30%）的利率计息。

现金及现金等价物的减值评估详情载于

附注33。

21. PLEDGED BANK DEPOSITS

As at 31 March 2025, the Group entered into banking

facilities agrements with the amount in agregate up

to aproximately HK$7,800,000 (2024: HK$20,000,000).

Bank deposits of HK$4,000,000 (2024: HK$9,000,000) was

pledged to secure the facilities as at 31 March 2025.

The pledged bank deposits cary interest rates with 0.4%

(2024: from 1.0% to 4.2%) per anum.

Details of impairment asesment of pledged bank

deposits are set out in note 33.

22. CASH AND CASH EQUIVALENTS

Cash and cash equivalents include demand deposits

and short term deposits for the purpose of meting the

Group’s short term cash comitments.

As at 31 March 2025, bank balances of aproximately

HK$27,172,000 (2024: HK$25,105,000), HK$64,875,000

(2024: HK$2,561,000), HK$21,000 (2024: HK$36,000) and

HK$5,000 (2024: HK$17,000) are amounts denominated

in HKD, Japanese Yen (“JPY”), USD and Renminbi (“RMB”)

respectively, the curencies other than the functional

curencies of the respective group entities.

The bank balances cary interest rates with a range from

0.01% to 0.39% (2024: 0.10% to 4.30%).

Details of impairment asesment of cash and cash

equivalents are set out in note 33.

2025
二零二五年
HK$’000
千港元
17,451
1,152
8,645
4,552
31,800

2025
二零二五年
HK$’000
千港元
5,590
1,303
5,313
5,245
17,451

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

23. TRADE AND OTHER PAYABLES AND

ACRUALS

二零二四年

HK$’000

千港元

Trade payables贸易应付款项32,880

Acrued staf costs应计员工成本1,163

Acrued expenses应计开支9,020

Other payables其他应付款项9,021

52,084

The folowing is an aging analysis of trade payables

presented based on the invoice date at the end of

reporting period.

二零二四年

HK$’000

千港元

1 – 30 days1至30日17,957

31 – 60 days31至60日10,619

61 – 90 days61至90日1,190

Over 90 days90日以上3,114

32,880

The credit period ranges from 30 to 45 days. The Group

has financial risk management policies in place to ensure

that al payables are within the credit timeframe.

Trade and other payables of aproximately HK$5,959,000

(2024: HK$2,926,000) were denominated in RMB against

USD as at 31 March 2025, the curency other than the

functional curencies of the respective group entities.

23. 贸易及其他应付款项以及应计费

用

以下为于报告期末根据发票日期载列之

贸易应付款项的账龄分析。

信贷期介乎30至45日。本集团已制定财

务风险管理政策，以确保所有应付款项

按期支付。

于二零二五年三月三十一日，为数约

5,959,000港元（二零二四年：2,926,000港

元）之贸易及其他应付款项以人民币兑美

元计值，而有关货币并非各集团实体之

功能货币。

2025
二零二五年
HK$’000
千港元
2,617
751
417
3,785
(2,617)
1,168

2025
二零二五年
HK$’000
千港元
970

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

24. LEASE LIABILITIES

二零二四年

HK$’000

千港元

Within one year于一年内2,606

Within a period of more than one

year but les than two years

超过一年但不超过两年的

期间内1,512

Within a period of more than two

years but les than five years

超过两年但不超过五年的

期间内–

4,118

Les: A mount due for setlement

with 12 months shown under

curent liabilities

减：于流动负债项下列示的12

个月内到期偿还款项

(2,606)

Amount due for setlement after 12

months shown under non-curent

liabilities

于非流动负债项下列示的12个

月后到期偿还款项

1,512

Lease liabilities that are denominated in curencies other

than the functional curencies of the relevant group

entities are set out below:

二零二四年

HK$’000

千港元

Denominated at HK$ against USD以港元兑美元计值2,051

The incremental borowing rates aplied to lease liabilities

range from 3.1% to 8.1% (2024: from 3.7% to 8.1%).

24. 租赁负债

以相关集团实体之功能货币以外货币计

值之租赁负债载列如下：

租赁负债采纳的增量借款利率介乎3.1%

至8.1%（二零二四年：3.7%至8.1%）。

2025
二零二五年
HK$’000
千港元
209
293
10,167
10,669

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

25. CONTRACT LIABILITIES

二零二四年

HK$’000

千港元

Contract liabilities from trading of

aparel products

来自服装产品贸易的合约

负债216

Contract liabilities from trading of

healthcare products

来自保健产品贸易的

合约负债822

Contract liabilities from provision of IRO

and CRO services

来自提供IRO及CRO服务的

合约负债2,231

3,269

As at 1 April 2023, there are contract liability amounted to

aproximately HK$5,648,000.

Contract liabilities are clasified as curent liabilities

because the Group expects to setle them within 12

months after the end of the reporting period.

Typical payment terms which impact on the amount of

contract liabilities recognised are as folows:

When the Group receives a deposit before the garment

and healthcare products delivery, this wil give rise to

contract liabilities at the start of a contract, until the

revenue recognised on the specific contract exceds the

amount of the deposit. The Group receives a 5% to 10%

deposit on aceptance of orders for trading of garment

and healthcare products from certain customers.

When the Group receives a deposit before the completion

of milestones under provision of IRO and CRO services,

this wil give rise to contract liabilities at the start of a

contract, until the revenue recognised on the specific

contract exceds the amount of the deposit. The Group

receives a 10% to 20% deposit on from certain customers

when the contract for healthcare services signed.

25. 合约负债

于二零二三年四月一日，合约负债金额

约为5,648,000港元。

合约负债分类为流动负债，原因为本集

团预期于报告期末后十二个月内偿付合

约负债。

对已确认合约负债金额产生影响的一般

支付条款如下：

当本集团于服装及保健产品交付前收到

订金，则此将于合约开始时产生合约负

债，直至就指定合约确认的收益超过订

金额。本集团于自若干客户收到服装

及保健产品贸易订单后收取5%至10%的

订金。

当本集团于提供IRO及CRO服务的疗程完

成前收到订金，则此将于合约开始时产

生合约负债，直至就指定合约确认的收

益超过订金额。本集团于保健服务的

合约经签署时自若干客户收取10%至20%

的订金。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

25. CONTRACT LIABILITIES (CONTINUED)

The folowing table shows how much of the revenue

recognised in the curent year relates to caried-forward

contract liabilities.

HK$’000

千港元

For the year ended 31 March 2025截至二零二五年三月三十一日止年度

Revenue recognised that was included in the

contract liabilities balance at the begining of

the year

计入年初合约负债结余的已确认收益

3,269

For the year ended 31 March 2024截至二零二四年三月三十一日止年度

Revenue recognised that was included in the

contract liabilities balance at the begining of

the year

计入年初合约负债结余的已确认收益

5,648

26. AMOUNTS DUE TO RELATED PARTIES/

ULTIMATE HOLDING COMPANY/NON-

CONTROLING INTERESTS

(a) Amounts due to related parties

Except from the amounts due to related parties of

HK$51,281,000 (2024: HK$56,434,000) as disclosed

in note 38(b), the remaining balances due to

related parties (which are felow subsidiaries of the

Group) are unsecured, interest fre and repayable

on demand.

(b) Amount due to ultimate holding company

At 31 March 2024, amount due to ultimate holding

company of HK$40,471,000 is unsecured, caried at

fixed interest rate of 1.4% per anum and repayable

on 30 September 2024. The remaining balance is

unsecured, interest fre and repayable on demand.

At 31 March 2025, except for HK$29,987,000 (2024:

HK$50,204,000) of amount due to non-controling

interests that is caried at FVTPL in relation to

contingent consideration for acquisition of Taiga

Group, the remaining balance is unsecured, interest

fre and repayable on demand.

（续）

下表列示于本年度确认的收益金额，涉

及结转合约负债。

╱最终控股公司╱非

控股权益款项

(a) 应付关联方款项

除附注38(b)披露之应付关联方款

项51,281,000港元（二零二四年：

56,434,000港元）外，余下应付关

联方（为本集团旗下同系附属公

司）款项均为无抵押、免息及按要

求偿还。

(b) 应付最终控股公司款项

于二零二四年三月三十一日，应

付最终控股公司款项40,471,000港

元为无抵押、按固定年利率1.4%

计息及须于二零二四年九月三十

日偿还。余额则为无抵押、免息

及按要求偿还。

于二零二五年三月三十一日，除

与收购大河集团的或然代价有关

的应付非控股权益款项29,987,000

港元（二零二四年：50,204,000港元）

乃按公平值计入损益外，余额均

为无抵押、免息及按要求偿还。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

27. 雇员退休福利

本集团根据香港强制性公积金计划条例

为受香港雇佣条例管辖的香港雇员设立

强制性公积金计划（「强积金计划」）。强

积金计划为由独立受托人管理的定额供

款退休计划。根据强积金计划，雇主及

其雇员各自须向强积金计划供款，供款

额为雇员有关收入的5%，惟不得超过每

月相关收入1,500港元（二零二四年：1,500

港元）的上限。向该计划作出的供款会即

时归属有关人士。

本集团并无动用已没收的供款以减低本

集团强积金计划的现有供款水平。

本集团于中国及日本的附属公司的雇员

须参与相关政府设立的国家管理退休福

利计划。本公司于中国的附属公司须按

雇员基本薪酬的若干百分比向该等退休

福利计划供款，为该等福利提供资金。

本集团对退休福利计划的唯一责任为根

据计划作出所需供款。本集团概无进一

步缴纳供款的法律推定义务。

27. EMPLOYE RETIREMENT BENEFITS

The Group operates a Mandatory Provident Fund

Scheme (the “MPF Scheme”) under the Hong Kong

Mandatory Provident Fund Schemes Ordinance for

employes in Hong Kong under the jurisdiction of the

Hong Kong Employment Ordinance. The MPF Scheme is

a defined contribution retirement scheme administered

by independent trustes. Under the MPF Scheme, the

employer and its employes are each required to make

contributions to the MPF Scheme at 5% of the employes’

relevant income, subject to a cap of monthly relevant

income of HK$1,500 (2024: HK$1,500). Contributions to the

plan vest imediately.

There were no forfeited contributions utilised by the

Group to reduce the existing level of contributions under

the Group’s MPF Scheme.

The employes of the Group’s subsidiaries in the PRC

and Japan are members of the state-managed retirement

benefit schemes operated by the respective government.

The Company’s subsidiaries in the PRC and Japan are

required to contribute a certain percentage of their

employes’ payrol to the retirement benefit schemes to

fund the benefits. The only obligation of the Group with

respect to the retirement benefit schemes is to make the

required contributions under the schemes. The Group

has no legal constructive obligations to pay further

contributions.

2025
二零二五年
HK$’000
千港元
12,409

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

28. DEFERED TAX

二零二四年

HK$’000

千港元

Defered tax liabilities递延税项负债34,957

The components of defered tax liabilities recognised in

the consolidated statement of financial position and the

movements during the year are as folows:

Intangible asets

无形资产

HK$’000

千港元

At 1 April 2023于二零二三年四月一日–

Arising on a acquisition of a subsidiary收购附属公司所产生37,015

Credited to profit or los于损益计入(1,317)

Exchange diference汇兑调整(741)

At 31 March 2024 and 1 April 2024于二零二四年三月三十一日及

二零二四年四月一日34,957

Credited to profit or los于损益计入(1,575)

Disposal of subsidiaries出售附属公司(21,033)

Exchange diference汇兑调整60

At 31 March 2025于二零二五年三月三十一日12,409

The Group has not recognised defered tax asets

in respect of cumulative tax loses of HK$30,548,000

(2024: HK$187,627,000) as it is not probable that future

taxable profits against which the loses can be utilised

wil be available in the relevant tax jurisdiction and

entity. The cumulative tax loses of HK$27,832,000

(2024: HK$168,780,000) wil expire at various dates up

to and including year 2035 and HK$2,716,000 (2024:

HK$18,847,000) do not expire under curent tax legislation.

28. 递延税项

于综合财务状况表确认之递延税项负债

的组成部分及年内变动如下：

本集团并无就累计税项亏损确认递延税

项资产约30,548,000港元（二零二四年：

187,627,000港元），乃由于有关税项司法

权区及实体日后不大可能有应课税溢利

可用以抵销亏损。根据现行税务法律，

累计税项亏损27,832,000港元（二零二四

年：168,780,000港元）将于二零三五年（包

括该年）之不同日期到期，而2,716,000港

元（二零二四年：18,847,000港元）将不会

到期。

2025
二零二五年
HK$’000
千港元
2,897

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

28. DEFERED TAX (CONTINUED)

At 31 March 2025, temporary diferences relating to

the undistributed profits of subsidiaries amounted to

HK$11,056,000 (2024: HK$13,457,000). Defered tax

liabilities of HK$1,824,000 (2024: HK$2,220,000) have

not ben recognised in respect of the tax that would

be payable on the distribution of these retained profits

as the Company controls the dividend policy of these

subsidiaries and it has ben determined that it is probable

that these profits wil not be distributed in the foreseable

future.

29. BANK BOROWINGS

二零二四年

HK$’000

千港元

The borowings are repayable as

folows:

借贷须按下列方式偿还：

On demand or within one year (shown

under curent liabilities)

按要求或于一年内偿还

（于流动负债项下列示）7,335

Bank borowings are aranged at fixed interest rate at 5.5%

(2024: 6.4% to 7%) as at 31 March 2025.

As at 31 March 2025, the bank borowings are secured

by the pledged bank deposits of HK4,000,000 (2024:

HK$9,000,000) as disclosed in note 21.

Bank borowings of aproximately HK$2,897,000 (2024:

HK$6,575,000) were denominated in HK$ against USD as

at 31 March 2025, the curency other than the functional

curency of the respective group entities.

（续）

于二零二五年三月三十一日，附属

公司之未分派溢利相关的暂时差异为

11,056,000港元（二零二四年：13,457,000

港元）。本集团并未就分派该等保留

溢利而应付的税项确认递延税项负债

1,824,000港元（二零二四年：2,220,000港

元），乃由于本公司可控制该等附属公司

的股息政策，并厘定该等溢利在可见将

来很可能不会分派。

29. 银行借贷

于二零二五年三月三十一日，银行借贷

按5.5%（二零二四年：6.4%至7%）的固定

利率计息。

于二零二五年三月三十一日，银行借贷

以已抵押银行存款4,000,000港元（二零二

四年：9,000,000港元）作抵押（于附注21

披露）。

于二零二五年三月三十一日，银行借贷

约2,897,000港元（二零二四年：6,575,000

港元）以港元兑美元（有关货币并非各集

团实体之功能货币）计值。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

30. SHARE CAPITAL

Details of movements of share capital of the Company are

as folows:

Number of

sharesShare capital

股份数目股本

HK$’000

千港元

Ordinary shares of HK$0.01 each每股面值0.01港元之普通股

Authorised:法定：

At 1 April 2023, 31 March 2024, 1

April 2024 and 31 March 2025

于二零二三年四月一日、

二零二四年三月三十一日、

二零二四年四月一日及

二零二五年三月三十一日1,000,000,00010,000

Isued and fuly paid:已发行及缴足：

At 1 April 2023, 31 March 2024 and

1 April 2024

于二零二三年四月一日、

二零二四年三月三十一日及

二零二四年四月一日500,000,0005,000

Isue of new shares under

subscription agrement (note)

根据认购协议发行新股（附注）

22,177,419222

At 31 March 2025于二零二五年三月三十一日 522,177,4195,222

522,177,4195,222

The holders of ordinary shares are entitled to receive

dividends as declared from time to time and are entitled

to one vote per share at metings of the Company. Al

ordinary shares rank equaly with regard to the Company’s

residual asets.

Note:

On 22 April 2024, 22,177,419 new ordinary shares were aloted

and isued to the subscribers at a subscription price of HK$0.992

per share. Details of which are set out in the Company’s

anouncements dated 9 April 2024 and 22 April 2024.

30. 股本

本公司之股本变动详情如下：

普通股持有人有权收取不时宣派之股

息，而每持有一股份可于本公司股东

大会上投一票。所有普通股在本公司剩

余资产方面均享有同等权益。

附注：

于二零二四年四月二十二日，22,177,419股新

普通股已按每股0.992港元的认购价配发及发

行予认购人。有关详情载于本公司日期为二

零二四年四月九日及二零二四年四月二十二

日的公告。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

31. 以股份为基础之付款交易

本公司于二零一七年五月三十一日采纳

一项购股权计划（「计划」）。计划主要旨

在向合资格雇员及计划指定之其他经选

定人士提供激励或奖励。

于行使所有根据计划及本集团任何其他

购股权计划已授出但尚未行使之未获行

使购股权时可发行股份之最高数目，须

不超过本公司不时已发行股本之30%。

未经股东事先批准情况下，计划及本集

团任何其他购股权计划项下将授出之所

有购股权（就此而言，不包括根据计划及

本集团任何其他购股权计划之条款而失

效之购股权）获行使时可予配发及发行的

股份总数目合共不得超过股份首次于联

交所开始买卖时已发行股份之10%。待

通函刊发后、在股东于股东大会批准之

情况下及╱或根据上市规则订明之其他

规定，本公司可随时更新此上限至于获

股东批准当日已发行股份总数之10%。

未经股东事先批准情况下，于任何12个

月期间行使根据计划及本集团任何其他

购股权计划已授出之购股权时已发行及

可能将发行予各参与者之股份总数，不

得超过本公司当时已发行股本之1%。倘

向主要股东或独立非执行董事或彼等各

自之联系人（定义见计划）授出之购股权

将导致行使于12个月期间直至授出日期

（包括该日）计划项下之所有已授出或将

授出之购股权（包括已行使、已注销及未

获行使之购股权）时已发行及将发行予该

人士之股份合共超过本公司已发行股本

之0.1%且总值超过5.0百万港元，有关授

出必须获得股东事先批准。

31. SHARE-BASED PAYMENT TRANSACTIONS

The Company adopted a share option scheme (the

“Scheme”) on 31 May 2017. The primary purpose of the

Scheme is to provide incentives or rewards to eligible

employes and other selected participants as specified

under the Scheme.

The maximum number of shares which may be isued

upon the exercise of al outstanding options granted

and yet to be exercised under the Scheme and any other

share option scheme of the Group must not exced 30%

of the isued share capital of the Company from time to

time. The total number of shares which may be aloted

and isued upon exercise of al options (excluding, for

this purpose, options which have lapsed in acordance

with the terms of the Scheme and any other share option

scheme of the Group) to be granted under the Scheme

and any other share option scheme of the Group must

not in agregate exced 10% of the Shares in isue at the

time dealings in the Shares first comence on the Stock

Exchange, without prior aproval from the Shareholders.

The Company may, subject to the isue of a circular, the

Shareholders’ aproval in general meting and/or such

other requirements prescribed under the Listing Rules,

refresh this limit at any time to 10% of the total number of

shares in isue as at the date of the Shareholders’ aproval.

The total number of shares isued and which may fal to

be isued upon exercise of the options granted under

the Scheme and any other share option scheme of the

Group to each participant in any 12-month period shal

not exced 1% of the isued share capital of the Company

for the time being, without prior aproval from the

Shareholders. Options granted to substantial shareholders

or independent non-executive directors or any of their

respective asociates as defined under the Scheme which

would result in the shares isued and to be isued upon

exercise of al options under the Scheme already granted

and to be granted (including options exercised, canceled

and outstanding) to such person in the 12-month period

up to and including the date of such grant represent in

agregate in exces of 0.1% of the Company’s isued share

capital and with an agregate value in exces of HK$5.0

milion must be aproved in advance by the Shareholders.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

购股权须于提呈授出购股权要约日期起

21日内获接纳，接纳授出购股权时应付

名义代价1.00港元。

购股权可于购股权获接纳日期起至董事

厘定的有关日期（惟无论如何不超过10

年）内随时行使。行使价由董事厘定，

惟不得低于(i)股份于授出要约日期（须为

营业日）在联交所每日报价表所报的收市

价；(i)股份于紧接提呈授出购股权要约

日期前五个交易日在联交所每日报价表

所报的平均收市价；及(i)股份面值的最

高者。

于二零二五年二月二十八日，本公司根

据计划向本集团雇员授出购股权以认购

合共5,600,000股份。购股权之行使期

为自购股权授出日期起计三年，惟须受

归属计划所限。所授出之购股权按约

16%、16%、16%、16%、16%及20%的

比例分六批分别于二零二五年二月二十

八日、二零二五年八月二十八日、二零

二六年二月二十八日、二零二六年八月

二十八日、二零二七年二月二十八日及

二零二七年八月二十八日归属。

31. SHARE-BASED PAYMENT TRANSACTIONS

(CONTINUED)

Options granted must be taken up within 21 days of

the date of the ofer of grant of the option. A nominal

consideration of HK$1.00 is payable on aceptance of the

grant of an option.

Options may be exercised at any time from the date of

aceptance of the share option to such date as determined

by the directors but in any event not exceding 10 years.

The exercise price is determined by the directors, but shal

not be les than the highest of (i) the closing price of the

shares as stated in the Stock Exchange’s daily quotation

shets on the date of the ofer of grant, which must be a

busines day; (i) the average closing price of the shares as

stated in the Stock Exchange’s daily quotation shets for

the five trading days imediately preceding the date of

the ofer of grant of the option; and (i) the nominal value

of a share.

On 28 February 2025, the Company granted share options

to employes of the Group to subscribe for a total of

5,600,000 Shares under the Scheme. The exercise period of

the options is 3 years from the date of grant of the options

subject to the vesting schedule. The share options granted

shal vest in six tranches of aproximately 16%, 16%, 16%,

16%, 16% and 20% on 28 February 2025, 28 August 2025,

28 February 2026, 28 August 2026, 28 February 2027 and

28 August 2027, respectively.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（续）

授出之以权益结算之购股权的公平值乃

于授出日期采用二项式期权定价模型估

计，并已计及授出购股权所依据之条款

及条件。下表载列模型所采用之输入数

据：

购股权预期年期乃根据合约年期厘定，

未必为可能出现之行使模式指标。预期

波幅反映历史波幅为未来走势指标之假

设，其未必为实际结果。

于二零二五年二月二十八日，已授出之

购股权的公平值为1,197,000港元。每份

已授出购股权的公平值约为0.21港元。

截至二零二五年三月三十一日止年度，

本集团确认以股份为基础之付款开支

266,000港元。

于二零二五年三月三十一日，根据计划

可授出之购股权数目为44,400,000份（二

零二四年：50,000,000份）。计划仍将于

计划采纳日期起计十年期间内有效期。

31. SHARE-BASED PAYMENT TRANSACTIONS

(CONTINUED)

The fair value of equity-setled share options granted was

estimated as at the date of grant, using a Binomial model,

taking into acount the terms and conditions upon which

the options were granted and the folowing inputs to the

model:

Fair value (HK$)公平值（港元）0.21

Exercise price (HK$)行使价（港元）0.60

Share price at the date of grant (HK$)于授出日期之股价（港元）0.49

Dividend yield (%)股息收益率(%)–

Expected volatility (%)预期波幅(%)72.99

Risk-fre interest rate (%)无风险利率(%)3.18

Expected life of options (years)预期购股权年期（年）3.00

The expected life of the options is based on the

contractual life and is not necesarily indicative of the

exercise paterns that may ocur. The expected volatility

reflects the asumption that the historical volatility is

indicative of future trends, which may also not necesarily

be the actual outcome.

The fair value of the share options granted on 28 February

2025 was HK$1,197,000. The fair value per option granted

was aproximately to HK$0.21. The Group recognised the

share-based payment expense of HK$266,000 during the

year ended 31 March 2025.

As at 31 March 2025, the number of options which may

be granted under the scheme was 44,400,000 (2024:

50,000,000). The Scheme wil remain in force for a period

of 10 years comencing on the date on which the

Scheme is adopted.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

32. 资本风险管理

本集团管理资本的主要目的是保障本集

团持续经营的能力，使其得以继续透过

按风险水平进行产品及服务定价及以合

理成本取得融资，为股东提供回报及为

其他持份者带来利益。

本集团积极及定期对资本架构进行检讨

及管理，以在可能具有较高借贷水平的

较高股东回报与良好的资本状况带来的

好处及保障之间保持平衡，并因应经济

状况的变动对资本架构作出调整。

于二零二五年三月三十一日，本集团有

未偿还应付关联方款项约51,281,000港

元（二零二四年：56,434,000港元）（附注

38(b)）及银行借贷2,897,000港元（二零二

四年：7,335,000港元）（附注29）。

32. CAPITAL RISK MANAGEMENT

The Group’s primary objectives when managing capital

are to safeguard the Group’s ability to continue as a

going concern, so that it can continue to provide returns

for shareholders and benefits for other stakeholders,

by pricing products and services comensurately with

the level of risk and by securing aces to finance at a

reasonable cost.

The Group actively and regularly reviews and manages

its capital structure to maintain a balance betwen the

higher shareholder returns that might be posible with

higher levels of borowings and the advantages and

security aforded by a sound capital position, and makes

adjustments to the capital structure in light of changes in

economic conditions.

As at 31 March 2025, the Group has outstanding

amounts due to related parties as disclosed in note 38(b)

amounting to HK$51,281,000 (2024: HK$56,434,000) and

bank borowings of HK$2,897,000 (2024: HK$7,335,000)

(note 29).

2025
二零二五年
HK$’000
千港元
260
184,896
104,084
29,991

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

33. FINANCIAL INSTRUMENTS

Categories of financial instruments

二零二四年

HK$’000

千港元

Financial asets金融资产

Financial asets at FVTPL按公平值计入损益之金融资产2,977

Financial asets at amortised cost按摊销成本计量之金融资产189,270

Financial liabilities金融负债

Financial liabilities ar amortised cost按摊销成本计量之金融负债185,094

Financial liabilities at FVTPL按公平值计入损益之金融负债50,204

The Group’s major financial instruments include financial

asets at FVTPL, trade and other receivables, pledged

bank deposits, cash and cash equivalents, trade and other

payables, amounts due to ultimate holding company,

related parties and non-controling interests and lease

liabilities. Details of these financial instruments are

disclosed in respective notes. The risk asociated with

these financial instruments include market risk (interest

rate risk and curency risk), credit risk and liquidity risk. The

policies on how to mitigate these risks are set out below.

The directors of the Company manage and monitor

these exposures to ensure apropriate measures are

implemented on a timely and efective maner.

33. 金融工具

金融工具之类别

本集团之主要金融工具包括按公平值计

入损益之金融资产、贸易及其他应收款

项、已抵押银行存款、现金及现金等价

物、贸易及其他应付款项、应付最终控

股公司款项、应付关联方款项、应付非

控股权益款项及租赁负债。此等金融工

具之详情于有关附注披露。与此等金融

工具有关之风险包括市场风险（利率风险

及货币风险）、信贷风险及流动资金风

险。减低有关风险之政策载于下文。本

公司董事管理及监察该等风险，确保及

时采取适当有效措施。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

财务风险管理目标及政策

市场风险

(i) 货币风险

综合财务报表以港元呈列，其为

本公司之呈列货币及功能货币。

本集团旗下多家附属公司以外币

进行买卖交易，因而令本集团须

承受外币风险。此外，本集团有

若干银行结余、贸易应付款项、

租赁负债及银行借贷以港元、人

民币、美元及日圆（均非有关集团

实体之功能货币）计值，分别于附

注22、23、24及29披露。

本集团现时并无就外币交易、资

产及负债制定外币对冲政策。本

集团将密切监察外币风险，并将

于有需要时考虑对冲重大外币风

险。

由于港元汇率与美元挂钩，本集

团预期美元╱港元之汇率不会出

现任何重大变动。

本集团因人民币及日圆而面临之

货币风险并不重大，故并无呈列

敏感度分析。

33. FINANCIAL INSTRUMENTS (CONTINUED)

Financial risk management objectives and policies

Market risk

(i) Curency risk

The consolidated financial statements are presented

in HK$, which is the Company’s presentation

curency and functional curency.

Several subsidiaries of the Group have foreign

curency sales and purchases, which expose the

Group to foreign curency risk. In adition, certain

bank balances, trade payables, lease liabilities and

bank borowings of the Group are denominated in

HK$, RMB, USD and JPY, the curencies other than

the functional curency of the respective group

entities as disclosed in notes 22, 23, 24 and 29

respectively.

The Group curently does not have a foreign

curency hedging policy in respect of foreign

curency transactions, asets and liabilities. The

Group wil monitor its foreign curency exposure

closely and wil consider hedging significant foreign

curency exposure should the ned arise.

Since the exchange rate of HK$ is peged with

USD, the Group does not expect any significant

movements in the USD/HK$ exchange rates.

The Group’s exposure to curency risk to RMB

and JPY is not significant and hence no sensitivity

analysis is presented.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（续）

财务风险管理目标及政策（续）

市场风险（续）

(i) 利率风险

于二零二五年及二零二四年三月

三十一日，本集团之利率风险主

要来自银行现金、已抵押银行存

款、租赁负债、应付关联方款项

及应付最终控股公司款项。

于二零二五年及二零二四年三月

三十一日，按固定利率计息之

租赁负债、应付最终控股公司款

项、应付关联方款项及银行借贷

令本集团面临公平值利率风险。

本集团所面临之利率风险并不重

大，故并无呈列敏感度分析。

信贷风险及减值评估

信贷风险指对手方未能履行其合约责任

而导致本集团蒙受财务损失之风险。

本集团的信贷风险主要来自应收贸易款

项。本集团所面临来自现金及现金等价

物以及应收票据之信贷风险有限，乃由

于对手方为拥有高信用评级之银行及金

融机构。

33. FINANCIAL INSTRUMENTS (CONTINUED)

Financial risk management objectives and policies

(Continued)

Market risk (Continued)

(i) Interest rate risk

The Group’s interest rate risk arises primarily from

cash at bank, pledged bank deposits, lease liabilities,

amounts due to related parties and amount due to

ultimate holding company as at 31 March 2025 and

2024.

Lease liabilities, amount due to ultimate holding

company, amounts due to related parties and bank

borowings at fixed rates expose the Group to fair

value interest rate risk as at 31 March 2025 and

2024.

The Group’s exposure to interest rate risk is not

significant and hence no sensitivity analysis is

presented.

Credit risk and impairment asesment

Credit risk refers to the risk that a counterparty wil default

on its contractual obligations resulting in a financial los to

the Group. The Group’s credit risk is primarily atributable

to trade receivables. The Group’s exposure to credit risk

arising from cash and cash equivalents and bils receivable

is limited because the counterparties are banks and

financial institutions with high credit rating.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

财务风险管理目标及政策（续）

信贷风险及减值评估（续）

客户合约产生之贸易应收款项及合约资

产

为尽量减低信贷风险，本公司董事已指

派团队负责厘定信贷限额及批核信贷。

于接受任何新客户前，本集团采用信贷

风险管理政策评估潜在客户之信贷质素

及界定客户之信贷额度。该等评估会参

照经常性客户的偿还历史、新客户现时

已逾期的金额及客户经营所处的经济环

境。合约资产与相同类型合约的贸易应

收款项具有大致相同的风险特征。

本集团在客户营运所在行业或国家存在

信贷风险高度集中之情况。信贷风险高

度集中之情况主要于本集团对个别客户

面临重大风险时产生。于报告期末，本

集团服装分部之最大客户及五大客户分

别占应收贸易款项总额之24%（二零二四

年：11%）及58%（二零二四年：38%）。

作为本集团信贷风险管理的一部分，本

集团通过为其贸易应收款项分配损失率

来使用内部信用评级。估计的损失率基

于贸易应收款项的账龄、债务人预期寿

命内的历史观察到的违约率以及无需花

费过多成本或精力即可获得的前瞻性资

料。

33. FINANCIAL INSTRUMENTS (CONTINUED)

Financial risk management objectives and policies

(Continued)

Credit risk and impairment asesment (Continued)

Trade receivables and contract asets arising from

contracts with customers

To minimise the credit risk, the directors of the Company

have delegated a team responsible for determination of

credit limits and credit aprovals. Before acepting any

new customer, the Group uses the credit risk management

policy to ases the potential customer’s credit quality

and defines credit limits by customers. These evaluations

are referenced to the repayment histories for recuring

customers, curent past due exposure for the new

customers and the economic environment in which the

customers operate. The contract asets have substantialy

the same risk characteristics as the trade receivables for

the same type of contracts.

The Group has significant concentration of credit risk in

industries or countries in which the customers operate.

Significant concentrations of credit risk primarily arise

when the Group has significant exposure to individual

customers. At the end of the reporting period, 24% (2024:

11%) and 58% (2024: 38%) of the total trade receivables

was due from the Group’s largest customer and the

five largest customers respectively within the garment

segment.

As part of the Group’s credit risk management, the Group

used an internal credit rating by asigning los rates to

its trade receivables. The estimated los rates are based

on the aging of trade receivables as wel as historical

observed default rates over the expected life of the

debtors and forward-loking information that is available

without undue cost or efort.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（续）

财务风险管理目标及政策（续）

信贷风险及减值评估（续）

客户合约产生之贸易应收款项及合约资

产（续）

本集团按相当于全期预期信贷亏损（使用

拨备矩阵计算）之金额计量应收贸易款项

及合约资产之亏损拨备。由于本集团之

过往信贷亏损经验并无显示不同客户分

部之亏损模式出现重大差异，故并无进

一步区分本集团不同客户群之亏损拨备。

预期亏损率乃基于过去12个月之实际亏

损经验得出。该等比率已予调整，以反

映收集过往数据期间之经济状况、当前

状况及本集团对预期应收款项年期之经

济状况的看法之间的差异。

本公司董事认为，本集团应收贸易款项

及合约资产的未偿还结余并无固有的重

大信贷风险。本集团评估应收贸易款项

及合约资产的预期信贷亏损甚微。因

此，并无确认亏损拨备。

其他应收款项及订金

至于其他应收款项及订金，本公司董事

会根据历史偿还记录、过往经验以及合

理及有理据支持的定量及定性资料以及

前瞻性资料对其他应收款项及订金进行

个别评估。本公司董事认为，本集团其

他应收款项及订金的未偿还结余并无固

有的重大信贷风险。本集团评估其他应

收款项及订金的预期信贷亏损甚微。因

此，并无确认亏损拨备。

33. FINANCIAL INSTRUMENTS (CONTINUED)

Financial risk management objectives and policies

(Continued)

Credit risk and impairment asesment (Continued)

Trade receivables and contract asets arising from

contracts with customers (Continued)

The Group measures los alowances for trade receivables

and contract asets at an amount equal to lifetime ECLs,

which is calculated using a provision matrix. As the

Group’s historical credit los experience does not indicate

significantly diferent los paterns for diferent customer

segments, the los alowance is not further distinguished

betwen the Group’s diferent customer bases.

Expected los rates are based on actual los experience

over the past 12 months. These rates are adjusted to

reflect diferences betwen economic conditions during

the period over which the historic data has ben colected,

curent conditions and the Group’s view of economic

conditions over the expected lives of the receivables.

The directors of the Company believe that there is no

material credit risk inherent in the Group’s outstanding

balance of trade receivables and contract asets. The

Group asesed the ECL for trade receivables and contract

asets were imaterial. Thus no los alowance was

recognised.

Other receivables and deposits

For other receivables and deposits, the directors of the

Company make individual asesment on other receivables

and deposits based on historical setlement records,

past experience, and also quantitative and qualitative

information that is reasonable and suportive forward-

loking information. The directors of the Company believe

that there is no material credit risk inherent in the Group’s

outstanding balance of other receivables and deposits.

The Group asesed the ECL for other receivables and

deposits were imaterial. Thus, no los alowance was

recognised.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

财务风险管理目标及政策（续）

信贷风险及减值评估（续）

已抵押银行存款╱现金及现金等价物

本集团仅会与获国际信贷评级机构给予

高信贷评级且信誉良好的银行交易，因

此，本公司董事认为违约风险不高。本

集团使用12个月预期信贷亏损模式，基

于平均亏损率并参照国际信贷评级机构

之信贷评级，个别评估已抵押银行存款

及现金及现金等价物的预期信贷亏损。

本集团评估已抵押银行存款及现金及现

金等价物的预期信贷亏损甚微。因此，

并无确认亏损拨备。

流动资金风险

在管理流动资金风险时，本集团监察及

保持管理层认为足够的现金及现金等价

物水平，以为本集团的业务营运提供资

金及减低现金流量波动的影响。

下表显示根据合约未贴现金流量（包括

按合约利率或（如为浮动利率）按报告期

末现行利率计算之利息付款）及要求本集

团偿还之最早日期计算之本集团金融负

债及合约负债之剩余合约到期情况。

下表包括利息及本金现金流量。倘利息

流为按浮动利率计息，则未贴现金额按

报告期末之当前市场利率计算。

33. FINANCIAL INSTRUMENTS (CONTINUED)

Financial risk management objectives and policies

(Continued)

Credit risk and impairment asesment (Continued)

Pledged bank deposits/Cash and cash equivalents

The Group only transacts with reputable banks with high

credit ratings asigned by international credit-rating

agencies and therefore the directors of the Company

consider the risk of default is low. The Group uses

12-month ECL to perform the asesment under ECL on

pledged bank deposits and cash and cash equivalents

individualy based on the average los rate by reference

to credit ratings asigned by international credit-rating

agencies. The Group asesed the ECL for pledged bank

deposits and cash and cash equivalents were imaterial.

Thus, no los alowance was recognised.

Liquidity risk

In the management of the liquidity risk, the Group

monitors and maintains a level of cash and cash

equivalents demed adequate by the management to

finance the Group’s operations and mitigate the efects of

fluctuations in cash flows.

The folowing tables show the remaining Group’s

contractual maturities for its financial liabilities and lease

liabilities based on contractual undiscounted cash flows

(including interest payments computed using contractual

rates or, if floating, based on rates curent at the end of

the reporting period) and the earliest date the Group can

be required to pay.

The table includes both interest and principal cash flows.

To the extent that interest flows are floating rate, the

undiscounted amount is derived from prevailing market

rate at the end of the reporting period.

Weighted average effective interest rate	On demand or within 3 months	3 months to 1 year	1 year to 2 years	2 years to 5 years	Over 5 years	Total undiscounted cash flows	Carrying amount at 31 March 2025
加权平均实际利率	按要求或三个月内	三个月至一年	一年至两年	两年至五年	超过五年	未贴现现金流量总额	二零二五年三月三十一日之账面值
%	HK$’000	HK$’000	HK$’000	HK$’000	HK$’000	HK$’000	HK$’000
%	千港元	千港元	千港元	千港元	千港元	千港元	千港元
N/A不适用	22,003	–	–	–	–	22,003	22,003
13.08	14,779	4,552	53,870	–	–	73,201	65,315
N/A不适用	10,084	–	–	–	–	10,084	10,084
5.49	2,897	–	–	–	–	2,897	2,897
5.57	776	1,952	775	422	–	3,925	3,785
5.57	50,539	6,504	54,645	422	–	112,110	104,084

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

33. FINANCIAL INSTRUMENTS (CONTINUED)

Financial risk management objectives and policies

(Continued)

Liquidity risk (Continued)

Liquidity tables

2025二零二五年

Trade and other payables贸易及其他应付款项

Amounts due to related parties应付关联方款项

Amount due to non-controling interests应付非控股权益款项

Secured bank borowings有抵押银行借贷

Lease liabilities租赁负债

Weighted

average

efective

interest rate

demand or

within

3 months

to 1 year

1 year to

2 years

2 years to

5 years

Over 5

years

Total

undiscounted

cash flows

Carying

amount at 31

March 2024

加权平均

实际利率

按要求或

三个月内

三个月至

一年

一年至

两年

两年至

五年超过五年

未贴现金

流量总额

二零二四年

三月三十一日

之账面值

%HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000HK$’000

%千港元千港元千港元千港元千港元千港元千港元

2024二零二四年

Trade and other payables贸易及其他应付款项N/A不适用41,901–41,90141,901

Amounts due to related parties应付关联方款项N/A不适用35,00043,594–78,59478,360

Amount due to non-controling interests应付非控股权益款项N/A不适用–11,759–11,75911,759

Secured bank borowings有抵押银行借贷6.887,335–7,3357,335

Amount due to ultimate holding

company

应付最终控股公司

款项1.405,26843,304–48,57245,739

Lease liabilities租赁负债7.208081,9991,556–4,3634,118

90,312100,6561,556–192,524189,212

（续）

财务风险管理目标及政策（续）

流动资金风险（续）

流动资金表

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

财务风险管理目标及政策（续）

流动资金风险（续）

流动资金表（续）

于二零二五年三月三十一日，具有按要

求偿还条款之银行借贷计入上述到期分

析「按要求偿还」期限内。于二零二五年

三月三十一日，该等银行借贷的账面值

为2,897,000港元（二零二四年：7,335,000

港元）。考虑到本集团的财务状况及为

该等银行借贷作抵押的资产，本公司董

事认为金融机构不大可能行使酌情权要

求即时还款。于二零二五年三月三十一

日，本公司董事认为该等借贷将按照贷

款协议所载的既定还款日期偿还。于二

零二五年三月三十一日，本金及利息现

金流出总额为2,914,000港元（二零二四

年：7,487,000港元），有关款项将于一年

内偿还。

金融工具之公平值计量

此附注提供本集团如何厘订金融资产公

平值之资料。

按公平值计量之金融资产

本公司管理层负责厘定适当的估值方法

及公平值计量主要输入数据。

33. FINANCIAL INSTRUMENTS (CONTINUED)

Financial risk management objectives and policies

(Continued)

Liquidity risk (Continued)

Liquidity tables (Continued)

Bank borowings with a repayment on demand clause as

at 31 March 2025 are include in the “on demand” time

band in the above maturity analysis. The carying amount

of the bank borowings amounted to HK$2,897,000 as at

31 March 2025 (2024: HK$7,335,000). Taking into acount

the Group’s financial position and asets pledged for the

bank borowings, the directors of the Company do not

believe that it is probable that the financial institutions

would exercise the discretionary rights to demand

imediate payment. As at 31 March 2025, the directors

of the Company believed that such borowings wil be

repaid in acordance with the scheduled repayment dates

set out in the loan agrements. The agregate principal

and interest cash outflows amounted to HK$2,914,000 as

at 31 March 2025 (2024: HK$7,487,000)and the amount

wil be repaid within one year.

Fair value measurement of financial instruments

This note provides information about how the Group

determines fair value of financial aset.

Financial asets measured at fair value

The management of the Company is responsible to

determine the apropriate valuation techniques and key

inputs for fair value measurements.

2025
二零二五年
HK$’000
千港元
260
29,987
4

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

33. FINANCIAL INSTRUMENTS (CONTINUED)

Fair value measurement of financial instruments

(Continued)

Financial asets measured at fair value (Continued)

Information about the valuation techniques and key inputs

used in determining the fair value of the financial aset are

disclosed below.

Financial instrumentsFair value as at 31 March

Fair value

hierarchy

Valuation technique(s)and key

input(s)

金融工具于十二月三十一日之公平值公平值级别估值方法及主要输入数据

二零二四年

HK$’000

千港元

Other financial asets2,977Level 3Aset-based aproach with adjusted

net aset values as key unobservable

input

其他金融资产第三级以经调整资产净值为主要不可观察输

入输入的资产法

Amount due to

non-controling interests

50,204Level 3(i) actual and projected profits interests

before interests, taxes, depreciation

and amortisation of Taiga Group for

thre years from 1 April 2023 to 31

March 2026 of HK$58,250,000; and

(i) projected adjusted Isue price of

HK$1.00 per share and (i) market

price of HK$1.01 per share

(1)

应付非控股权益款项第三级(i)自二零二三年四月一日起至二零二

六年三月三十一日止三个年度大河

集团未扣除利息、税项、折旧及摊

销前的实际及预测溢利58,250,000港

元；(i)预测经调整发行价每股1.00

港元；及(i)市价每股1.01港元

(1)

Amount due to a related party–Level 3Probability-weighted method with

income aproach by reference to

the present value of the discounted

cash flows model to be derived from

the future cash flow, based on an

apropriate discount rate

(2)

应付关联方款项第三级基于适当的贴现率，参考自未来现金

流中得出的贴现金流模型的现值，

采用收益法的概率加权法

(2)

（续）

金融工具之公平值计量（续）

按公平值计量之金融资产（续）

有关厘定金融资产公平值所用的估值方

法及主要输入数据的资料于下文披露。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

33. FINANCIAL INSTRUMENTS (CONTINUED)

Fair value measurement of financial instruments

(Continued)

Financial asets measured at fair value (Continued)

Notes:

, taxes,

depreciation and amortisation of Taiga Group are key

unobservable input. A 5% increase/decrease in the actual

and projected profits before interest, taxes, depreciation

and amortization holding al other variables constant

would increase/increase the fair value of amount due to

non-controling interests by HK$550,000.

, taxes,

depreciation and amortisation of Sped Aparel (BVI)

Limited and its subsidiaries is key unobservable input. A

5% increase/decrease in the actual and projected profits

before interest, taxes, depreciation and amortisation

holding al other variables constant would increase/

increase the fair value of amount due to a related party

by HK$3,000.

Reconciliation of Level 3 fair value measurements

Other

financial

asets

Amount

due to non-

controling

interests

Amount

due to

a related

party

其他

金融资产

应付非控股

权益款项

应付

关联方款项

HK$’000HK$’000HK$’000

千港元千港元千港元

At 1 April 2023于二零二三年四月一日2,977–

Acquisition of subsidiaries收购附属公司–66,263–

Fair value change recognised in profit

or los

于损益内确认的公平值

变动–(16,059)–

At 31 March 2024 and 1 April 2024于二零二四年三月三十一日

及二零二四年四月一日2,97750,204–

Aditions添置260–

Disposal of subsidiaries出售附属公司(2,977)–

Fair value change recognised in profit

or los

于损益内确认的公平值

变动–(20,217)4

At 31 March 2025于二零二五年三月三十一日26029,9874

（续）

金融工具之公平值计量（续）

按公平值计量之金融资产（续）

附注：

、税项、折旧

及摊销前的实际及预测溢利为主要不

可观察输入数据。未扣除利息、税

项、折旧及摊销前的实际及预测溢利

增加╱减少5%而所有其他变量维持不

变，则应付非控股权益款项的公平值

将增加╱减少550,000港元。

(2) Sped Aparel (BVI) Limited及其附属

公司未扣除利息、税项、折旧及摊销

前的实际及预测溢利为主要不可观察

输入数据。未扣除利息、税项、折旧

及摊销前的实际及预测溢利增加╱减

少5%而所有其他变量维持不变，则应

付关联方款项的公平值将增加╱减少

3,000港元。

第三级公平值计量的对账

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（续）

金融工具之公平值计量（续）

第三级公平值计量的对账（续）

截至二零二五年及二零二四年三月三十

一日止年度，第一级及第二级之间并无

转移，亦概无自第三级转入或转出。本

集团之政策为于发生公平值层级转移之

报告期末确认有关转移。

重新计量按公平值计入损益之其他金融

资产及应付非控股权益款项所产生的公

平值变动于综合损益表之「其他收入、收

益及亏损」项目内呈列。

按公平值以外价值列账之金融资产之公

平值

本集团按摊销成本列账之金融工具之账

面值与其于二零二五年及二零二四年三

月三十一日之公平值并无重大不同。

34. 出售附属公司

(a) 出售EPS Inovative Medicine

(Hong Kong) Limited（「EPS

Inovative」）及其附属公司（「出

售集团」）

于二零二五年二月十九日，(i)本公

司有条件同意出售而EPS Holdings,

Inc.（为本公司的控股东）有条

件同意收购EPS Inovative的全部

已发行股本，代价为1.00日圆；

及(i)本公司亦有条件同意出售或

促使出售而EPS Holdings, Inc.有

条件同意收购销售贷款，代价为

1,250,000,000日圆。交易已于二零

二五年三月三十一日完成。

33. FINANCIAL INSTRUMENTS (CONTINUED)

Fair value measurement of financial instruments

(Continued)

Reconciliation of Level 3 fair value measurements

(Continued)

During the years ended 31 March 2025 and 2024, there

were no transfers betwen Level 1 and Level 2, or transfers

into or out of Level 3. The Group’s policy is to recognise

transfers betwen levels of fair value hierarchy as at the

end of the reporting period in which they ocur.

The fair value change arising from the remeasurement of the

other financial asets and amount due to non-controling

interests measured at FVTPL are presented in the “Other

income, gains and loses” line item in the consolidated

statement of profit or los.

Fair value of financial asets caried at other than

fair value

The carying amounts of the Group’s financial instruments

caried at amortised cost were not materialy diferent

from their fair values as at 31 March 2025 and 2024.

34. DISPOSALS OF SUBSIDIARIES

(a) Disposal of EPS Inovative Medicine (Hong

Kong) Limited (“EPS Inovative”) and its

subsidiaries (“Disposal Group”)

On 19 February 2025, (i) the Company conditionaly

agred to sel, and EPS Holdings, Inc., the controling

shareholder of the Company, conditionaly agred

to acquire the entire isued share capital of EPS

Inovative, at a consideration of JPY1.00; and (i) the

Company also conditionaly agred to sel or procure

to sel, and EPS Holdings, Inc. conditionaly agred

to purchase the sale loans for a consideration of

JPY1,250,000,000. The transaction was completed on

31 March 2025.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

34. DISPOSALS OF SUBSIDIARIES (CONTINUED)

(a) Disposal of EPS Inovative Medicine (Hong

Kong) Limited (“EPS Inovative”) and its

subsidiaries (“Disposal Group”) (Continued)

The respective amounts of asets and liabilities of

the Disposal Group on the relevant date of disposal

were as folows:

HK$’000

千港元

Analysis of asets and liabilities over which control was lost:失去控制权的资产及负债分析如下：

Property, plant and equipment物业、厂房及设备33

Other financial asets其他金融资产2,977

Intangible asets无形资产70,204

Godwil商誉11,549

Trade and other receivables贸易及其他应收款项6,839

Amounts due from related parties应收关联方款项6,759

Cash and cash equivalents现金及现金等价物7,516

Trade and other payables and acruals贸易及其他应付款项以及应计费用(2,068)

Amounts due to related parties应付关联方款项(362)

Amount due to ultimate holding company应付最终控股公司款项(87,699)

Tax payables应付税项(286)

Defered tax liabilities递延税项负债(21,033)

Net liabilities disposed of已出售的负债净额(5,571)

Gain on disposal of subsidiaries出售附属公司产生的收益

Consideration received已收取的代价63,958

Net liabilities disposed of已出售的负债净额5,571

Sale loans disposed of已出售的销售贷款(63,980)

Non-controling interests非控股权益22,666

Reclasification of cumulative exchange reserve重新分类累计汇兑储备1,822

Reclasification of other reserve重新分类其他储备3,267

33,304

Net cash inflow arising on disposal of subsidiaries:出售附属公司产生的现金流入净额：

Cash consideration received已收取的现金代价63,958

Les: cash and cash equivalents disposed of减：已出售的现金及现金等价物(7,516)

56,442

（续）

(a) 出售EPS Inovative Medicine

(Hong Kong) Limited（「EPS

Inovative」）及其附属公司（「出

售集团」）（续）

出售集团于相关出售日期的相关

资产及负债金额如下：

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

34. DISPOSALS OF SUBSIDIARIES (CONTINUED)

(b) Disposal of EPS Medical Consultancy (Japan)

Limited (“Disposal Company”)

On 2 October 2024, the Group entered into the sale

and purchase agrement with EPS Holdings, Inc., a

controling shareholder of the Company, to dispose

of al its 100% equity interest of the Disposal

Company, a wholy-owned subsidiary of the Group

which is principaly engaged in the provision of

IRO services. The consideration in respect of the

disposal is JPY1.00 in cash.

The respective amounts of asets and liabilities

of the Disposal Company on the relevant date of

disposal were as folows:

HK$’000

千港元

Analysis of asets and liabilities over which control was lost:失去控制权的资产及负债分析如下：

Contract asets合约资产1,674

Trade and other receivables贸易及其他应收款项4,273

Amounts due from related parties应收关联方款项949

Cash and cash equivalents现金及现金等价物1,637

Trade and other payables and acruals贸易及其他应付款项以及应计费用(1,103)

Contract liabilities合约负债(217)

Amounts due to related parties应付关联方款项(14,019)

Amount due to ultimate holding company应付最终控股公司款项(2,431)

Tax payable应付税项(9)

Net liabilities disposed of已出售的负债净额(9,246)

Gain on disposal of a subsidiary出售附属公司产生的收益

Consideration received已收取的代价–

Net liabilities disposed of已出售的负债净额9,246

Reclasification of cumulative exchange reserve重新分类累计汇兑储备697

9,943

Net cash outflow arising on disposal of a subsidiary:出售附属公司产生的现金流出净额：

Cash consideration received已收取的现金代价–

Les: cash and cash equivalents disposed of减：已出售的现金及现金等价物(1,637)

(1,637)

（续）

(b) 出售EPS Medical Consultancy

(Japan) Limited（「出售公司」）

于二零二四年十月二日，本集团

与EPS Holdings, Inc.（为本公司的控

股东）订立买卖协议，以出售其

于出售公司（为本集团的全资附属

公司，主要从事提供IRO服务）的

全部股本权益。出售事项之代价

为现金1.00日圆。

出售公司于相关出售日期的相关

资产及负债金额如下：

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

35. PARTICULARS OF PRINCIPAL SUBSIDIARIES

AND NON-CONTROLING INTERESTS

The folowing list contains only the particulars of

subsidiaries which principaly afected the results, asets or

liabilities of the Group. The clas of shares held is ordinary

unles otherwise stated.

Proportion of ownership interest

所有权益比例

Name of subsidiaries

Place of

incorporation

Place of

operation

Isued and paid

up share capital/

registered capital

Group’s

efective

interest

Held

by the

Company

Held

by a

subsidiary

Principal

activities

附属公司名称注册成立地点经营地点已发行及缴足

股本╱注册资本

本集团

实际权益

本公司

持有

一间附属

公司持有

主要业务

Knit World International

Limited

Hong KongHong KongOrdinary shares

HK$4,000,000

100%–100%Aparel suply chain

management services

Knit World International

Limited

香港香港普通股4,000,000港元100%–100%服装供应链管理服务

Sped Aparel (BVI) LimitedBVIHong KongOrdinary shares

US$101

100%100%–Investment holding

Sped Aparel (BVI) Limited英属处女群岛香港普通股101美元100%100%–投资控股

Sped Aparel (HK) LimitedHong KongHong KongOrdinary shares

HK$10,000

100%–100%Aparel suply chain

management services

尚捷（香港）有限公司香港香港普通股10,000港元100%–100%服装供应链管理服务

尚捷时(深圳)贸易有限公司The PRCThe PRCRegistered capital

RMB800,000

100%–100%Aparel suply chain

Management services

尚捷时（深圳）贸易有限公司

(1)

中国中国注册资本人民币

800,000元

100%–100%服装供应链管理服务

Sped Aparel Japan 合同会社JapanJapanRegistered capital

Japanese Yen

(“JPY”) 5,500,000

100%–100%Design and customers

acount services

Sped Aparel Japan 合同会社日本日本注册资本5,500,000日圆100%–100%设计及客户服务

Shanghai EPS Pharmaceutical

Development Co., Ltd. (上海

日新医药发展有限公司)

(2)

The PRCThe PRCRegistered capital

RMB5,320,944

95%–100%Development of new

drugs

上海日新医药发展有限公司

(2)

中国中国注册资本人民币

5,320,944元

95%–100%开发新药物

Suzhou EPS Tigermed

Pharmaceutical Technology

Co., Ltd. (苏州益新泰格医

药科技有限公司)

(2)

The PRCThe PRCRegistered capital

RMB9,803,900

51%–100%Development of new

drugs

苏州益新泰格医药科技有限

公司

(2)

中国中国注册资本人民币

9,803,900元

51%–100%开发新药物

Beijing Global Pharmaceutical

Research Co., Ltd. (北京格

锐博医药研发有限公司)

(2)

The PRCThe PRCRegistered capital

RMB500,000

51%–100%Development of new

drugs

北京格锐博医药研发有限公司

(2)

中国中国注册资本人民币

500,000元

51%–100%开发新药物

EP Trading Co., Ltd. (EP贸易有

限公司/EPトレーディング

株式会社)

JapanJapanRegistered capital

JPY80,000,000

100%–100%Trading of healthcare

products

EP贸易有限公司╱EPトレー

ディング株式会社

日本日本注册资本80,000,000日圆100%–100%保健产品贸易

35. 主要附属公司及非控股权益之详

情

下表仅载列对本集团业绩、资产或负债

有重大影响的附属公司的详情。除另有

说明外，所持股份类别均指普通股。

2025
二零二五年
35%
–
49%
–

2025
二零二五年
35%
–
49%
–

2025		2025
二零二五年		二零二五年
HK$’000		HK$’000
千港元		千港元
(3,239)	(605) 1,575 1,618 2,781 299	39,523
9,035		–
108		1,972
2,652		–
(234)		344
5,668
8,322		41,839

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

35. PARTICULARS OF PRINCIPAL SUBSIDIARIES

AND NON-CONTROLING INTERESTS

(CONTINUED)

Details of non-wholy owned subsidiary that have

material non-controling interests

The table below shows details of non-wholy owned

subsidiaries of the Group that have material non-

controling interests:

Name of subsidiaries

Incorporation/

principal place of

busines

Proportion of ownership

interest held by non-

controling interests

Proportion of voting

power held by non-

controling interests

Los alocated to non-

controling interests

Acumulated non-

controling interests

附属公司名称

注册成立╱

主要经营地点

非控股权益持有的

所有权益比例

非控股权益持有的

投票权比例分配予非控股权益的亏损累计非控股权益

二零二四年二零二四年二零二四年

HK$’000

千港元

R&E Corporation Limited

(3)

Hong Kong35%35%36,285

瑞益股份有限公司

(3)

香港

BiotubeJapan49%49%37,235

Biotube日本

Suzhou EPS Tigermed

Pharmaceutical

Technology Co., Ltd.

(2)

The PRC49%49%2,080

苏州益新泰格医药科技有限公司

(2)

中国

EPD 株式会社Japan49%49%(2,883)

EPD 株式会社日本

Individualy imaterial subsidiaries

with non-controling interests110

个别不重大非控股权益附属公司

72,827

35. 主要附属公司及非控股权益之详

情（续）

拥有重大非控股权益的非全资附属公司

详情

下表载列拥有重大非控股权益的本集团

非全资附属公司的详情：

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

35. 主要附属公司及非控股权益之详

情（续）

拥有重大非控股权益的非全资附属公司

详情（续）

附注：

，并为外商独资企

业。

，并为股本合营

企业。

(3) 瑞益股份有限公司的附属公司包括在

中国成立的外商独资企业大河供应链

管理（深圳）公司。

本公司董事认为，上表列载之资料乃属

对本集团本年度之业绩具重大影响力或

构成本集团资产净值重大部份之附属公

司。上表列载之所有附属公司均为有限

责任公司。

下文所载有关大河集团财务资料的截至

二零二五年及二零二四年三月三十一日

止年度之财务资料概要，乃指集团内公

司间撇销前的金额。

35. PARTICULARS OF PRINCIPAL SUBSIDIARIES

AND NON-CONTROLING INTERESTS

(CONTINUED)

Details of non-wholy owned subsidiary that have

material non-controling interests (Continued)

Notes:

(1) This entity was established as wholy foreign-owned

enterprise in the PRC.

(2) These entities were established as equity joint venture

enterprises in the PRC.

&E Corporation Limited is Taiga SCM

(Shenzhen) Co., Ltd, a company established as wholy

foreign-owned enterprise in the PRC.

The above table lists the subsidiaries of the Group which,

in opinion of the directors of the Company, principaly

afected the results of the year or formed a substantial

portion of the net asets of the Group. Al subsidiaries

listed above are limited liability companies.

Sumarised financial information for the years ended

31 March 2025 and 2024 in respect of the Taiga Group’s

financial information below represents amounts before

intragroup eliminations.

2025
二零二五年
HK$’000
千港元
94,712
49,995
(19,392)
(12,409)
112,906
98,491
1,747
(88,641)
(1,506)
10,091
(838)
9,253
6,559
3,532
10,091
(545)
(293)
(838)
6,014
3,239
9,253
(1,629)
(1,690)
(3,319)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

35. PARTICULARS OF PRINCIPAL SUBSIDIARIES

AND NON-CONTROLING INTERESTS

(CONTINUED)

Details of non-wholy owned subsidiary that have

material non-controling interests (Continued)

Taiga Group

二零二四年

HK$’000

千港元

Non-curent asets非流动资产104,824

Curent asets流动资产32,638

Curent liabilities流动负债(19,749)

Non-curent liabilities非流动负债(14,284)

Total equity权益总额103,429

Revenue收益91,680

Other income, gains and loses其他收入、收益及亏损796

Expenses开支(87,302)

Income tax expenses所得税开支(1,769)

Profit for the year年内溢利3,405

Other comprehensive expense for the year年内其他全面开支(1,198)

Total comprehensive income for the year年内全面收益总额2,207

Profit for the year atributable to以下人士应占年内溢利

– the owner of the Company－本公司的拥有人2,213

– non-controling interests of Taiga Group－大河集团的非控股权益1,192

Profit for the year年内溢利3,405

Other comprehensive expense for the

year atributable to

以下人士应占年内其他

全面开支

– the owner of the Company－本公司的拥有人(611)

– non-controling interests of Taiga Group－大河集团的非控股权益(587)

Other comprehensive expense for the year年内其他全面开支(1,198)

Total comprehensive income for the year

atributable to

以下人士应占年内全面

收益总额

– the owner of the Company－本公司的拥有人1,602

– non-controling interests of Taiga Group－大河集团的非控股权益605

Total comprehensive income for the year年内全面收益总额2,207

Net cash (outflow) inflow from operating

activities

经营活动产生现金（流出）

流入净额6,794

Net cash (outflow) inflow from financing

activities

融资活动产生现金（流出）

流入净额15

Net cash (outflow) inflow现金（流出）流入净额6,809

35. 主要附属公司及非控股权益之详

情（续）

拥有重大非控股权益的非全资附属公司

详情（续）

大河集团

2025
二零二五年
HK$’000
千港元
–

4,118	7,335	78,360	45,739	135,552
(3,278)	(4,856)	(8,731)	(19,478)	(36,343)
254	418	4,795	398	5,865
2,770	–	–	–	2,770
–	–	(6,673)	(26,150)	(32,823)
–	–	4	–	4
–	–	(2,136)	–	(2,136)
(79)	–	(300)	(509)	(888)
3,785	2,897	65,319	–	72,001

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

36. COMITMENTS

Capital comitments outstanding, which is not provided

for, in the consolidated financial statements were as

folows:

二零二四年

HK$’000

千港元

Contracted for已订约

Investments in limited partnership于有限合伙企业之投资2,585

As at 31 March 2024, the comitment relates to the

unpaid capital comitment on investment in the limited

partnership included in other financial asets.

37. RECONCILIATION OF LIABILITIES ARISING

FROM FINANCING ACTIVITIES

The table below details changes in the Group’s liabilities

arising from financing activities, including both cash

and non-cash changes. Liabilities arising from financing

activities are those for which cash flows were, or future

cash flows wil be clasified in the Group’s consolidated

statement of cash flows from financing activities.

Lease

liabilities

Bank

borowings

Amounts

due to

parties

Amount due

to ultimate

holding

companyTotal

租赁负债银行借贷

应付

关联方款项

应付最终控

股公司款项总额

HK$’000HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元千港元

At 1 April 2023于二零二三年四月一日2,705–91,11031894,133

Financing cash flows:融资现金流量：(3,505)7,022(12,294)46,42737,650

Finance costs融资成本1383132,628–3,079

Adition添置4,967–4,967

Exchange diference汇兑调整(187)–(3,084)(1,006)(4,277)

At 31 March 2024 and

1 April 2024

于二零二四年三月三十一日及

二零二四年四月一日

Financing cash flows:融资现金流量：

Finance costs融资成本

Adition添置

Disposals of subsidiaries出售附属公司

Fair value los on financial

liabilities at FVTPL

按公平值计入损益之金融负

债之公平值亏损

Waiver of amounts due to

related parties

豁免应付关联方款项

Exchange diference汇兑调整

At 31 March 2025于二零二五年三月三十一日

36. 承担

并未在综合财务报表作出拨备之未支付

资本承担如下：

于二零二四年三月三十一日，与于有限

合伙企业之投资的未支付资本承担有关

之承担乃计入其他金融资产。

37. 融资活动所产生负债的对账

下表载列本集团的融资活动所产生负债

的变动详情，包括现金及非现金变动。

融资活动所产生的负债为现金流量或未

来现金流量会于本集团综合现金流量表

中被分类为融资活动现金流量的负债。

2025
二零二五年
HK$’000
千港元
1,200
690
970
513
6,176
9,236
–
7,619
110
26,016
65,003

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

38. MATERIAL RELATED PARTY TRANSACTIONS

(a) Related party transaction

In adition to the transactions detailed elsewhere

in the consolidated financial statements, the Group

had the folowing transactions with related parties:

二零二四年

HK$’000

千港元

Interest expenses on lease liabilities

paid to a related party (note a)

向关联方支付之租赁负债

利息开支（附注a）1,200

Interest expenses on lease liabilities

paid to ultimate controling party

(note b)

向最终控股方支付之租赁

负债利息开支（附注b）

Lease liabilities incured to a

related party (note a)

应付关联方之租赁负债

（附注a）2,051

Lease liabilities incured to ultimate

controling party (note b)

应付最终控股公司之租赁

负债（附注b）1,144

Administrative expenses and

service cost recharge by ultimate

holding company

最终控股公司收取之行政

开支及服务成本

7,677

Administrative expenses recharge

by related parties

关联方收取之行政开支

12,916

Revenue to ultimate holding

company

向最终控股公司支付之

收益8

Revenue to related parties向关联方支付之收益4,423

Purchase from ultimate holding

company

向最终控股公司采购

–

Purchase from related parties向关联方采购19,150

Purchase from non-controling

interests

向非控股权益采购

56,747

Notes:

, a subsidiary of the Group

leased a property from Firenze Aparel Limited

(“Firenze”), a company beneficialy owned by Mr.

Chan Wing Kai, who is also a director of Firenze.

, a subsidiary of the Group

leased a property from Mr. Yan Hao (controling

shareholder of ultimate holding company), who is

the ultimate beneficial owner of the property.

38. 重大关联方交易

(a) 关联方交易

除综合财务报表其他章节详述之

交易外，本集团与关联方已进行

下列交易：

附注：

，本集团一间附属公司向Firenze

Aparel Limited（「Firenze」）租用一所

物业。Firenze为一间由陈永启先生

实益拥有的公司。陈永启先生亦为

Firenze的董事。

，本集团一间附属公司向严浩先

生（最终控股公司的控股东）租用一

所物业，而严浩先生为该物业的最终

实益拥有人。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

(b) 与买卖协议、奖励协议及认购协

议相关之借贷及溢利保证

于二零二一年四月二十六日，

于本集团的控股权益由陈永启

先生控制的本公司前控股东

Sped Development Co. Ltd出

售予EPS Holdings, Inc.（「出售事

项」）。根据买卖协议（「该协议」），

Sped Development Co. Ltd以EPS

Holdings, Inc.为受益人提供直至二

零二四年三月三十一日止的溢利

及收益保证，陈永启先生则为该

溢利及收益保证担供担保。在出

售事项后，陈永启先生将继续担

任本集团服装业务的管理层，而

Sped Development Co. Ltd将被视

为本集团的关联方。

根据买卖协议，本公司的附属

公司Sped Aparel (BVI) Limited

（「Sped Aparel BVI」）向Sped

Development Co. Ltd发行三张本

金总额为65百万港元的免息票据

（「二零二一年票据」），作为截至

二零二年三月三十一日、二零

二三年三月三十一日及二零二四

年三月三十一日止年度的溢利及

收益保证。倘溢利或收益低于保

证溢利或保证收益，相关年度

的部分或全部二零二一年票据将

获豁免，而Sped Development

Co. Ltd将承担向本公司支付相

当于相关年度服装业务经审核

除税后亏损金额的责任。Sped

Development Co. Ltd亦已向本公

司提供35百万港元的免息循环融

资，该票据将于二零二四年三月

三十一日到期偿还。

38. MATERIAL RELATED PARTY TRANSACTIONS

(CONTINUED)

(b) Borowing and profit guarante in relation

to a sale and purchase agrement, incentive

agrement and subscription agrement

On 26 April 2021, the controling interest in the

Group was disposed to EPS Holdings, Inc. by Sped

Development Co. Ltd, the preceding controling

shareholder of the Company which was controled

by Mr. Chan Wing Kai (the “Disposal”). Pursuant

to the sale and purchase agrement, Sped

Development Co. Ltd provided profit and revenue

guarantes and Mr. Chan Wing Kai provides

guarante on the profit and revenue guarantes,

in favour of EPS Holdings, Inc. up to 31 March 2024

(the “Agrement”). Mr. Chan Wing Kai retains as a

management of the garment busines of the Group

after the Disposal and Sped Development Co. Ltd

is considered to be a related party of the Group.

Pursuant to the sale and purchase agrement,

Sped Aparel (BVI) Limited (“Sped Aparel

BVI”), a subsidiary of the Company, isued to Sped

Development Co. Ltd thre interest-fre notes (the

“2021 Notes”) with a total principal amount of

HK$65 milion in relation to the profit and revenue

guarantes for the years ended 31 March 2022,

31 March 2023 and 31 March 2024. If the profit or

the revenue is lower than the guaranted profit

or guaranted revenue, part or the entire 2021

Notes of the respective year wil be waived and

Sped Development Co. Ltd wil be obliged to pay

the amount equal to the audited los after tax of

garment busines for the year to the Company.

Sped Development Co. Ltd has also provided a

HK$35 milion interest-fre revolving facility to the

Company which is due for repayment on 31 March

2024.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

（续）

(b) 与买卖协议、奖励协议及认购协

议相关之借贷及溢利保证（续）

截至二零二四年三月三十一日

止年度，本集团归属于服装业

务的收益及除税后溢利分别为

466,977,764港元及7,863,869港

元，而目标收益及溢利分别为

240,000,000港元及10,000,000

港元。由于除税后溢利低于

该协议所载保证溢利，Sped

Development Co. Ltd及陈永启先

生被要求豁免部分二零二一年票

据以补偿本公司。因此，二零

二一年票据21,666,000港元中的

2,136,131港元将获豁免。溢利保

证调整在收取相关利益的合约权

利确立后由本集团入账。截至二

零二五年三月三十一日止年度，

就截至二零二四年三月三十一日

止年度之2,136,000港元（截至二零

二四年三月三十一日止年度：就

截至二零二三年三月三十一日止

年度之393,000港元）作出溢利保证

调整，并于损益内「其他收入、收

益及亏损」项下入账（附注7）。

于二零二四年三月六日，本公司

与Sped Aparel (BVI) Limited董事

陈永启先生订立奖励协议（「奖励

协议」），据此，陈永启先生已向

本公司承诺会促使Sped Aparel

BVI及其附属公司于截至二零二六

年三月三十一日止两个财政年度

达致溢利及收益方面的若干绩效

目标，而达成溢利及收益目标后

陈永启先生将有权收取若干绩效

花红。倘溢利或收益实际金额低

于溢利及收益目标，陈永启先生

将就差额向本公司支付若干金额。

38. MATERIAL RELATED PARTY TRANSACTIONS

(CONTINUED)

(b) Borowing and profit guarante in relation

to a sale and purchase agrement, incentive

agrement and subscription agrement

(Continued)

The revenue and profit after tax of the Group

atributable to the Garment Busines for the year

ended 31 March 2024 is HK$466,977,764 and

HK$7,863,869 respectively while the targeted

revenue and profit is HK$240,000,000 and

HK$10,000,000 respectively. As the profit after tax

is lower than the guaranted profit pursuant to

the Agrement, Sped Development Co. Ltd and

Mr. Chan Wing Kai were required to compensate

the Company by waiving a portion of the 2021

Notes. As such, HK$2,136,131 out of HK$21,666,000

of the Notes wil be waived. The profit guarante

adjustment is recorded by the Group after the

contractual right to receive the related benefit is

established. During the year ended 31 March 2025,

there is profit guarante adjustment relating to the

year ended 31 March 2024 of HK$2,136,000 (year

ended 31 March 2024 relating to the year ended 31

March 2023: HK$393,000), being recorded in profit

and los as “Other income, gains and loses” (note 7).

On 6 March 2024, the Company entered into the

incentive agrement (the “Incentive Agrement”)

with Mr. Chan Wing Kai, a director of Sped

Aparel (BVI) Limited, pursuant to which Mr. Chan

Wing Kai has undertaken to the Company to met

certain performance targets in respect of the

profits and revenue of Sped Aparel BVI and its

subsidiaries for the two financial years ending 31

March 2026, Mr. Chan Wing Kai would entitle to

certain performance bonuses upon fulfilment of

the profits and revenue targets. In the case if the

actual profit or revenue is lower than the profit and

revenue targets, Mr. Chan Wing Kai shal pay to the

Company certain amount for the shortfal.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

（续）

(b) 与买卖协议、奖励协议及认购协

议相关之借贷及溢利保证（续）

于二零二四年三月六日，本公司

与陈永启先生订立认购协议，据

此，本公司向陈永启先生发行一

张本金额为50百万港元、按6厘计

息并于二零二六年六月三十日到

期的票据（「二零二四年票据」）。

发行二零二四年票据后，二零二

一年票据及免息循环融资的余下

尚未偿还结余即予偿还。

应付Sped Development Co. Ltd及

陈永启先生的款项初步按公平值

计量，其后按摊销成本计量。

于二零二五年三月三十一日，

应付Sped Development Co. Ltd

的款项为零港元（二零二四年：

56,434,000港元）；及于二零二五

年三月三十一日，应付陈永启先

生的款项为51,281,000港元（包括

(i)按公平值计入损益且与奖励协

议应付或然款项有关之4,000港

元；(i)与二零二四年票据有关之

50,535,000港元；及(i)无抵押、免

息及按要求偿还之742,000港元）

（二零二四年：无），已于综合财

务状况表内「应付关联方款项」项

下入账，并于附注26披露。

38. MATERIAL RELATED PARTY TRANSACTIONS

(CONTINUED)

(b) Borowing and profit guarante in relation

to a sale and purchase agrement, incentive

agrement and subscription agrement

(Continued)

On 6 March 2024, the Company entered into a

subscription agrement with Mr. Chan Wing Kai,

pursuant to which the Company isued to Mr.

Chan Wing Kai a note with principal amount of

HK$50 milion, interest-bearing at 6% and due for

repayment on 30 June 2026 (the “2024 Note”).

Upon the isuance of the 2024 Note, the remaining

outstanding balance of 2021 Notes and the

interest-fre revolving facility were setled.

The amounts due to Sped Development Co. Ltd

and Mr. Chan Wing Kai are initialy measured at fair

value and subsequently measured at amortised

cost.

Included in “amounts due to related parties” line

item of the consolidated statement of financial

position and as disclosed in note 26, were amount

due to Sped Development Co. Ltd of nil at 31

March 2025 (2024: HK$56,434,000); and amounts

due to Mr. Chan Wing Kai of HK$51,281,000, which

comprised of (i) HK$4,000 is caried at FVTPL

in relation to contingent payable for Incentive

Agrement; (i) HK$50,535,000 in relation to the

2024 Note and (i) HK$742,000 is unsecured,

interest-fre and repayable on demand at 31 March

2025 (2024: nil).

5,208
104
256
5,568

4,420
3,841
2,306
125
23
17
10,732

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

38. MATERIAL RELATED PARTY TRANSACTIONS

(CONTINUED)

Remuneration for key management personel

of the Group, including amounts paid to the

Company’s directors and certain of the highest paid

employes as disclosed in note 11, is as folows:

二零二五年二零二四年

HK$’000HK$’000

千港元千港元

Salaries and other benefits薪金及其他福利3,428

Retirement benefit scheme and

contributions

退休福利计划及供款

Equity-setled share-based expense以权益结算以股份为

基础之付款开支–

3,457

Total remuneration is included in “staf costs” (se

note 11).

39. OPERATING LEASING ARANGEMENTS

The Group as lesor

Al of the machineries held by the Group for rental

purposes have comited leses for one to ten years.

Undiscounted lease payments receivable on leases are as

folows:

二零二五年二零二四年

HK$’000HK$’000

千港元千港元

Within one year于一年内2,715

In the second year第二年1,511

In the third year第三年937

In the fourth year第四年54

In the fifth year第五年15

After five years五年后7

5,239

（续）

本集团主要管理层之薪酬（包括附

注11所披露支付予本公司董事及

若干最高薪酬雇员之金额）如下：

薪酬总额已计入「员工成本」（请参

阅附注11）。

39. 经营租赁安排

本集团作为出租人

本集团已向承租人承诺其持作租赁用途

的所有机器将于一至十年内供使用。

该等租赁的未贴现应收租赁款项如下：

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

40. 非现金交易

诚如附注38(b)所披露，于二零二四年

三月三十一日，本公司因于二零二四

年三月三十一日到期偿还之二零二一年

票据而应付关联方Sped Development

Co. Ltd款项约56,434,000港元。于截

至二零二五年三月三十一日止年度，

应付Sped Development Co. Ltd款项

56,434,000港元以下列方式偿付：(i)抵

销本金额50,000,000港元之二零二四年

票据；(i)根据二零二一年票据之条款豁

免约2,136,000港元；及(i)以现金偿付约

4,298,000港元。

40. NON-CASH TRANSACTIONS

As disclosed in note 38(b), the Company had amount

due to related parties, Sped Development Co. Ltd, of

aproximately HK$56,434,000 in relation to the 2021

Notes as at 31 March 2024, which was due for repayment

on 31 March 2024. During the year ended 31 March

2025, the amount due to Sped Development Co. Ltd

of HK$56,434,000 was setled by (i) ofseting with the

2024 Note with principal amount of HK$50,000,000; (i)

aproximately of HK$2,136,000 was waived pursuant

to the terms of 2021 Notes and (i) setled in cash for

aproximately HK$4,298,000.

1,011
128
94,035
65,563
159,726
2,429
4,217
12,530
19,176
140,550
141,561
50,540
29,987
80,527
61,034
5,222
55,812
61,034

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

41. STATEMENT OF FINANCIAL POSITION OF

THE COMPANY

二零二五年二零二四年

HK$’000HK$’000

千港元千港元

Non-curent aset非流动资产

Investment in subsidiaries投资于附属公司1,021

Curent asets流动资产

Prepayments, deposits and other

receivables

预付款项、按金及

其他应收款项70

Amounts due from subsidiaries应收附属公司款项173,071

Cash and cash equivalents现金及现金等价物554

173,695

Curent liabilities流动负债

Acruals and other payables应计费用及其他应付款项3,160

Amounts due to related parties应付关联方款项–

Amounts due to a subsidiary应付一间附属公司款项64,782

67,942

Net curent asets净流动资产105,753

Total asets les curent liabilities总资产减流动负债106,774

Non-curent liabilities非流动负债

Amounts due to a related party应付关联方款项–

Amount due to non-controling interests应付非控股权益款项50,204

50,204

Net asets净资产56,570

Capital and reserves资本及储备

Share capital股本5,000

Reserves储备51,570

Total equity权益总额56,570

41. 本公司财务状况表

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

综合财务报表附注

For the year ended 31 March 2025

截至二零二五年三月三十一日止年度

ANUAL REPORT 2024/2025

2024/2025 年报

41. STATEMENT OF FINANCIAL POSITION OF

THE COMPANY (CONTINUED)

Movement of the share capital and reserves are stated as

below:

capital

premium

option

reserve

Retained

earnings

(acumulated

loses)Total

股本股份溢价

购股权

储备

保留盈利

（累计亏损）总额

HK$’000HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元千港元

At 1 April 2023于二零二三年四月一日5,00047,656–(4,053)48,603

Profit and total comprehensive

income for the year

年内溢利及全面收益

总额–7,9677,967

At 31 March 2024

and 1 April 2024

于二零二四年三月三十

一日及二零二四年

四月一日5,00047,656–3,91456,570

Los and total comprehensive

expense for the year

年内亏损及全面开支

总额–(17,802)(17,802)

Isue of new shares,

net of share isue expenses

发行新股，扣除股份

发行费用22221,778–22,000

Recognition of equity-setled

share-based payment

确认以权益结算以股份

为基础之付款开支–266–266

At 31 March 2025于二零二五年三月

三十一日5,22269,434266(13,888)61,034

（续）

股本及储备之变动载述如下：

2025
二零二五年
HK$’000
千港元
544,522
33,416
(3,022)
30,394
38,585
(8,191)
30,394

2025
二零二五年
HK$’000
千港元
231,761
105,088
336,849
80,222
94,104
174,326
162,523
120,684
41,839
162,523

FIVE-YEAR FINANCIAL SUMARY OF THE GROUP

本集团五年财务概要

(Expresed in Hong Kong dolars)

（以港币呈列）

EPS Creative Health Technology Group Limited

EPS创健科技集团有限公司

CONSOLIDATED STATEMENT OF PROFIT OR LOS

二零二四年二零二三年二零二年二零二一年

HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元

Revenue收益644,615452,906519,947405,445

Profit (los) before tax除税前溢利（亏损）(24,052)(48,161)(22,744)7,136

Income tax expense所得税开支(2,444)(2,125)(3,529)(631)

Profit (los) for the year年内溢利（亏损）(26,496)(50,286)(26,273)6,505

Atributable to:以下人士应占：

Owners of the Company本公司拥有人(22,066)(45,737)(22,600)6,505

Non-controling interests非控股权益(4,430)(4,549)(3,673)–

(26,496)(50,286)(26,273)6,505

CONSOLIDATED STATEMENT OF FINANCIAL

POSITION

二零二四年二零二三年二零二年二零二一年

HK$’000HK$’000HK$’000HK$’000

千港元千港元千港元千港元

Curent asets流动资产211,929216,732284,643146,955

Non-curent asets非流动资产217,95610,76211,9174,212

Total asets总资产429,885227,494296,560151,167

Curent liabilities流动负债205,030115,18482,28817,892

Non-curent liabilities非流动负债86,67320,66674,408130

Total liabilities总负债291,703135,850156,69618,022

Net asets净资产138,18291,644139,864133,145

Equity权益

Equity atributable to

owners of the Company

本公司拥有人应占

权益65,35587,639131,319133,145

Non-controling interests非控股权益72,8274,0058,545–

138,18291,644139,864133,145

综合损益表

综合财务状况表

2024/20252024/2025

ANUAL REPORT年报

(于开曼群岛注册成立之有限公司)

股份代号

年

报

2025
二零二五年
Pieces ’000	%
件数千件
3,214	89.0
318	8.8
81	2.2
3,613	100.0

2025
二零二五年
HK’000	%
千港元
286,080	86.8
39,320	11.9
4,316	1.3
329,716	100.0

2024/20252024/2025

ANUAL REPORT年报

CONTENTS

目录

CORPORATE INFORMATION

公司资料

CORPORATE INFORMATION

公司资料

CORPORATE INFORMATION

公司资料

CHAIRMAN’S STATEMENT

主席报告

CHAIRMAN’S STATEMENT

主席报告

CHAIRMAN’S STATEMENT

主席报告

1. Strengthening and Expanding Existing Profit-

Health and medicated fod distribution busines:

Laboratory suply distribution busines:

Garment busines:

2. Optimising the Busines Portfolio:

3. Exploring and Launching New Profit-generating

Busineses:

CHAIRMAN’S STATEMENT

主席报告

CHAIRMAN’S STATEMENT

主席报告

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

Group is curently engaged in thre core busines segments:

Health and medicated fod distribution busines:

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

Laboratory suply distribution busines:

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

Note: The average seling price per piece represents the revenue for

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

2024. The increase in gros profit was mainly atributed to the

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

1. Strengthening and expanding existing profit-generating

2. Optimising the busines portfolio

3. Exploring and launching new profit-generating busineses

MANAGEMENT DISCUSION AND ANALYSIS

管理层讨论与分析

BIOGRAPHICAL DETAILS OF DIRECTORS AND SENIOR MANAGEMENT

董事及高级管理层之履历详情

BIOGRAPHICAL DETAILS OF DIRECTORS AND SENIOR MANAGEMENT

董事及高级管理层之履历详情

BIOGRAPHICAL DETAILS OF DIRECTORS AND SENIOR MANAGEMENT

董事及高级管理层之履历详情

BIOGRAPHICAL DETAILS OF DIRECTORS AND SENIOR MANAGEMENT